

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 03:30:58 ; Search time 1643.83 Seconds
(without alignments)
166.765 Million cell updates/sec

Title: US-09-310-844B-23

Perfect score: 29

Sequence: 1 nngauuncuuuunguaagccnangnngn 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 10228115 seqs, 4726426750 residues

Total number of hits satisfying chosen parameters: 20456230

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

EST:*

1: gb_est1:*
2: gb_est2:*
3: gb_est3:*
4: gb_est4:*
5: gb_est5:*
6: gb_est6:*
7: gb_est7:*
8: gb_est8:*
9: gb_est9:*
10: gb_est10:*
11: gb_est11:*
12: gb_est12:*
13: gb_est13:*
14: gb_est14:*
15: gb_est15:*
16: gb_est16:*
17: gb_est17:*
18: gb_est18:*
19: gb_est19:*
20: gb_est20:*
21: gb_est21:*
22: gb_est22:*
23: gb_est23:*
24: gb_est24:*
25: gb_est25:*
26: gb_est26:*
27: gb_est27:*
28: gb_est28:*
29: gb_est29:*
30: gb_est30:*
31: gb_est31:*
32: gb_est32:*
33: gb_est33:*
34: gb_est34:*
35: gb_est35:*
36: gb_est36:*
37: gb_est37:*
38: gb_est38:*
39: gb_est39:*
40: gb_est40:*
41: gb_est41:*
42: gb_est42:*
43: gb_est43:*

44: em_esthum10:*
45: em_esthum11:*
46: em_esthum12:*
47: em_esthum13:*
48: em_esthum14:*
49: em_esthum15:*
50: em_esthum16:*
51: em_esthum17:*
52: em_esthum18:*
53: em_esthum19:*
54: em_esthum20:*
55: em_esthum21:*
56: em_esthum22:*
57: em_esthum23:*
58: em_esthum24:*
59: em_esthum25:*
60: em_esthum26:*
61: em_esthum27:*
62: em_esthum28:*
63: em_esthum29:*
64: em_esthum30:*
65: em_esthum31:*
66: em_esthum32:*
67: em_esthum33:*
68: em_esthum34:*
69: em_esthum35:*
70: em_esthum36:*
71: em_esthum37:*
72: em_esthum38:*
73: em_esthum39:*
74: em_esthum40:*
75: em_esthum41:*
76: em_esthum42:*
77: em_esthum43:*
78: em_esthum44:*
79: em_esthum45:*
80: em_esthum46:*
81: em_esthum47:*
82: em_esthum48:*
83: em_esthum49:*
84: em_esthum50:*
85: em_esthum51:*
86: em_esthum52:*
87: em_esthum53:*
88: em_esthum54:*
89: em_esthum55:*
90: em_esthum56:*
91: em_esthum57:*
92: em_esthum58:*
93: em_esthum59:*
94: em_esthum60:*
95: em_esthum61:*
96: em_esthum62:*
97: em_esthum63:*
98: em_esthum64:*
99: em_esthum65:*
100: em_esthum66:*
101: em_esthum67:*
102: em_esthum68:*
103: em_esthum69:*
104: em_esthum70:*
105: em_esthum71:*
106: em_esthum72:*
107: em_esthum73:*
108: em_esthum74:*
109: em_esthum75:*
110: em_esthum76:*
111: em_esthum77:*
112: em_esthum78:*
113: em_esthum79:*
114: em_esthum80:*
115: em_esthum81:*
116: em_esthum82:*

117: gb_est48:*
118: gb_est49:*
119: gb_est50:*
120: gb_est51:*
121: gb_est52:*
122: gb_est53:*
123: gb_est54:*
124: gb_est55:*
125: gb_est56:*
126: gb_est57:*
127: gb_est58:*
128: gb_est59:*
129: gb_est60:*
130: gb_est61:*
131: gb_est62:*
132: gb_est63:*
133: gb_est64:*
134: gb_est65:*
135: gb_est66:*
136: gb_est67:*
137: gb_est68:*
138: gb_est69:*
139: gb_est70:*
140: gb_est71:*
141: gb_est72:*
142: gb_est73:*
143: gb_est74:*
144: gb_est75:*
145: gb_est76:*
146: gb_est77:*
147: gb_est78:*
148: gb_est79:*
149: gb_est80:*
150: gb_est81:*
151: gb_est82:*
152: gb_est83:*
153: gb_est84:*
154: gb_est85:*
155: gb_est86:*
156: gb_est87:*
157: gb_est88:*
158: gb_est89:*
159: gb_est90:*
160: gb_est91:*
161: gb_est92:*
162: gb_est93:*
163: gb_est94:*
164: gb_est95:*
165: gb_est96:*
166: gb_est97:*
167: gb_est98:*
168: gb_est99:*
169: gb_est100:*
170: gb_est101:*
171: gb_est102:*
172: gb_est103:*
173: gb_est104:*
174: gb_est105:*
175: gb_est106:*
176: gb_est107:*
177: gb_est108:*
178: gb_est109:*
179: gb_est110:*
180: gb_est111:*
181: gb_est112:*
182: gb_est113:*
183: gb_est114:*
184: gb_est115:*
185: gb_est116:*
186: gb_est117:*
187: gb_est118:*
188: gb_est119:*
189: gb_est120:*

190: gb_est121:*
191: gb_est122:*
192: gb_est123:*
193: gb_est124:*
194: gb_est125:*
195: gb_est126:*
196: gb_est127:*
197: gb_est128:*
198: gb_est129:*
199: gb_est130:*
200: gb_est131:*
201: gb_est132:*
202: gb_est133:*
203: gb_est134:*
204: gb_est135:*
205: gb_est136:*
206: gb_est137:*
207: gb_est138:*
208: gb_est139:*
209: gb_est140:*
210: gb_est141:*
211: gb_est142:*
212: gb_est143:*
213: gb_est144:*
214: gb_est145:*
215: gb_est146:*
216: gb_est147:*
217: gb_est148:*
218: gb_est149:*
219: gb_est150:*
220: gb_est151:*
221: gb_est152:*
222: gb_est153:*
223: gb_est154:*
224: gb_est155:*
225: gb_est156:*
226: gb_est157:*
227: gb_est158:*
228: gb_est159:*
229: gb_est160:*
230: gb_est161:*
231: gb_est162:*
232: gb_est163:*
233: gb_est164:*
234: gb_est165:*
235: gb_est166:*
236: gb_est167:*
237: gb_est168:*
238: gb_est169:*
239: gb_est170:*
240: gb_est171:*
241: gb_est172:*
242: gb_est173:*
243: gb_est174:*
244: gb_est175:*
245: gb_est176:*
246: gb_est177:*
247: gb_est178:*
248: gb_est179:*
249: gb_est180:*
250: gb_est181:*
251: gb_est182:*
252: gb_est183:*
253: gb_est184:*
254: gb_est185:*
255: gb_est186:*
256: gb_est187:*
257: gb_est188:*
258: gb_est189:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Query Match	Length	DB	ID	Description
---------------	----------------	--------	----	----	-------------

C	1	18	62.1	325	4	AA290106
C	2	18	62.1	527	226	AQ267968
C	3	18	62.1	596	226	AQ267210
C	4	17	58.6	681	219	CNS0044W
C	5	17	58.6	943	219	CNS000CW
C	6	17	58.6	985	219	CNS000DS
C	7	17	58.6	988	219	CNS000TC
C	8	17	58.6	1101	219	CNS000BM
C	9	17	58.6	1101	219	CNS000CH
C	10	16	55.2	1301	162	BE065429
C	11	16	55.2	494	163	AM240011
C	12	16	55.2	888	119	BF795148
C	13	15.4	53.1	145	150	BF522395
C	14	15.4	53.1	272	26	AV205618
C	15	15.4	53.1	311	224	AQ091856
C	16	15.4	53.1	316	249	AZ762135
C	17	15.4	53.1	397	21	AI535204
C	18	15.4	53.1	408	224	AO148119
C	19	15.4	53.1	417	223	AO065332
C	20	15.4	53.1	533	103	AI914074
C	21	15.4	53.1	554	164	BE173543
C	22	15.4	53.1	591	242	AZ377159
C	23	15.4	53.1	602	234	AQ0970351
C	24	15.4	53.1	604	246	AZ486340
C	25	15.4	53.1	691	149	BE172495
C	26	15.4	53.1	693	164	BE174575
C	27	15.4	53.1	707	241	AZ291529
C	28	15.4	53.1	828	220	CNS01MP
C	29	15.4	53.1	851	221	CNS03KAZ
C	30	15.4	53.1	1048	221	CNS03K91
C	31	15.4	53.1	1086	221	CNS040A8
C	32	15.4	53.1	1665	154	BF120703
C	33	15	51.7	234	25	AV130117
C	34	15	51.7	268	25	AV142328
C	35	15	51.7	436	189	T999738
C	36	15	51.7	501	152	BG370061
C	37	15	51.7	584	229	AQ465094
C	38	15	51.7	660	230	AQ586492
C	39	15	51.7	915	153	BG390703
C	40	14.8	51.0	138	144	BF077310
C	41	14.8	51.0	189	249	BF077310
C	42	14.8	51.0	248	191	AZ28552
C	43	14.8	51.0	289	25	AV154534
C	44	14.8	51.0	293	15	AI057753
C	45	14.8	51.0	316	147	BF377814
						AA290106
						vb32e03.r
						AQ267968
						RC111-73
						AO267210
						RC111-73
						AL078497
						Drosophil1
						AL058429
						Drosophil1
						AL076625
						Drosophil1
						AL076711
						Drosophil1
						AL056770
						Drosophil1
						AL058573
						Drosophil1
						BE065429
						RC3-BT031</

RESULT	1
LOCUS	AA290106
DEFINITION	325 bp mRNA EST 14-APR-1997 v32ae03.r1 Soares mouse lymph node NbMln Mus musculus cdna clone IMAGE:750652.5' similar to gb:M16762 mouse interleukin 2 (MOUSE);,
ACCESSION	AA290106
VERSION	AA290106.1
KEYWORDS	GI:1936335
SOURCE	house mouse.
ORGANISM	Mus musculus

REFERENCE
AUTHORS

1 (bases 1 to 325)

Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisel, S., Kucaba, F., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B.,

TITLE	JOURNAL	COMMENT
Thiesing,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and Mesterzon,R.	The Washu-HHMI Mouse EST Project Unpublished (1996)	Contact: Marra M/Mouse EST Project Washu-HHMI Mouse EST Project Washington University School of Medicine 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108 Tel: 314 286 1800 Fax: 314 286 1810 Email: mouseest@watson.wustl.edu This clone is available royalty-free through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information. MGI:459636
	Putative full length read vector to vector length is 422 Seq primer: -28ml3 rev3 ET from Amersham.	Location/Qualifiers 1..325

/organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="IMAGE:750652"
 /clone_lib="Soares mouse lymph node NbMLN"
 /sex="male"
 /tissue_type="lymph node"
 /dev_stage="4 weeks"
 /lab_host="DH10B"
 /note="Organ: lymph node; Vector: pT7T3D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer"
 15.
 TGGTACCAATCTGAAGTGGAGCGCGGATACCTTTTTTTTTTTTTTTTTTTT
 3'1': double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT7T3 vector. RNA provided by Dr. Bertrand Jordan, library constructed and normalized by Bento Soares and M.Fatima Bonaldo."

Query Match	62.1%;	Score 18;	DB 4;	Length 325;
Best Local Similarity	54.2%;	Pred. No. 9.5;		
Matches 13;	Conservative 5;	Mismatches 6;	Indels 0;	Gaps 0;
OY	4	gauncuunungaaagccnangng	27	
	:	-:-:- -		
Db	170	GAATCTTTTGTAAAGCCCCAAGG	193	

LOCUS	AO267968	527 bp	DNA	GSS	27-APR-1999
DEFINITION	Rpci11-73E11.TJ Rpci-11 Homo sapiens genomic clone Rpci-11-73E11, DNA sequence.				
ACCESSION	AO267968				
VERSION	AO267968.1				
KEYWORDS	GI:3795572				
SOURCE	GSS.				
ORGANISM	human.				
	Homo sapiens				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
REFERENCE	1 (bases 1 to 527)				
AUTHORS	Adams,M.D., Rounsley,S.D., Zhao,S., Bass,S., Linher,K., Golden,K., Berry,K., Granger,D., Suh,E., Wible,C., de Jong,P., and Venter,J.C.				
TITLE	Use of human BAC End Sequences for Sequence-Ready Map Building				
JOURNAL	Unpublished (1998)				
COMMENT	Other_GSSs: Rpci11-73E11.TK				

Contact: Mark Adams
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA

RESULT 5

CNS00C4M 943 bp DNA GSS 04-JUN-1999

LOCUS Drosophila melanogaster genome survey sequence T7 end of BAC #

DEFINITION BACR25E15 of RPC1-98 library from Drosophila melanogaster (fruit

fly), genomic survey sequence.

ACCESSION AL058429

VERSION AL058429.1 GI:4946310

KEYWORDS GSS.

ORGANISM fruit fly.

SOURCE Drosophila melanogaster

Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;

Pterygota; Neoptera; Endopterygota; Diptera; Brachycera;

Muscomorpha; Ephydroidea; Drosophilidae; Drosophila.

REFERENCE 1 (bases 1 to 943)

AUTHORS GenomeScope.

TITLE Direct Submission

JOURNAL Submitted (02-JUN-1999) GenomeScope - Centre National de Sequencage ; BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr

MENT - Web : www.genoscope.cns.fr)

Determination of this BAC-end sequence was carried out as part of a

collaboration with the Berkeley Drosophila Genome Project (BDGP).

The BDGP is constructing a physical map of the Drosophila

melanogaster genome using these BACs. For further information

please see http://www.fruitfly.org/The_BDGP_Drosophila_melanogaster_BAC_library

Aaron Mammoter in Pieter de Jong's laboratory in the Department of

Cancer Genetics at the Roswell Park Cancer Institute in Buffalo,

NY. The library is named RPC1-98 and was constructed by partial

EcoRI digestion of Drosophila DNA provided by the BDGP from the

isogenic strain Y2: cn bw sp, the same strain used for the BDGP's

P1 and EST libraries. A more detailed description of the library

and how to order individual BAC clones, the entire library, or

filters for hybridization from the BACPAC Resource Center can be

found at http://bacpac.med.buffalo.edu/drosophila_bac.htm.

FEATURES

source

1..943

/organism="Drosophila melanogaster"

/db_xref="taxon:7227"

/clone_lib="RPC1-98"

/clone="BACR25E15"

/note="end : T7"

BASE COUNT 331 a 166 c 143 g 265 t 38 others

ORIGIN

Query Match 58.6%; Score 17; DB 219; Length 943;

Best Local Similarity 52.2%; Pred. No. 45;

Matches 12; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 5 auncununguaagccnangng 27

1::: 1:11111 1 1

Db 398 ATCTTTGGGTAGCCCGAAGTG 420

RESULT 6

CNS00J05 965 bp DNA GSS 03-JUN-1999

LOCUS Drosophila melanogaster genome survey sequence TET3 end of BAC:

DEFINITION BACR31L15 of RPC1-98 library from Drosophila melanogaster (fruit

fly), genomic survey sequence.

ACCESSION AL076625

VERSION AL076625.1 GI:4956102

KEYWORDS GSS.

SOURCE fruit fly.

ORGANISM Drosophila melanogaster

Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;

Pterygota; Neoptera; Endopterygota; Diptera; Brachycera;

Muscomorpha; Ephydroidea; Drosophilidae; Drosophila.

REFERENCE 1 (bases 1 to 965)

AUTHORS GenomeScope.

TITLE Direct Submission

JOURNAL	Submitted (02-JUN-1999) Genoscope - Centre National de Sequencage BP 191 91006 Evry cedex - FRANCE (E-mail : segre@genoscope.cns.fr)					
COMMENT	<p>- Web : www.genoscope.cns.fr</p> <p>Determination of this BAC-end sequence was carried out as part of a collaboration with the Berkeley Drosophila Genome Project (BDGP). The BDGP is constructing a physical map of the Drosophila melanogaster genome using these BACs. For further information please see http://www.fruitfly.org/The BDGP Drosophila melanogaster BAC library was prepared by Kazutoyo Osoegawa and Aaron Mammossier in Pieter de Jong's laboratory in the Department of Cancer Genetics at the Roswell Park Cancer Institute in Buffalo, NY. The library is named RPCI-98 and was constructed by partial EcoRI digestion of Drosophila DNA provided by the BDGP from the isogenic strain y2; cn bw sp, the same strain used for the BDGP's p1 and EST libraries. A more detailed description of the library and how to order individual BAC clones, the entire library, or filters for hybridization from the BACPAC Resource Center can be found at http://bacpac.med.buffalo.edu/drosophila_bac.htm.</p>					
FEATURES						
SOURCE	1. 985 /organism="Drosophila melanogaster" /db_xref="taxon:7227" /clone_lib="RPCI-98" /clone="BACR38L15" /note="end : TET3"					
BASE COUNT	323 a 172 c 148 g 303 t 39 others					
ORIGIN						
Query Match	58.6%; Score 17; DB 219; Length 985;					
Best Local Similarity	52.2%; Pred. No. 45;					
Matches	12; Conservative 5; Mismatches 6; Indels 0; Gaps 0;					
Oy	5 auncununguaagccnang 27 ::: :: :: ::					
Db	462 ATCTTGGGTAAGCCCAAGTG 484					
RESULT 7						
CNS00JTC	CNS00JTC 988 bp DNA GSS 03-JUN-1999					
LOCUS	CNS00JTC melanogaster genome survey sequence TET3 end of BAC:					
DEFINITION	BACR3J107 of RPCI-98 library from Drosophila melanogaster (fruit fly), genomic survey sequence.					
ACCESSION	AL076711					
VERSION	AL076711.1 GI:4956289					
KEYWORDS	GSS.					
SOURCE	fruit fly.					
ORGANISM	Drosophila melanogaster					
REFERENCE	Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta; Pterygota; Ephemeroptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Ephydroidea; Drosophilidae; Drosophila.					
AUTHORS	Genoscope.					
TITLE	Direct Submission					
JOURNAL	Submitted (02-JUN-1999) Genoscope - Centre National de Sequencage : BP 191 91006 Evry cedex - FRANCE (E-mail : segre@genoscope.cns.fr)					
COMMENT	<p>- Web : www.genoscope.cns.fr</p> <p>Determination of this BAC-end sequence was carried out as part of a collaboration with the Berkeley Drosophila Genome Project (BDGP). The BDGP is constructing a physical map of the Drosophila melanogaster genome using these BACs. For further information please see http://www.fruitfly.org/The BDGP Drosophila melanogaster BAC library was prepared by Kazutoyo Osoegawa and Aaron Mammossier in Pieter de Jong's laboratory in the Department of Cancer Genetics at the Roswell Park Cancer Institute in Buffalo, NY. The library is named RPCI-98 and was constructed by partial EcoRI digestion of Drosophila DNA provided by the BDGP from the isogenic strain y2; cn bw sp, the same strain used for the BDGP's p1 and EST libraries. A more detailed description of the library and how to order individual BAC clones, the entire library, or filters for hybridization from the BACPAC Resource Center can be found at http://bacpac.med.buffalo.edu/drosophila_bac.htm.</p>					

TITLE	JOURNAL	MEDLINE	COMMENT
Shotgun sequencing of the human transcriptome with ORF expressed sequence tags	Proc. Natl. Acad. Sci. U.S.A.	97 (7), 3491-3496 (2000)	20202663
Contact: Simpson A.J.G.			

Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: aslimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome
Project. This entry can be seen in the following URL
(<http://www.ludwig.org.br/scripts/gethtml2.pl?el=et2-RC3-BF0316-0711>)
299-011-e01a13=1999-12-07&L4=1)
Seq primer: puc 18 forward
High quality sequence stop: 330.

ATTURES	Location/Qualifiers
source	1. .330

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="BR0316"
/dev_stage="Adult"
/note="Organ: breast; Vector: puc18; Site_1: SmaI; Site_2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 1967,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."
BASE COUNT      100 a      64 c      73 g      93 t

```

Query Match	55.2%	Score 16:	DB 162;	Length 330;
Best Local Similarity	52.4%	Pred. NO.	1.3e+02;	
Matches 11; Conservative	5;	Mismatches	5;	Indels 0; Gaps 0;

```

Qy      5 auncuunguaagcccnang 25
          | : | :: : | : | | | | | |
Db     184 ATGCTTTATGTAGCCCAAG 204

```

RESULT 11
AM240011

Accession	Gene	Size	Library	Species	Source
AW240011	494 bp	EST	27-APR-2000		
ptc1c.pk001.120	chicken T cell cDNA library			Gallus gallus	CDN
clone ptc1c.pk001.120 5'	RNA sequence.				

ACCESSION	AW240011	GI:6579751
VERSION	AW240011.1	
KEYWORDS	EST.	
SOURCE	chicken.	

ORGANISM
Gallus gallus
Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 494)

AUTHORS	Morgan, R.
TITLE	Chicken T cell ESTs
JOURNAL	Unpublished (1999)
COMMENT	Contact: Robin Morgan

University of Delaware
Townsend Hall, Newark, DE 19717, USA
Tel: 302-831-1341

Fax: 302-831-2822
 Email: morgan@udel.edu
 Clones can be ordered online at <http://www.chickest.udel.edu>
 Location/Qualifiers
 1. 494

Query Match	Best Local Similarity	Score	DB	Length
Matches 12; Conservative <td>55.2%;</td> <td>60.0%;</td> <td>1.4e+02;</td> <td>494;</td>	55.2%;	60.0%;	1.4e+02;	494;
			Pred. No. 1.4e+02;	
			Mismatches 5;	Indels 0;
			Gaps 0;	
OY 4 gauncuunguaagccna 23				
db 18 GATGCTTTTGTAAAGCCCA 37				

Query Match	55.28;	Score 16:	DB 113;	Length 494;
Best Local Similarity	60.08;	Pred. No.	1.4e+02;	
Matches 12;	Conservative 5;	Mismatches 3;	Indels 0;	Gaps 0;

QY	4	gauncuunguaagccca	23
		: :: :	
Db	18	GATGCTTTTGTAGCCCA	37

RESULT 12
BF795148/C

LOCUS	BF195148	888 bp	mRNA	EST	12-JAN-2001
DEFINITION	602256488f1 NIH_MGC_85 Homo sapiens cDNA clone IMAGE:4339844 5' mRNA sequence.				

ACCESSION	BF795148	GI:12100202
VERSION	BF795148.1	
KEYWORDS	EST.	
SOURCE	human.	

ORGANISM	REFERENCE
Homo sapiens	1 (bases 1 to 888)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi	
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo	

AUTHORS NIH-MGC <http://mgc.nci.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.

Email: cgabbs-r@mail.nih.gov
Tissue Procurement: Louis Staudt, M.D., Ph.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LILN)

DNA sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>

```

Plate: LLAM9950 row: p column: 21
High quality sequence stop: 678.
location/Qualifiers
    source
    1..888

```

```
/organism="Homo sapiens"  
/db_xref="taxon:9606"  
/clone="IMAGE:4339844"  
/clone_lib="NIN_MGC_85"
```

```

/tissue_type="lymphoma, cell_line"
/lab_host="DH10B (phage-resistant)"
/note="Organ: lymph. Vector: pCMV-Sport6; Site_1: NotI;
Site_2: SalI; Cloned unidirectionally; oligo-ct primed.

```

Average insert size 1.867 kb. Library enriched for full-length clones and constructed by Life Technologies Note: this is a NIH_MGC Library."

ORIGIN	
Query Match	55.2% Score 16; DB 169; Length 888;

Best Local Similarity 50.0%; Pred. No. 1.7e+02;
Matches 11; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

817 TCCTTCCGTAAGCCCCAAGTG 796

RESULT 13
 BE522395/c 145 bp mRNA EST 11-DEC-2000
 LOCUS UI-R-C3-ta-e-05-0-UI.r2 UI-R-C3 Rattus norvegicus cDNA clone
 DEFINITION UI-R-C3-ta-e-05-0-UI 5', mRNA sequence.
 ACCESSION BE522395
 VERSION BE522395.1 GI:11630362
 KEYWORDS EST.
 SOURCE Norway rat.
 ORGANISM Rattus norvegicus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
 Rattus.
 1 (bases 1 to 145)
 Bonaldo, M.F., Lennon, G. and Soares, M.B.
 Normalization and subtraction: two approaches to facilitate gene
 discovery
 JOURNAL Genome Res. 6 (9), 791-806 (1996)
 MEDLINE 9704447
 MEMENT Contact: Soares, MB
 Program for Rat Gene Discovery and Mapping
 University of Iowa
 451 Eckstein Medical Research Building Iowa City, IA 52242, USA
 Tel: 319 335 8250
 Fax: 319 335 9565
 Email: msoares@iuiiue.weeg.uiowa.edu
 cDNA library preparation: M.B. Soares Lab Clone distribution:
 clones will be available through Research Genetics (www.resgen.com)
 This clone is also available through the I.M.A.G.E. Consortium at
 LMN (info@image.liml.gov). IMAGE ID-1769254
 Seq primer: M13 Forward
 Location/Qualifiers
 1..145
 /organism="Rattus norvegicus"
 /strain="Sprague-Dawley"
 /db_xref="taxon:10116"
 /clone="UI-R-C3-ta-e-05-0-UI"
 /clone_lib="UI-R-C3"
 /dev_stage="adult"
 /lab_host="DH10B (Life Technologies)"
 /note="Vector: pRT3D-Pac (Pharmacia) with a modified
 polylinker. Site 1: Not I; Site 2: Eco RI; The UI-R-C3
 library is a subtracted library of a series, ultimately
 derived from a mixture of individually tagged normalized
 libraries from rat placenta, adult lung, brain, liver,
 kidney, heart, spleen, ovary, muscle, and 8, 12 and 18-day
 embryos, after a series of subtractions to reduce the
 representation of cDNAs from which ESTs had already been
 generated. The following serially subtracted libraries
 were generated in this process: UI-R-C3, UI-R-C2P, UI-R-C1
 , UI-R-C0, UI-R-A1, UI-R-E1. The tag is a string of 3-5
 nucleotides present between the Not I site and the
 oligo-dT track which allows identification of the library
 of origin of a clone within the mixture. The subtracted
 library (UI-R-C3) was constructed as follows: PCR amplified
 cDNA inserts from UI-R-C2P clones from which 3' ESTs had
 been derived was used as a driver in a hybridization with
 the UI-R-C2P library in the form of single-stranded
 circles. The remaining single-stranded circles (subtracted
 library) was purified by hydroxyapatite column
 chromatography, converted to double-stranded circles and
 electroporated into DH10B bacteria (Life Technologies) to
 generate the UI-R-C3 library. This procedure has been
 previously described (Bonaldo, Lennon and Soares, Genome
 Research 6:791-806, 1996)"

BASE COUNT 23 a 39 c 40 g 43 t
 ORIGIN

Query Match 53.1%; Score 15.4; DB 150; Length 145;
 Best Local Similarity 50.0%; Pred. No. 2.4e+02;
 Matches 11; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 4 gauncuununguaagcccnang 25
 DB 75 GATGCTTTCCTAAGCCACAG 54
 RESULT 14
 AV205618/c 272 bp mRNA EST 30-OCT-1999
 LOCUS AV205618
 DEFINITION AV205618 RIKEN full-length enriched, adult male testis Mus musculus
 cDNA clone 1700081C10 3', mRNA sequence.
 ACCESSION AV205618
 VERSION AV205618.1 GI:6146471
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 272)
 Konno, H., Aizawa, K., Akahira, S., Akiyama, J., Carninci, P., Endo, T.,
 Fukuda, S., Fukunishi, Y., Hara, A., Hayatsu, N., Hirozane, T., Hori, F.,
 Ishii, Y., Ishikawa, T., Itoh, M., Izawa, M., Kadota, K., Kagawa, I., Kai,
 C., Kawai, J., Kikuchi, N., Kojima, Y., Koya, S., Kusakabe, M.,
 Matsuyama, T., Miki, R., Mizuno, Y., Nakamura, M., Oda, H., Okazaki, Y.,
 Owa, C., Ozawa, Y., Saito, H., Sano, M., Sato, K., Shibata, K., Shibata,
 Y., Shigemoto, Y., Shiraki, T., Sogabe, Y., Suganara, Y., Suzuki, H.,
 Suzuki, H., Takahashi, F., Tateo, M., Tomimaga, N., Tsunoda, Y.,
 Watahiki, A., Watanabe, S., Yamamura, T., Yasunishi, A., Yokota, T.,
 Yoshiki, A., Yoshino, M., Muramatsu, M. and Hayashizaki, Y.
 RIKEN Mouse ESTs (Konno, H., et al. 1999)
 Unpublished (1999)
 Contact: Yoshihide Hayashizaki
 Genome Exploration Research Group, Life Science Tsukuba Center,
 Genome Science Laboratory
 The Institute of Physical and Chemical Research (RIKEN), Genomic
 Sciences Center
 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan
 Tel: +81-298-36-9013
 Fax: +81-298-36-9098
 Email: genome-res@rcc.riken.go.jp,
 URL: http://genome.rcc.riken.go.jp/
 Sasaki, N., Izawa, M., Watahiki, M., Ozawa, K., Tanaka, T., Yoneda, Y.,
 Matsura, S., Carninci, P., Muramatsu, M., Okazaki, Y. and Hayashizaki,
 Y.
 Transcriptional sequencing: A method for DNA sequencing using RNA
 polymerase. Proc. Natl. Acad. Sci. U.S.A. 95 (7), 3455-3460 (1998)
 Itoh, M., Kitsuai, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J.,
 Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki,
 Y. and Hayashizaki, Y.
 Automated filtration-based high-throughput plasmid preparation
 system. Genome Res. 9 (5), 463-470 (1999)
 Carninci, P. and Hayashizaki, Y.
 High-efficiency full-length cDNA cloning. Methods Enzymol. 303,
 19-44 (1999)
 Please visit our web site (<http://genome.rcc.riken.go.jp>) for
 further details.
 Location/Qualifiers
 1..272
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="1700081C10"
 /clone_lib="RIKEN full-length enriched, adult male testis"
 /sex="male"
 /tissue_type="testis"
 /dev_stage="adult"
 /lab_host="SOLR"
 /note="Site 1: XhoI; Site 2: BamHI; cDNA library was
 prepared and sequenced in Mouse Genome Encyclopedia
 Project of Genome Exploration Research Group in Riken
 Genomic Sciences Center and Genome Science Laboratory in
 RIKEN. Division of Experimental Animal Research in Riken
 contributed to prepare mouse tissues. 1st strand cDNA was
 primed with a primer [5'

Tue Oct 2 09:31:45 2001

```
Search completed: October  2, 2001, 04:38:38
Job time: 4060 sec
```

BASE COUNT
ORIGIN

Best Local
Matches 1

Db 112 GAT

SULT 15
091856

DEFINITION	S	ACCESSION
------------	---	-----------

ACCESSION A

KEYWORDS

SOURCE

ORGANISM H

REFERENCE 1
AUTHORS M

MEDLINE	9
COMMENT	C

Class: BAC ends
High quality sequence stop: 311.

FEATURES
SOURCE

BASE COUNT
ORIGIN

Best Local
Matches 1

Db 217 GAT

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 03:33:13 ; Search time 57.41 Seconds
(without alignments)
95.628 Million cell updates/sec

Title: US-09-310-844B-23

Perfect score: 29

Sequence: 1 nngaucununguaagccnangnn 29

Scoring table: IDENTITY_NUC

Gapop 10.0, Gapext 1.0

Searched: 324599 seqs, 94655562 residues 649198

total number of hits satisfying chosen parameters:

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : Issued_Patents_NA:*

1: /cgn2_6/pdata/2/ina/5A.COMB.seq:*
2: /cgn2_6/pdata/2/ina/5B.COMB.seq:*
3: /cgn2_6/pdata/2/ina/6A.COMB.seq:*
4: /cgn2_6/pdata/2/ina/6B.COMB.seq:*
5: /cgn2_6/pdata/2/ina/PCUS.COMB.seq:*
6: /cgn2_6/pdata/2/ina/Backfile1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	18	62.1	209	1	US-08-510-032A-8
2	18	62.1	209	3	US-08-688-514-8
3	18	62.1	801	6	5314995-8
4	18	62.1	8491	2	US-08-757-439-1
5	14.4	49.7	1894	4	US-09-004-731-29
6	14.4	49.7	1894	4	US-09-004-731-31
7	14.4	49.7	1894	4	US-09-032-215-3
8	14.4	49.7	1894	4	US-08-749-699-29
9	14.4	49.7	1894	4	US-08-749-699-31
10	14.4	49.7	10409	3	US-08-772-440-33
11	14.4	49.7	21126	1	US-08-008-216-19
12	14.4	49.7	21126	1	US-08-459-569-19
13	14.4	49.7	21126	1	US-08-458-831-19
14	14.4	49.7	21126	1	US-08-121-713D-61
15	13.8	47.6	2670	1	US-08-835-268-61
16	13.8	47.6	2670	2	US-09-060-692-61
17	13.8	47.6	2670	2	US-08-833-391-61
18	13.8	47.6	2670	5	PCT-US94-10151A-61
19	13.4	46.2	2829	3	US-08-851-843A-53
20	13.4	46.2	2829	4	US-08-974-549A-220
21	13.2	45.5	945	4	US-09-434-774-15
22	13.2	45.5	3867	3	US-08-762-428A-5
23	13.2	45.5	4016	3	US-08-762-428A-7
24	13.2	45.5	4884	1	US-07-665-792E-10
25	13	44.8	172	1	US-08-480-910-8
26	13	44.8	300	1	US-08-480-910-2
27	13	44.8	1285	1	US-08-480-910-1

28	13	44.8	1285	5	PCT-US95-00052-1	Sequence 1, Appl
29	12.8	44.1	423	1	US-08-470-179-41	Sequence 41, Appl
30	12.8	44.1	423	1	US-08-470-179-120	Sequence 120, Appl
31	12.8	44.1	423	1	US-08-470-179-123	Sequence 123, Appl
32	12.8	44.1	705	4	US-08-998-416-1136	Sequence 1136, Ap
33	12.8	44.1	1210	3	US-09-002-298-2	Sequence 2, Appl
34	12.8	44.1	1212	3	US-08-188-930-249	Sequence 249, Appl
35	12.8	44.1	1803	3	US-08-458-922-2	Sequence 2, Appl
36	12.8	44.1	2221	1	US-08-418-782-2	Sequence 2, Appl
37	12.8	44.1	2221	1	US-08-228-662-2	Sequence 2, Appl
38	12.8	44.1	2221	2	US-08-852-219-2	Sequence 2, Appl
39	12.8	44.1	2235	1	US-08-418-782-1	Sequence 1, Appl
40	12.8	44.1	2235	1	US-08-228-662-1	Sequence 1, Appl
41	12.8	44.1	2235	2	US-08-852-219-1	Sequence 1, Appl
42	12.8	44.1	2331	1	US-08-418-782-20	Sequence 20, Appl
43	12.8	44.1	2331	2	US-08-852-219-20	Sequence 20, Appl
44	12.8	44.1	2955	2	US-08-867-941-4	Sequence 4, Appl
45	12.8	44.1	2955	4	US-09-074-658-4	Sequence 4, Appl

ALIGNMENTS

RESULT 1

US-08-510-032A-8

Sequence 8, Appl

Patent No. 5712126

GENERAL INFORMATION:

APPLICANT: Sherman Weissman and Yalindra Prashar

TITLE OF INVENTION: Analysis of Gene Expression By Display of 3'-

NUMBER OF SEQUENCES: 12

CORRESPONDENCE ADDRESS:

ADDRESSER: Yahwak & Associates

STREET: 25 Skytop Drive

CITY: Trumbull

STATE: Connecticut

COUNTRY: USA

ZIP: 06611

COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk

COMPUTER: Macintosh

OPERATING SYSTEM: MS-DOS

SOFTWARE: Microsoft Word 4.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/510,032A

FILING DATE:

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: George M. Yahwak

REGISTRATION NUMBER: 26,824

TELEPHONE: (203)268-1951

TELECOMMUNICATION INFORMATION:

TELEFAX: (203)268-1951

INFORMATION FOR SEQ. ID NO: 8:

SEQUENCE CHARACTERISTICS:

LENGTH: 209 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

US-08-510-032A-8

Query Match 62.1%; Score 18; DB 1; Length 209;

Best local Similarity 54.2%; Pred. No. 0.064;

Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 4 gauncununguaagccnangnn 27

DB 36 GATCTTTTGTAAAGCCCTAGGGG 59

RESULT 2
US-08-688-514-8

; Sequence 8, Application US/08688514

; Patent No. 6010850

; GENERAL INFORMATION:

; APPLICANT: Shetman Weissman and Yarlindra Prashar

; TITLE OF INVENTION: Analysis of Gene Expression By Display of 3'-

; NUMBER OF SEQUENCES: 14

; CORRESPONDENCE ADDRESS:

; STREET: 25 Skytop Drive

; CITY: Trumbull

; STATE: Connecticut

; COUNTRY: USA

; ZIP: 06611

; COMPUTER READABLE FORM:

; MEDIUM TYPE: floppy disk

; COMPUTER: Macintosh

; OPERATING SYSTEM: MS-DOS

; SOFTWARE: Microsoft Word 4.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/688,514

; FILING DATE:

; CLASSIFICATION: 536

; ATTORNEY/AGENT INFORMATION:

; NAME: George M. Yahwak

; REGISTRATION NUMBER: 26,824

; REFERENCE/DOCKET NUMBER: Yale

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (203)268-1951

; TELEFAX: (203)268-1951

; INFORMATION FOR SEQ ID NO: 8:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 209 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: DNA

US-08-688-514-8

Query Match 62.1%; Score 18; DB 3; Length 209;

Best Local Similarity 54.2%; Pred. NO. 0.064;

Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

4 gauncuununguaagcccnangng 27

||:|::|:||||| | | |

36 GATCTCTTTGTGAAGCCCTAGGCG 59

RESULT 3

5314995-8

; Patent No. 5314995

; APPLICANT: FELL, HENRY P.; GAYLE, MARGIT A.

; TITLE OF INVENTION: THERAPEUTIC INTERLEUKIN-2-ANTIBODY

; BASED FUSION PROTEINS

; NUMBER OF SEQUENCES: 8

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/07/468,390

; FILING DATE: 22-JAN-1990

; SEQ ID NO: 8:

; LENGTH: 801

5314995-8

Query Match 62.1%; Score 18; DB 6; Length 801;

Best Local Similarity 54.2%; Pred. NO. 0.086;

Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

4 gauncuununguaagcccnangng 27

||:|::|:||||| | | |

Db 653 gatctctttgtgaagccctagggg 676

RESULT 4

US-08-757-439-1/c

; Sequence 1, Application US/08757439

; Patent No. 5866371

; GENERAL INFORMATION:

; APPLICANT: BADZONG, Werner

; APPLICANT: HABERMANN, Paul

; APPLICANT: MOELLER, Joerg

; APPLICANT: ARETZ, Werner

; TITLE OF INVENTION: PROCESS FOR USING THE YEAST ADH II

; TITLE OF INVENTION: PROMOTER SYSTEM FOR THE PRODUCTION OF HETEROLOGOUS

; NUMBER OF SEQUENCES: 1

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Foley & Lardner

; STREET: 3000 K Street, N.W., Suite 500

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20007-5109

; COMPUTER READABLE FORM:

; MEDIUM TYPE: floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentin Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/757,439

; FILING DATE: 27-NOV-1996

; CLASSIFICATION: 530

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: DE 19544233.4

; FILING DATE: 28-NOV-1995

; ATTORNEY/AGENT INFORMATION:

; NAME: SANDERCOCK, Colin G.

; REGISTRATION NUMBER: 31,298

; REFERENCE/DOCKET NUMBER: 18748/303/HOCE

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202)672-5300

; TELEFAX: (202)672-5399

; TELEX: 904136

; INFORMATION FOR SEQ ID NO: 1:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 8491 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-757-439-1

Query Match 62.1%; Score 18; DB 2; Length 8491;

Best Local Similarity 54.2%; Pred. NO. 0.15;

Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

4 gauncuununguaagcccnangng 27

||:|::|:||||| | | |

Db 6651 GATCTCTTTGTGAAGCCCTAGGCG 6628

RESULT 5

US-09-004-731-29/c

; Sequence 29, Application US/09004731

; Patent No. 6177258

; GENERAL INFORMATION:

; APPLICANT: Wu Hunter, Shirley

; APPLICANT: Stiegler, Gary

; APPLICANT: Gaines, Patrick J.

; TITLE OF INVENTION: FLEA PROTEASE PROTEINS, NUCLEIC ACID

; NUMBER OF SEQUENCES: 103

; CORRESPONDENCE ADDRESS:

```

CLASSIFICATION:
PROR APPLICATION DATA:
APPLICATION NUMBER: US/08/749,699
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Connell, Gary J.
REGISTRATION NUMBER: 32,020
REFERENCE/DOCKET NUMBER: 2618-25-C3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 863-9700
TELEFAX: (303) 863-0223
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 1894 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-004-731-31

Query Match          49.7%; Score 14.4; DB 4; Length 1894;
Best Local Similarity 47.6%; Pred. No. 15;
Matches 10; Conservative 5; Mismatches 6; Indels 0; Gaps 0.

QY      5 aaucuunnguagccnang 25
      1::: 1:1111 1 1
Db      328 ATACTTGTGTAAGCTCGATG 348

RESULT      7
US-09-032-215-3/c
; Sequence 3, Application US/09032215
; Patent No. 6204010
; GENERAL INFORMATION:
; APPLICANT: Stiegler, Gary L.
; APPLICANT: Gaines, Patrick J.
; TITLE OF INVENTION: FLEA PROTEASE PROTEINS, NUCLEIC
; TITLE OF INVENTION: ACID MOLECULES, AND USES THEREOF
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheridan Ross P.C.
; STREET: 1700 Lincoln Street, Suite 3500
; CITY: Denver
; STATE: Colorado
; COUNTRY: U.S.A.
; ZIP: 80203
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII DOS TEXT
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/032,215
; FILING DATE: 27-FEB-1998
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Connell, Gary J.
; REGISTRATION NUMBER: 32,020
; REFERENCE/DOCKET NUMBER: 2618-25-C6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 863-9700
; TELEFAX: (303) 863-0223
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1894 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA

```



```

PatentNO: 5366887
GENERAL INFORMATION:
APPLICANT: Slightom, Jerry L.
APPLICANT: Tepler, David A.
TITLE OF INVENTION: R1 T-DNA Promoters
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESS: GRAY, CARY, AMES & FRYE
STREET: 401 B Street, Suite 1700
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92101-4297
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/008,216
FILING DATE: 25-JAN-1993
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 06/725,368
FILING DATE: 22-APR-1985
ATTORNEY/AGENT INFORMATION:
NAME: Barnhorst, Marlene W.
REGISTRATION NUMBER: 36,740
REFERENCE/DOCKET NUMBER: PI1020U1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 699-2700
TELEFAX: (619) 236-1048
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 21126 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
ORGANISM: Agrobacterium rhizogenes
STRAIN: STRAIN M4
IMMEDIATE SOURCE:
LIBRARY: CONVOLVULUS ARVENSIS PLANT CELLS
CLONE: CLONE 7
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (937..2262)
OTHER INFORMATION: /label= ORF1SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (2649..3458)
OTHER INFORMATION: /label= ORF2SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: 3726..4799
OTHER INFORMATION: /label= ORF3SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (4607..4918)
OTHER INFORMATION: /label= ORF5SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: 5143..6216
OTHER INFORMATION: /label= ORF6SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (5071..5663)

```

```
OTHER INFORMATION: /label= ORF7SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: 6609..888
OTHER INFORMATION: /label= ORF8SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (6576..6830)
OTHER INFORMATION: /label= ORF9SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: 9748..10044
OTHER INFORMATION: /label= ORF10SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (10509..11282)
OTHER INFORMATION: /label= ORF11SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: 12466..13002
OTHER INFORMATION: /label= ORF12SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: 13723..14319
OTHER INFORMATION: /label= ORF13SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: 15659..16210
OTHER INFORMATION: /label= ORF14SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (16517..17545)
OTHER INFORMATION: /label= ORF15SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (17737..18189)
OTHER INFORMATION: /label= ORF16SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (18177..18743)
OTHER INFORMATION: /label= ORF17SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (19031..19390)
OTHER INFORMATION: /label= ORF18SUBSEQUENCE
US-08-008-216-19
Query Match 49.7%; Score 14.4; DB 1; Length 21126;
Best Local Similarity 47.6%; Pred. No. 25;
Matches 10; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
OY 5 auncuunungaaagcccnang 25
Db 20133 ATCTTCGGRAGACGAG 20153
RESULT 12
US-08-459-569-19
Sequence 19, Application US/08459569
Patent No. 5543501
GENERAL INFORMATION:
APPLICANT: Slightom, Jerry L.
TITLE OF INVENTION: R1 T-DNA Promoters
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: GRAY, CARY, AMES & FRYE
STREET: 401 B Street, Suite 1700
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92101-4297
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/459, 569
FILING DATE: 02-JUN-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/008,216
FILING DATE: 25-JAN-1993
APPLICATION NUMBER: US 06/725,368
FILING DATE: 22-APR-1985
ATTORNEY/AGENT INFORMATION:
NAME: Barnhorst, Marilee W.
REGISTRATION NUMBER: 36,740
REFERENCE/DOCKET NUMBER: P1020US1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 699-2700
TELEFAX: (619) 236-1048
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 21126 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
ORGANISM: Agrobacterium rhizogenes
STRAIN: STRAIN A4
IMMEDIATE SOURCE:
LIBRARY: CONVOLVULUS ARVENSIS PLANT CELLS
CLONE: CLONE 7
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (937..2262)
OTHER INFORMATION: /label= ORF1SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (2649..3458)
OTHER INFORMATION: /label= ORF2SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: 3726..4799
OTHER INFORMATION: /label= ORF3SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (4041..4400)
OTHER INFORMATION: /label= ORF4SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (4607..4918)
OTHER INFORMATION: /label= ORF5SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: 5143..6216
OTHER INFORMATION: /label= ORF6SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (5071..5643)
OTHER INFORMATION: /label= ORF7SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: 6609..8888
OTHER INFORMATION: /label= ORF8SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (6576..6830)
OTHER INFORMATION: /label= ORF9SUBSEQUENCE
FEATURE:
NAME/KEY: misc_feature
```

LOCATION: 9748..10044
OTHER INFORMATION: /label= ORF10SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (10509..11282)
OTHER INFORMATION: /label= ORF11SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 12466..13002
OTHER INFORMATION: /label= ORF12SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 13723..14319
OTHER INFORMATION: /label= ORF13SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 15659..16210
OTHER INFORMATION: /label= ORF14SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (16517..17545)
OTHER INFORMATION: /label= ORF15SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (17737..18189)
OTHER INFORMATION: /label= ORF16SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (18177..18743)
OTHER INFORMATION: /label= ORF17SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (19031..19390)
OTHER INFORMATION: /label= ORF18SUBSEQUENC
US-08-459-569-19

Query Match 49.7%; Score 14.4; DB 1; Length 21126;
Best Local Similarity 47.6%; Pred. No. 25;
Matches 10; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 5 auncununguaagccnang 25
Db 20133 ATTCTTCGCTAGACCGAAG 20153

RESULT 13
US-08-458-831-19
Sequence 19, Application US/08458831
Patent No. 5824866
GENERAL INFORMATION:
APPLICANT: Slightom, Jerry L.
TITLE OF INVENTION: Tefter, David A.
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: GRAY, CARY, AMES & FRYE
STREET: 401 B Street, Suite 1700
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92101-4297
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/458,831
FILING DATE: 02-JUN-1995
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/008,216

FILING DATE: 25-JAN-1993
APPLICATION NUMBER: US 06/725,368
FILING DATE: 22-APR-1985
ATTORNEY/AGENT INFORMATION:
NAME: Barnhorst, Marilee W.
REGISTRATION NUMBER: 36,740
REFERENCE/DOCKET NUMBER: P1020US1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 699-2700
TELEFAX: (619) 236-1048
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 21126 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
ORGANISM: Agrobacterium rhizogenes
STRAIN: STRAIN A4
IMMEDIATE SOURCE:
LIBRARY: CONVOLVULUS ARVENSIS PLANT CELLS
CLONE: CLONE 7
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (937..2262)
OTHER INFORMATION: /label= ORF1SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (2649..3458)
OTHER INFORMATION: /label= ORF2SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 3726..4799
OTHER INFORMATION: /label= ORF3SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (4041..4400)
OTHER INFORMATION: /label= ORF4SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 5143..6216
OTHER INFORMATION: /label= ORF6SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (5071..5643)
OTHER INFORMATION: /label= ORF7SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 6609..8888
OTHER INFORMATION: /label= ORF8SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (6576..6830)
OTHER INFORMATION: /label= ORF9SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 9748..10044
OTHER INFORMATION: /label= ORF10SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: complement (10509..11282)
OTHER INFORMATION: /label= ORF11SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 12466..13002
OTHER INFORMATION: /label= ORF12SUBSEQUENC
FEATURE:

```
NAME/KEY: misc_feature
LOCATION: 13723..14319
OTHER INFORMATION: /label= ORF13SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 15659..16210
OTHER INFORMATION: /label= ORF14SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 16517..17545
OTHER INFORMATION: /label= ORF15SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 17737..18189
OTHER INFORMATION: /label= ORF16SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18177..18743
OTHER INFORMATION: /label= ORF17SUBSEQUENC
FEATURE:
NAME/KEY: misc_feature
LOCATION: 19031..19390
OTHER INFORMATION: /label= ORF18SUBSEQUENC
US-08-458-831-19
```

```
Query Match 49.7%; Score 14.4; DB 1; Length 21126;
Best Local Similarity 47.6%; Pred. No. 25;
Matches 10; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
```

OY 5 auncuununguaagcccnang 25

Db 20133 ATCTTTCGTAAGACCGAAG 20153

```
RESULT 14
US-08-121-713D-61
Sequence 61, Application US/08121713D
Patent No. 5639856
GENERAL INFORMATION:
APPLICANT: Goodman, Corey S.
APPLICANT: Kolodkin, Alex L.
APPLICANT: Mathes, David
APPLICANT: Bentley, David R.
APPLICANT: O'Connor, Timothy
TITLE OF INVENTION: The Semaphorin Gene Family
NUMBER OF SEQUENCES: 100
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
STREET: 268 Bush Street, Suite 3200
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/121,713D
FILING DATE: 13-SEP-1993
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Osman, Richard A.
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: B94-002-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415)343-4341
TELEFAX: (415) 343-4342
TELEX:
INFORMATION FOR SEQ ID NO: 61:
SEQUENCE CHARACTERISTICS:
```

```
LENGTH: 2670 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 268..2439
US-08-121-713D-61
```

```
Query Match 47.6%; Score 13.8; DB 1; Length 2670;
Best Local Similarity 50.0%; Pred. No. 37;
Matches 11; Conservative 4; Mismatches 7; Indels 0; Gaps 0;
```

OY 4 gauncuununguaagcccnang 25

Db 2416 GAGATTTCGTAAGCCCATG 2437

```
RESULT 15
US-08-835-268-61
Sequence 61, Application US/08835268
Patent No. 5807826
GENERAL INFORMATION:
```

```
APPLICANT: Goodman, Corey S.
APPLICANT: Kolodkin, Alex L.
APPLICANT: Mathes, David
APPLICANT: Bentley, David R.
APPLICANT: O'Connor, Timothy
TITLE OF INVENTION: The Semaphorin Gene Family
NUMBER OF SEQUENCES: 100
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
STREET: 268 Bush Street, Suite 3200
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/835,268
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/121,713
FILING DATE: 13-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: Osman, Richard A.
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: B94-002-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415)343-4341
TELEFAX: (415) 343-4342
TELEX:
INFORMATION FOR SEQ ID NO: 61:
SEQUENCE CHARACTERISTICS:
LENGTH: 2670 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 268..2439
US-08-835-268-61
Query Match 47.6%; Score 13.8; DB 1; Length 2670;
```

Best Local Similarity 50.0%; Pred. No. 37;
Matches 11; Conservative 4; Mismatches

7; Indels 0; Gaps 0;

QY 4 gauncuununguaagccnang 25
|| ::::|:|||||
Db 2416 GAGATTTCGTAAGCCCAATG 2437

Search completed: October 2, 2001, 05:01:46
Job time: 5313 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 03:31:53 ; Search time 1315.38 Seconds

(without alignments)
341.015 Million cell updates/sec

Title: US-09-310-844B-23

Sequence: 1 nngauncuununguaagcccnahngnn 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1344157 segs, 773874588 residues

Total number of hits satisfying chosen parameters: 2688314

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:*

1: gb_ba1:*
2: gb_ba2:*
3: gb_ba3:*
4: gb_in1:*
5: gb_in2:*
6: gb_in3:*
7: gb_om:*
8: gb_ov:*
9: gb_pat1:*
10: gb_pat2:*
11: gb_ph:*
12: gb_pl1:*
13: gb_pl2:*
14: gb_pl3:*
15: gb_pl4:*
16: em_ba1:*
17: em_ba2:*
18: em_fun:*
19: em_hcgo_hum:*
20: em_hcgo_inv:*
21: em_hcgo_rod:*
22: em_hcgo_hum1:*
23: em_hcgo_hum2:*
24: em_hcgo_hum3:*
25: em_hcgo_hum4:*
26: em_hcgo_hum5:*
27: em_hcgo_hum6:*
28: em_hcgo_hum7:*
29: em_hcgo_hum8:*
30: em_hcgo_inv1:*
31: em_hcgo_inv2:*
32: em_hcgo_other:*
33: em_hcgo_rod:*
34: em_hum1:*
35: em_hum2:*
36: em_hum3:*
37: em_hum4:*
38: em_hum5:*
39: em_hum6:*
40: em_hum7:*
41: em_in:*
42: em_om:*
43: em_or:*

44: em_ov:*
45: em_pat:*
46: em_ph:*
47: em_pl:*
48: em_rod:*
49: em_sts:*
50: em_sy:*
51: em_un:*
52: em_v1:*
53: gb_sts1:*
54: gb_sts2:*
55: gb_sts3:*
56: gb_sy:*
57: gb_un:*
58: gb_v11:*
59: gb_v12:*
60: gb_hcgo1:*
61: gb_hcgo2:*
62: gb_hcgo3:*
63: gb_hcgo4:*
64: gb_hcgo5:*
65: gb_hcgo6:*
66: gb_hcgo7:*
67: gb_hcgo8:*
68: gb_hcgo9:*
69: gb_hcgo10:*
70: gb_hcgo11:*
71: gb_hcgo12:*
72: gb_hcgo13:*
73: gb_hcgo14:*
74: gb_hcgo15:*
75: gb_hcgo16:*
76: gb_hcgo17:*
77: gb_hcgo18:*
78: gb_hcgo19:*
79: gb_hcgo20:*
80: gb_hcgo21:*
81: gb_hcgo22:*
82: gb_hcgo23:*
83: gb_hcgo24:*
84: gb_hcgo25:*
85: gb_pr1:*
86: gb_pr2:*
87: gb_pr3:*
88: gb_pr4:*
89: gb_pr5:*
90: gb_pr6:*
91: gb_pr7:*
92: gb_pr8:*
93: gb_pr9:*
94: gb_pr10:*
95: gb_pr11:*
96: gb_pr12:*
97: gb_pr13:*
98: em_ba3:*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	18	62.1	209	10	182323 Sequence 8
2	18	62.1	292	54	G06364 human STS W
3	18	62.1	664	7	MAU79187
4	18	62.1	689	9	A17717 plasmid pnc
5	18	62.1	698	9	A02159 Synthetic g
6	18	62.1	698	9	A04681 Synthetic g
7	18	62.1	698	9	A14089 Synthetic D
8	18	62.1	722	10	I03416 Sequence 2

```

9      18      62.1      730      91      GIBL12      K03174 Ape (gibbon
10     18      62.1      740      95      RATL12      M22899 Rat interle
11     18      62.1      750      10      I01391      M12791 Sequence 3
12     18      62.1      764      7      BOVL12      E01460 Bovine inte
13     18      62.1      769      10      E01460      E02201 DNA encodi
14     18      62.1      769      10      E02201      U28141 Canis faml1
15     18      62.1      773      7      CRTL2A      L19402 Felis catu
16     18      62.1      779      7      CRTL2A      A06879 Artificial
17     18      62.1      782      10      I01101      A14095 Synthetic D
18     18      62.1      784      9      A14095      A17732 Plasmid pTG
19     18      62.1      784      9      A17732      E00250 DNA coding
20     18      62.1      784      10      E00250      I08366 Sequence 2
21     18      62.1      784      10      E00250      I07944 Sequence 1
22     18      62.1      788      10      I07944      I04498 Sequence 1
23     18      62.1      790      10      I04498      I08377 Sequence 1
24     18      62.1      790      10      I08377      A1007463 Meleagris
25     18      62.1      791      8      MGA7463      E00210 CDNA encodi
26     18      62.1      791      8      MGA7463      E00211 CDNA encodi
27     18      62.1      794      10      E00211      E00215 CDNA encodi
28     18      62.1      794      10      E00215      E02011 CDNA encodi
29     18      62.1      794      10      E02011      E02018 CDNA encodi
30     18      62.1      794      10      E02018      E00214 CDNA encodi
31     18      62.1      795      10      E00214      E00267 DNA sequenc
32     18      62.1      795      10      E00267      E00271 DNA sequenc
33     18      62.1      795      10      E00271      AF033563 Gallus ga
34     18      62.1      798      8      AF033563      AF017645 Gallus ga
35     18      62.1      798      8      AF017645      E59473 Novel cyto
36     18      62.1      800      10      E59473      A04961 Artificial
37     18      62.1      801      9      A04961      A06759 Artificial
38     18      62.1      801      9      A06759      E00336 Human Inter
39     18      62.1      801      10      E00336      I01197 Sequence 1
40     18      62.1      801      10      I01197      I04318 Sequence 3
41     18      62.1      801      10      I04318      V00564 Human mRNA
42     18      62.1      801      93      HSL02      E00978 CDNA sequen
43     18      62.1      810      10      E00978      I01387 Sequence 1
44     18      62.1      810      10      I01387
45     18      62.1      810      10      I01387

```

ALIGNMENTS

```

RESULT 1
LOCUS 182323 209 bp DNA
DEFINITION Sequence 8 from patent US 5712126.
ACCESSION 182323
VERSION 182323.1 GI:3210620
KEYWORDS
SOURCE
ORIGIN
ORGANISM
REFERENCE
1 (bases 1 to 209)
AUTHORS
Weissman,S.M. and Prashar,Y.
TITLE
Analysis of gene expression by display of 3-end restriction
fragments of cDNA
JOURNAL
Patent: US 5712126-A 8 27-JAN-1998;
FEATURES
source
1..209
location/Qualifiers
BASE COUNT 56 a 30 c 33 g 90 t
ORIGIN

```

```

Query Match 62.1%; Score 18; DB 10; Length 209;
Best Local Similarity 54.2%; Pred. NO. 1.5;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
OY 4 gauncununguaagcccnang 27
||:|::|:|:|:|:|:|:|:|
Db 36 GATCTTTTGTAAAGCCCTAGGG 59

```

```

RESULT 2
LOCUS G06364 292 bp DNA
DEFINITION human STS WI-7035.
ACCESSION G06364
VERSION G06364.1 GI:859609
KEYWORDS
SOURCE
human STS derived from sequences in dbEST and the Unigene
collection.
ORGANISM
Homo sapiens
Eukaryota; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Gnathostomata; Osteichthyes; Sarcopterygii; Chonata;
Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Archonta; Primates;
Carnivora; Hominoidea; Hominidae; Homo.
REFERENCE
1 (bases 1 to 292)
AUTHORS
Hudson,T.
TITLE
Whitehead Institute/MIT Center for Genome Research; Physically
Mapped ESTs
JOURNAL
Unpublished (1995)
COMMENT
Contact: Thomas Hudson
Whitehead Institute/MIT Center for Genome Research
Whitehead Institute for Biomedical Research
9 Cambridge Center, Cambridge MA 02142 USA
Tel: 617 252 1900
Fax: 617 252 1902
Email: thudson@genome.wi.mit.edu
Primer A: TAATTAGTGTCTCCACCTTAAC
Primer B: ATTTCGATTAATTAAGTGAACCA
STS size: 200
PCR Profile:
Denaturation:
Annealing: 56 degrees C
Polymerization:
PCR Cycles: 35
Thermal Cycler:
Protocol:
Template: 10 ng
Primer: each 5 pm
dNTPs: each 4 mM
Tag Polymerase: 0.025 units/ul
Total Vol: 20 ul
Buffer:
MgCl2: 1.5 mM
KCl: 50 mM
Tris-HCL: 10 mM
pH: 9.3

```

```

FEATURES
source
1..292
location/Qualifiers
STS
primer_bind 1..25
complement(176..200)
BASE COUNT 92 a 32 c 32 g 124 t 12 others
ORIGIN

```

```

Query Match 62.1%; Score 18; DB 54; Length 292;
Best Local Similarity 54.2%; Pred. NO. 1.6;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
OY 4 gauncununguaagcccnang 27
||:|::|:|:|:|:|:|:|:|
Db 144 GATCTTTTGTAAAGCCCTAGGG 167

```

```

RESULT 3
MAU79187

```


Tue Oct 2 09:31:40 2001

LOCUS MAU79187 664 bp mRNA MAM 03-APR-1998
 DEFINITION Mirounga angustirostris interleukin 2 precursor mRNA, complete cds.
 ACCESSION U79187
 VERSION U79187.1 GI:3015531
 KEYWORDS
 SOURCE northern elephant seal.
 ORGANISM Mirounga angustirostris
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Carnivora; Pinnipedia; Phocidae; Mirounga.

REFERENCE
 AUTHORS Shoda, L.K.M., Brown, W.C. and Rice-Ficht, A.C.
 TITLE Sequence and characterization of phocine interleukin 2
 JOURNAL J. Wildl. Dis. 34 (1), 81-90 (1998)
 MEDLINE 98136706
 REFERENCE 2 (bases 1 to 664)
 AUTHORS Shoda, L.K.M., Brown, W.C. and Rice-Ficht, A.C.
 TITLE Direct Submission
 JOURNAL Submitted (22-NOV-1996) Veterinary Microbiology & Pathology,
 Washington State University, P.O. Box 647040, Pullman, WA
 99164-7040, USA

FEATURES
 source Location/Qualifiers
 1..664
 /organism="Mirounga angustirostris"
 /db_xref="taxon:9716"
 24..83
 sig_peptide
 CDS 24..488
 /codon_start=1
 /product="interleukin 2 precursor"
 /protein_id="AAC12258.1"
 /db_xref="GI:3015532"
 /translation="MCKKQLSLSCIALSLVANSAPPTSSSTKETOOLLEQLLDRLRL
 LNVANNEDPKLSRLMTFRFYVPRKATLTHQCAEELKPLEEVLVLAOSKPFHLTD
 IKELMSNINVTILKIKGSETRKCEYDEDTAITEFLNMWIFCOISIFSLT"
 mat_peptide 84..485
 /product="interleukin 2"
 BASE COUNT 219 a 131 c 106 g 208 t
 ORIGIN

Query Match 62.1%; Score 18; DB 7; Length 664;
 Best Local Similarity 54.2%; Pred. No. 1.9;
 Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncuununguaagccnang 27
 ||::: ||||| |||
 Db 635 GATTCTTTTGTAAAGCCTAAGCG 658

LOCUS A17717 689 bp mRNA PAT 17-MAY-1994
 DEFINITION Plasmid pTG 26 mRNA for human IL-2.
 ACCESSION A17717
 VERSION A17717.1 GI:513949
 KEYWORDS
 SOURCE unidentified.
 ORGANISM unidentified
 plasmid unidentified
 unclassified.
 1 (bases 1 to 689)
 REFERENCE Kieny, M.P., Sondemeyer, P. and Lecocq, J.P.
 AUTHORS Expression of human IL-2 in mammalian cells by a recombined pox
 TITLE virus
 JOURNAL Patent: EP 0206939-A 1 30-DEC-1986;
 TRANSGENE S.A
 FEATURES
 source Location/Qualifiers
 1..689
 /organism="unidentified"
 /plasmid="pTG26"
 /db_xref="taxon:32644"
 1..384
 CDS /partial
 /codon_start=1
 /product="human interleukin 2"

/protein_id="CAA01347.1"
 /db_xref="GI:513950"
 /translation="TKKTOLEPHLLDQMLINGINNYKNKRLRMKLFKRYMPKKA
 TELKHQCLEBEIKPLEEVLVLAOSKPFHLRPRDLISNINVTIVLELKGSETTFMCEYA
 DETATVEFLNMWIFCOISISTLT"

BASE COUNT 251 a 117 c 99 g 222 t
 ORIGIN

Query Match 62.1%; Score 18; DB 9; Length 689;
 Best Local Similarity 54.2%; Pred. No. 1.9;
 Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncuununguaagccnang 27
 ||:||||| |||
 Db 528 GATTCTTTTGTAAAGCCTAAGCG 551

RESULT 5
 LOCUS A02159 698 bp DNA PAT 21-MAY-1993
 DEFINITION Synthetic gene for interleukin 2 (IL-2) (partial).
 ACCESSION A02159
 VERSION A02159.1 GI:412310
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM synthetic construct.
 REFERENCE 1 (bases 1 to 698)
 AUTHORS
 TITLE VECTOR FOR THE EXPRESSION IN YEASTS OF INTERLEUKINE-2,
 YEASTS AND METHOD FOR PREPARING INTERLEUKINE-2
 JOURNAL Patent: WO 8503723-A 6 29-AUG-1985;
 FEATURES
 source Location/Qualifiers
 1..698
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 10..393
 CDS /partial
 /codon_start=1
 /transl_table=11
 /product="interleukin 2 (IL-2)"
 /protein_id="CAA00227.1"
 /db_xref="GI:412311"
 /translation="TKKTOLEPHLLDQMLINGINNYKNKRLRMKLFKRYMPKKA
 TELKHQCLEBEIKPLEEVLVLAOSKPFHLRPRDLISNINVTIVLELKGSETTFMCEYA
 DETATVEFLNMWIFCOISISTLT"

BASE COUNT 251 a 117 c 107 g 222 t
 ORIGIN

Query Match 62.1%; Score 18; DB 9; Length 698;
 Best Local Similarity 54.2%; Pred. No. 1.9;
 Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncuununguaagccnang 27
 ||:||||| |||
 Db 537 GATTCTTTTGTAAAGCCTAAGCG 560

RESULT 6
 LOCUS A04681 698 bp DNA PAT 24-MAY-1993
 DEFINITION Synthetic gene for interleukin 2 (IL-2) (partial).
 ACCESSION A04681
 VERSION A04681.1 GI:412434
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM synthetic construct.
 REFERENCE 1 (bases 1 to 698)
 AUTHORS Lemoine, Y., Sondemeyer, P., Loison, G., Aigle, M. and Lecocq, J.P.
 TITLE Yeast-expression vectors for interleukin-2, transformed yeasts and

Process for the preparation of interleukin-2
Patent: EP 0152358-A 5 21-AUG-1985;
TRANSGENE S.A

FEATURES
SOURCE
Location/Qualifiers
1..698
/organism="synthetic construct"
/db_xref="taxon:32630"

CDS
10..393
/partial
/codon_start=1
/transl_table=1
/product="interleukin 2 (IL-2)"
/protein_id="CAA00377.1"
/db_xref="GI:412435"

/translation="TKKTQQLQLEHLIDLMILNINNYKPKLTRMLTFEYFYPKKA
TELKHLQCLEELKPLEEVNLAKSKNFHRLPRDLISINIVIVLELKGSETFMCEVA
DETATVEFLNRWTFPCOSIISTLT"

BASE COUNT 251 a 118 c 106 g 222 t 1 others
ORIGIN

Query Match 62.1%; Score 18; DB 9; Length 698;
Best Local Similarity 54.2%; Pred. No. 1.9;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncununguaagccnangng 27
||:|:::|:||||| | | |
Db 537 GATCTTTTGTAAAGCCTAGGGG 560

RESULT 7
A14089
LOCUS A14089 698 bp DNA PAT 28-FEB-1994
DEFINITION Synthetic DNA (PTG26) for human interleukin-2 (partial).
ACCESSION A14089
VERSION A14089.1 GI:491760
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 698)
AUTHORS
TITLE EXPRESSION OF HUMAN IL-2 IN MAMMAL CELLS BY MEANS OF A RECOMBINED
JOURNAL
FEATURES
source
1..698
/organism="synthetic construct"
/db_xref="taxon:32630"

CDS
10..393
/partial
/codon_start=1
/transl_table=1
/product="interleukin 2"
/protein_id="CAA01145.1"
/db_xref="GI:491761"

/translation="TKKTQQLQLEHLIDLMILNINNYKPKLTRMLTFEYFYPKKA
TELKHLQCLEELKPLEEVNLAKSKNFHRLPRDLISINIVIVLELKGSETFMCEVA
DETATVEFLNRWTFPCOSIISTLT"

BASE COUNT 251 a 117 c 108 g 222 t
ORIGIN

Query Match 62.1%; Score 18; DB 9; Length 698;
Best Local Similarity 54.2%; Pred. No. 1.9;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncununguaagccnangng 27
||:|:::|:||||| | | |
Db 537 GATCTTTTGTAAAGCCTAGGGG 560

RESULT 8

103416
LOCUS 103416 722 bp ss-DNA PAT 21-MAY-1993
DEFINITION Sequence 2 from Patent US 4882282.
ACCESSION 103416
VERSION 103416.1 GI:270625
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 722)
AUTHORS Anderson,D.M., Baker,P.E., Cantrell,M.A., Cerretti,D.P.,
Cosman,D.J., Gimpel,S.D., Grabstein,K.H., Larsen,A.D. and
McKereghan,K.N.
TITLE DNA sequences encoding bovine interleukin-2
JOURNAL Patent: US 4882282-A 2 21-NOV-1989;
Immunex Corporation;
Seattle, WA

FEATURES
source
Location/Qualifiers
1..722
/organism="unknown"

BASE COUNT 245 a 130 c 112 g 235 t
ORIGIN

Query Match 62.1%; Score 18; DB 10; Length 722;
Best Local Similarity 54.2%; Pred. No. 1.9;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncununguaagccnangng 27
||:|:::|:||||| | | |
Db 613 GATCTTTTGTAAAGCCTAGGGG 636

RESULT 9
GIBL2
LOCUS GIBL2 730 bp mRNA PRI 27-APR-1993
DEFINITION Ape (gibbon) interleukin 2 mRNA.
ACCESSION K03174
VERSION K03174.1 GI:177012
KEYWORDS interleukin; interleukin 2.
SOURCE Gibbon ('normal gibbon'), cDNA to mRNA, clone CM11.
ORGANISM Hylobates lar
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hylobatidae; Hylobates.

REFERENCE 1 (bases 1 to 730)
AUTHORS Chen,S.J., Holbrook,N.J., Mitchell,K.F., Vallone,C.A.,
Greengard,J.S., Crabtree,G.R. and Lin,Y.
TITLE A viral long terminal repeat in the interleukin 2 gene of a cell
line that constitutively produces interleukin 2
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 82, 7284-7288 (1985)
COMMENT [1] also sequenced the IL-2 mRNA from gibbon cell line MLA 144 (see
separate entry).

FEATURES
source
Location/Qualifiers
1..730
/organism="Hylobates lar"
/db_xref="taxon:9580"

MRNA
CDS
25..486
/note="IL-2 mRNA"
/codon_start=1
/product="interleukin-2"
/protein_id="AAA35453.1"

/db_xref="GI:177013"
/translation="MYRMQLSCIALSLAVTNSPTSSSTKKTQLQLEHLIDLMILNINNYKPKLTRMLTFEYFYPKKA
TELKHLQCLEELKPLEEVNLAKSKNFHRLPRDLISINIVIVLELKGSETFMCEVADETATVEFLNRWTFPCOSIISTLT"

variation
BASE COUNT 247 a 138 c 110 g 235 t
ORIGIN 180 bp upstream of HinfI site.

Query Match 62.1%; Score 18; DB 91; Length 730;
 Best Local Similarity 54.2%; Pred. No. 1.9;
 Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncuununguaagcccnangng 27
 ||:|::|:||||| | | |
 Db 630 GATTCCTTTTGTAAAGCCCTAGGGG 653

RESULT 10

LOCUS RATTIL2 740 bp mRNA ROD 27-APR-1993
 DEFINITION Rat interleukin 2 mRNA, complete cds.
 ACCESSION M22899
 VERSION M22899.1 GI:204909
 KEYWORDS Interleukin 2
 SOURCE Rat activated T-lymphocytes, cDNA to mRNA, clone pIL-2.8.
 ORGANISM Rattus norvegicus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
 Rattus.

REFERENCE 1 (bases 1 to 740)
 McKnight,A.J., Mason,D.W. and Barclay,A.N.
 Sequence of rat interleukin 2 and anomalous binding of a mouse
 interleukin 2 cDNA probe to rat MHC class II-associated invariant
 chain mRNA

JOURNAL Immunogenetics 30, 145-147 (1989)

COMMENT Draft entry and computer-readable sequence for [1] kindly submitted
 by A.J. McKnight, 08-MAR-1989.

FEATURES

source 1..740
 /organism="Rattus norvegicus"
 /db_xref="taxon:10116"
 15..482
 /note="interleukin 2 precursor"
 /codon_start=1
 /protein_id="AA41427.1"
 /db_xref="GI:204909"
 /translation="MYSMLACVVALTVLVNSAPTSSPAKTOOHLLEQLLDLOVL
 LKGINVKNLKLPMULTEFYLPKQATEFKLQCLLENELGALQVLDITQSSPHLED
 AGNFISNIRVYVTLKSGSEKFECDPEDPATVVEFLRMVAICOSIISTMTQ"
 15..74
 /note="interleukin 2 signal peptide"
 75..479
 /note="interleukin 2"
 713..718
 /note="putative"
 polyA_signal /note="putative"
 141 c 143 g 228 t

BASE COUNT 228 a 141 c 143 g 228 t
 ORIGIN

Query Match 62.1%; Score 18; DB 95; Length 740;
 Best Local Similarity 54.2%; Pred. No. 1.9;
 Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncuununguaagcccnangng 27
 ||:|::|:||||| | | |
 Db 615 GATTCCTTTTGTAAAGCCCAAGGG 638

RESULT 11

LOCUS I01391 750 bp ss-DNA PAT 21-MAY-1993
 DEFINITION Sequence 3 from Patent US 4851512.
 ACCESSION I01391
 VERSION I01391.1 GI:270228

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 750)
 AUTHORS Miyaji,H. and Itoh,S.

TITLE Novel human interleukin-2 polypeptide derivative
 JOURNAL Patent: US 4851512-A 3 25-JUL-1989;
 Kyowa Hakko Kogyo Co., Ltd.;
 Tokyo, Jp;

FEATURES
 source Location/Qualifiers
 1..750
 /organism="unknown"

BASE COUNT 276 a 131 c 104 g 239 t
 ORIGIN

Query Match 62.1%; Score 18; DB 10; Length 750;
 Best Local Similarity 54.2%; Pred. No. 1.9;
 Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncuununguaagcccnangng 27
 ||:|::|:||||| | | |
 Db 591 GATTCCTTTTGTAAAGCCCTAGGGG 614

RESULT 12

LOCUS BOVIL2 764 bp mRNA MAM 27-APR-1993
 DEFINITION Bovine interleukin 2 (IL-2) mRNA, complete cds.
 ACCESSION M12791
 VERSION M12791.1 GI:163204
 KEYWORDS Interleukin 2.
 SOURCE Bovine lymph node, cDNA to mRNA, clone pIL-2-4.
 ORGANISM Bos taurus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 Bovidae; Bovinae; Bos.

REFERENCE 1 (bases 1 to 764)
 Cerretti,D.P., McKereghan,K., Larsen,A., Cantrell,M.A.,
 Anderson,D., Gillis,S., Cosman,D. and Baker,P.E.
 Cloning, sequence, and expression of bovine interleukin 2
 Proc. Natl. Acad. Sci. U.S.A. 83, 3223-3227 (1986)

COMMENT Draft entry and clean copy sequence for [1] kindly provided by
 D.Cerretti, 12-AUG-1986.

There is probably only one copy of the interleukin 2 gene in the
 bovine genome.

FEATURES
 source Location/Qualifiers
 1..764
 /organism="Bos taurus"
 /db_xref="taxon:9913"
 /tissue_type="lymph"
 <1..764
 /gene="IL-2"
 1..764
 /gene="IL-2"
 18..77
 /gene="IL-2"
 18..485
 /gene="IL-2"
 /note="prepeptide"
 /codon_start=1
 /product="interleukin 2"
 /protein_id="AAA30586.1"
 /db_xref="GI:163205"
 /translation="MYKIQLSCIALVTLAVNGAPTSSSGTGMKEVSKLLDLOVL
 LEKVNPEMLKLSRMHTDPFYKVNAPTEIKLKLLPEIKLLEFVLNAPSKNLNPR
 EIKDSMDNIRIVLELQSGSEFTCEYDDATVNAVDFLNKMTTFQCSISTYMT"

gene 1..764
 /gene="IL-2"
 18..77
 /gene="IL-2"
 18..485
 /gene="IL-2"
 /note="prepeptide"
 /codon_start=1
 /product="interleukin 2"
 /protein_id="AAA30586.1"
 /db_xref="GI:163205"
 /translation="MYKIQLSCIALVTLAVNGAPTSSSGTGMKEVSKLLDLOVL
 LEKVNPEMLKLSRMHTDPFYKVNAPTEIKLKLLPEIKLLEFVLNAPSKNLNPR
 EIKDSMDNIRIVLELQSGSEFTCEYDDATVNAVDFLNKMTTFQCSISTYMT"

sig_peptide 18..77
 /gene="IL-2"
 18..485
 /gene="IL-2"
 /note="prepeptide"
 /codon_start=1
 /product="interleukin 2"
 /protein_id="AAA30586.1"
 /db_xref="GI:163205"
 /translation="MYKIQLSCIALVTLAVNGAPTSSSGTGMKEVSKLLDLOVL
 LEKVNPEMLKLSRMHTDPFYKVNAPTEIKLKLLPEIKLLEFVLNAPSKNLNPR
 EIKDSMDNIRIVLELQSGSEFTCEYDDATVNAVDFLNKMTTFQCSISTYMT"

mat_peptide 78..482
 /gene="IL-2"
 /product="interleukin 2"
 133 c 123 g 251 t

BASE COUNT 257 a 133 c 123 g 251 t
 ORIGIN 80 bp upstream of HglaI site.

Query Match 62.1%; Score 18; DB 7; Length 764;
 Best Local Similarity 54.2%; Pred. No. 1.9;

Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncununguaagcccnangng 27
||:|::|:||||| | | |
Db 622 GATCTTTTGTAAAGCCCTAGCGG 645

RESULT 13
E01460 769 bp RNA PAT 29-SEP-1997
LOCUS DEFINITION CDNA encoding human interleukin 2.
ACCESSION E01460
VERSION E01460.1 GI:2169716
KEYWORDS JP 1987265992-A/1.
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 769)
AUTHORS Onomichi, K., Eto, Y. and Shibai, H.
TITLE PRODUCTION OF VALUABLE SUBSTANCE USING HUMAN CELL
JOURNAL Patent: JP 1987265992-A 1 18-NOV-1987;
AJINOMOTO CO INC

COMMENT OS Human
PN JP 1987265992-A/1
PD 18-NOV-1987
PF 12-MAY-1986 JP 1986107981
PI ONOMICHI KAZUYA, ETO YUZURU, SHIBAI HIROSHIRO PC
C12P21/00,C12N15/00,C12P21/02,(C12P21/02,C12R1:91); CC
strandedness: Double;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
CC *source: clone-PSDI;
FH Key Location/Qualifiers
FT 5'UTR 1..2
FT CDS 3..507
FT 3'UTR /product='human interleukin 2' FT 3'UTR
FT 508..814
FT mat_peptide 3..504
FT /product='human interleukin 2'.
FEATURES
source Location/Qualifiers
1..769
/organism='Homo sapiens'
/db_xref='taxon:9606'
BASE COUNT 280 a 132 c 112 g 245 t
ORIGIN

Query Match 62.1%; Score 18; DB 10; Length 769;
Best Local Similarity 54.2%; Pred. No. 1.9;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncununguaagcccnangng 27
||:|::|:||||| | | |
Db 608 GATCTTTTGTAAAGCCCTAGCGG 631

RESULT 14
E02201 769 bp RNA PAT 29-SEP-1997
LOCUS DEFINITION DNA encoding interleukin2 (IL-2).
ACCESSION E02201
VERSION E02201.1 GI:2170439
KEYWORDS JP 1990009388-A/2.
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 769)
AUTHORS Murata, M., Eto, Y. and Shibai, H.
TITLE PRODUCTION OF PHYSIOLOGICALLY ACTIVE PROTEIN

JOURNAL Patent: JP 1990009388-A 2 12-JAN-1990;
AJINOMOTO CO INC

COMMENT OS Homo sapiens
PN JP 1990009388-A/2
PD 08-JUL-1990
PF 12-JAN-1990 JP 1988170142
PR 09-MAR-1988 JP 88P 55270
PI MURATA MASAHIRO, ETO YUZURU, SHIBAI HIROSHIRO PC
C12P21/00,C12N15/12,C12N15/26,C12P21/02,(C12P21/02,C12R1:91); CC
strandedness: Double;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
CC *source: library-PSD(I)/IL-2;
CC Feature is identified by experimental;
FH Key Location/Qualifiers
FT 5'UTR 1..2
FT CDS 3..464
FT /product='interleukin2'
FT /note='IL-2'
FT mat_peptide 3..461
FT /product='interleukin2'
FT /note='IL-2'
FT 465..769.
FEATURES
source Location/Qualifiers
1..769
/organism='Homo sapiens'
/db_xref='taxon:9606'
BASE COUNT 280 a 132 c 112 g 245 t
ORIGIN

Query Match 62.1%; Score 18; DB 10; Length 769;
Best Local Similarity 54.2%; Pred. No. 1.9;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncununguaagcccnangng 27
||:|::|:||||| | | |
Db 608 GATCTTTTGTAAAGCCCTAGCGG 631

RESULT 15
CFU28141 773 bp mRNA MAM 29-JUN-1995
LOCUS DEFINITION Canis familiaris interleukin-2 mRNA, complete cds.
ACCESSION U28141
VERSION U28141.1 GI:881935
KEYWORDS
SOURCE dog.
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE 1 (bases 1 to 773)
AUTHORS Somberg, R.L., Tipold, A., Henthorn, P.S. and Felsburg, P.J.
JOURNAL Unpublished
2 (bases 1 to 773)
SOMBERG, R.L.
Direct Submission
Submitted (31-MAY-1995) Richard L. Somberg, Clinical Studies, PA
University of Pennsylvania, 3850 Spruce Street, Philadelphia, PA
19104, USA

FEATURES
source Location/Qualifiers
1..773
/organism='Canis familiaris'
/db_xref='taxon:9615'
39..506
/codon_start=1
/product='interleukin-2'
/protein_id='AA68969.1'
/db_xref='GI:881936'
/translation='MYKQLISCIATLTVLVANSAPITSSSTETEDQOMQLDLIDQL
LNGVNVENPQLSRMLTFKFKYPPKATFTTHLQCLAEELKNEEVLGLPQSKNVHLT

polyA_site 773
 BASE COUNT 265 a 145 c 118 g 245 t
 ORIGIN

Query Match 62.1%; Score 18; DB 7; Length 773;
 Best Local Similarity 54.2%; Pred. No. 1.9;
 Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

Qy 4 gauncuununguaagccnangng 27
 ||:|::|:||||| | | |
 Db 643 GATTCTTTTGTAAAGCCCTAGGCG 666

Search completed: October 2, 2001, 05:00:40
 Job time: 5327 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 04:00:28 ; Search time 122.48 Seconds
(without alignments)
148.670 Million cell updates/sec

Title: US-09-310-844B-23

Perfect score: 29

Sequence: 1 nngauncuununguaagcccnangnngn 29

Scoring table: IDENTITY-NUC

Gapop 10.0 , Gapext 1.0

Searched: 730101 seqs, 313950809 residues 1460202

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N.Geneseq_0601.*
1: /SIDSI/gcgdata/geneseq/geneseq/NA1980.DAT:*
2: /SIDSI/gcgdata/geneseq/geneseq/NA1981.DAT:*
3: /SIDSI/gcgdata/geneseq/geneseq/NA1982.DAT:*
4: /SIDSI/gcgdata/geneseq/geneseq/NA1983.DAT:*
5: /SIDSI/gcgdata/geneseq/geneseq/NA1984.DAT:*
6: /SIDSI/gcgdata/geneseq/geneseq/NA1985.DAT:*
7: /SIDSI/gcgdata/geneseq/geneseq/NA1986.DAT:*
8: /SIDSI/gcgdata/geneseq/geneseq/NA1987.DAT:*
9: /SIDSI/gcgdata/geneseq/geneseq/NA1988.DAT:*
10: /SIDSI/gcgdata/geneseq/geneseq/NA1989.DAT:*
11: /SIDSI/gcgdata/geneseq/geneseq/NA1990.DAT:*
12: /SIDSI/gcgdata/geneseq/geneseq/NA1991.DAT:*
13: /SIDSI/gcgdata/geneseq/geneseq/NA1992.DAT:*
14: /SIDSI/gcgdata/geneseq/geneseq/NA1993.DAT:*
15: /SIDSI/gcgdata/geneseq/geneseq/NA1994.DAT:*
16: /SIDSI/gcgdata/geneseq/geneseq/NA1995.DAT:*
17: /SIDSI/gcgdata/geneseq/geneseq/NA1996.DAT:*
18: /SIDSI/gcgdata/geneseq/geneseq/NA1997.DAT:*
19: /SIDSI/gcgdata/geneseq/geneseq/NA1998.DAT:*
20: /SIDSI/gcgdata/geneseq/geneseq/NA1999.DAT:*
21: /SIDSI/gcgdata/geneseq/geneseq/NA2000.DAT:*
22: /SIDSI/gcgdata/geneseq/geneseq/NA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	18	62.1	29	21	AAA70827
2	18	62.1	29	21	AAA70828
3	18	62.1	29	21	AAA70829
4	18	62.1	29	21	AAA70830
5	18	62.1	42	21	AAA71113
6	18	62.1	42	21	AAA71114
7	18	62.1	42	21	AAA71115
8	18	62.1	42	21	AAA71116
9	18	62.1	42	21	AAA71118
10	18	62.1	42	21	AAA71119
11	18	62.1	42	21	AAA71120

12	18	62.1	42	21	AAA71121	Molecular interact
13	18	62.1	42	21	AAA71123	Molecular interact
14	18	62.1	42	21	AAA71124	Molecular interact
15	18	62.1	42	21	AAA71126	Molecular interact
16	18	62.1	42	21	AAA71127	Molecular interact
17	18	62.1	42	21	AAA71128	Molecular interact
18	18	62.1	42	21	AAA71129	Molecular interact
19	18	62.1	42	21	AAA71131	Molecular interact
20	18	62.1	42	21	AAA71132	Molecular interact
21	18	62.1	44	21	AAA71112	Molecular interact
22	18	62.1	44	21	AAA71125	Molecular interact
23	18	62.1	44	21	AAA71133	Molecular interact
24	18	62.1	45	21	AAA70824	Molecular interact
25	18	62.1	45	21	AAA70825	Molecular interact
26	18	62.1	45	21	AAA70826	Molecular interact
27	18	62.1	46	21	AAA71085	Molecular interact
28	18	62.1	46	21	AAA71087	Molecular interact
29	18	62.1	46	21	AAA71088	Molecular interact
30	18	62.1	46	21	AAA71089	Molecular interact
31	18	62.1	46	21	AAA71090	Molecular interact
32	18	62.1	46	21	AAA71093	Molecular interact
33	18	62.1	46	21	AAA71094	Molecular interact
34	18	62.1	46	21	AAA71095	Molecular interact
35	18	62.1	46	21	AAA71096	Molecular interact
36	18	62.1	46	21	AAA71099	Molecular interact
37	18	62.1	46	21	AAA71100	Molecular interact
38	18	62.1	46	21	AAA71103	Molecular interact
39	18	62.1	46	21	AAA71104	Molecular interact
40	18	62.1	46	21	AAA71105	Molecular interact
41	18	62.1	46	21	AAA71106	Molecular interact
42	18	62.1	46	21	AAA71107	Molecular interact
43	18	62.1	46	21	AAA71109	Molecular interact
44	18	62.1	46	21	AAA71110	Molecular interact
45	18	62.1	46	21	AAA71111	Molecular interact

ALIGNMENTS

RESULT 1
ID AAA70827 standard; RNA: 29 BP.
AC AAA70827;
XX
XX 27-APR-2001 (first entry)
XX
XX Molecular interaction site RNA #27.
XX
XX Modulator; identification; molecular interaction; virtual library; ss.
XX
XX Synthetic.
XX
XX WO9958947-A2.
XX
XX 18-NOV-1999.
XX
XX 12-MAY-1999; 99WO-US10361.
XX
XX 12-MAY-1998; 98US-0076404.
XX
XX 12-MAY-1998; 98US-0085092.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Eckert DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX Hofstadler S, McNeil J;
XX WPI: 2000-086439/07.
XX
XX Identifying compounds which modulate activity of target biomolecules,
XX used to provide compounds which can be used as pharmacological,
XX agricultural and industrial compounds -

PS Claim 235; Page 235; 405pp; English.

XX This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACAUACUAGUUGUACGAAAUAC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

CC Sequence 29 BP; 4 A; 4 C; 5 G; 5 U; 11 other;

Query Match 62.1%; Score 18; DB 21; Length 29;

Best Local Similarity 100.0%; Pred. No. 0.35;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4 gauncuuunuaagcccnangng 27

||||| ||||||| |||||||

Db 4 gauncuuunuaagcccnangng 27

RESULT 2

AAA70828

ID AAA70828 standard; RNA; 29 BP.

XX AAA70828;

AC 27-APR-2001 (first entry)

DT 27-APR-2001 (first entry)

XX Molecular interaction site RNA #28.

DE Modulator: identification; molecular interaction; virtual library; ss.

XX Homo sapiens.

OS MO9958947-A2.

XX 18-NOV-1999.

PD 12-MAY-1999; 99WO-US10361.

XX 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hotstadler S, McNeil J;

PI WPI; 2000-086439/07.

DR Identifying compounds which modulate activity of target biomolecules,

XX used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -

XX

PS Claim 235; Page 235; 405pp; English.

XX This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACAUACUAGUUGUACGAAAUAC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

CC Sequence 29 BP; 5 A; 5 C; 7 G; 12 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 29;

Best Local Similarity 75.0%; Pred. No. 0.35;

Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncuuunuaagcccnangng 27

||||| ||||||| |||

Db 4 gauncuuunuaagcccnangng 27

RESULT 3

AAA70829

ID AAA70829 standard; RNA; 29 BP.

XX AAA70829;

AC 27-APR-2001 (first entry)

DT 27-APR-2001 (first entry)

XX Molecular interaction site RNA #29.

DE Modulator: identification; molecular interaction; virtual library; ss.

XX Mus sp.

OS MO9958947-A2.

XX 18-NOV-1999.

PD 12-MAY-1999; 99WO-US10361.

XX 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

PA Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hotstadler S, McNeil J;

PI WPI; 2000-086439/07.

DR Identifying compounds which modulate activity of target biomolecules,

XX used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -

XX

PS Claim 235; Page 235; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUAAUUCUUGUACACAAAUAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
SQ Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 29;
Best Local Similarity 75.0%; Pred. No. 0.35;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 4 gauncuununguagcccnang 27
||| |||| ||||| |||
DB 4 gauncuununguagcccaagg 27

RESULT 4
AAA70830
ID AAA70830 standard; RNA: 29 BP.
XX
AC AAA70830;
XX
DT 27-APR-2001 (first entry)
XX
Molecular interaction site RNA #30.

Modulator; Identification; molecular interaction; virtual library; ss.
OS Ratus sp.
XX
PN WO9558947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hostadler S, McNeil J;
DR WPI: 2000-086439/07.

Identifying compounds which modulate activity of target biomolecules,
used to provide compounds which can be used as pharmacological,
agricultural and industrial compounds -

PS Claim 235; Page 235; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUAAUUCUUGUACACAAAUAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
SQ Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 29;
Best Local Similarity 75.0%; Pred. No. 0.35;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 4 gauncuununguagcccnang 27
||| |||| ||||| |||
DB 4 gauncuununguagcccaagg 27

RESULT 5
AAA71113
ID AAA71113 standard; RNA: 42 BP.
XX
AC AAA71113;
XX
DT 27-APR-2001 (first entry)
XX
Molecular interaction site RNA #189.

Modulator; Identification; molecular interaction; virtual library; ss.
OS Unidentified.
XX
PN WO9558947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hostadler S, McNeil J;
DR WPI: 2000-086439/07.

Identifying compounds which modulate activity of target biomolecules,
used to provide compounds which can be used as pharmacological,
agricultural and industrial compounds -

Example 7; Figure 122; 405pp; English.

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating in silico a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of compounds to generate a hierarchy of the compounds ranked in accordance with their respective ability to form physical interactions with the molecular interaction site. The method also describes (1) RNA comprising a joined sequence of at least 24 nucleotides but not more than 70 nucleotides and having secondary structure defined by: (a) 3 nucleotides forming a first side of a first double stranded (ds) region; (b) 2 nucleotides forming a first side of an internal loop region; (c) 4 nucleotides forming a first side of a second ds region; (d) 4 or 5 nucleotides forming an end loop region; (e) 4 nucleotides forming a second side of the second ds region; and (f) 3 nucleotides forming a second side of the internal loop region; and (g) 3 nucleotides forming a second side of the first ds region; (2) a purified and isolated RNA fragment comprising the human sequence UUUACACUUAUUCAGUUNUACGAAAUU (ii). The methods and products can be used for identifying agents which modulate the activity of biomolecules, particularly RNA. Such agents can be used as pharmaceutical, agricultural or industrial compounds.

SQ Sequence 42 BP; 12 A; 7 C; 6 G; 17 U; 0 other;

Query Match	62.1%	Score 18:	DB 21;	Length 42;
Best Local Similarity	75.0%	Pred. NC.	0.37;	
Matches 18;	Conservative 0;	Mismatches 6;	Indels 0;	Gaps 0;

Qy	4	gauncuuuunguaagccccaangng	27
Db	7	gaucuuuuuuguaagccccaaggg	30

RESULT	6
AAA71114	.
ID	AAA71114 standard; RNA; 42 BP.

AC AAA71114

DT 27-APR-2001 (first entry)

DE Molecular interaction site RNA #190.

Modulator; identification; molecular interaction; virtual library; ss.

OS Unidentified.

PN W09958947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999; 99WO-US10361.

PR 12-MAY-1998; 98US-0076404.

XX

XX :

PI Hofstadler S, McNeill J;

DR WPI: 2000-086439/07.

Identifying compounds

PT Identifying compounds which modulate activity of target biomolecules
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
XX

PS Example 7; Figure 122; 405pp; English.

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating in silico a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of compounds to generate a hierarchy of the compounds ranked in accordance with their respective ability to form physical interactions with the molecular interaction site. The method also describes (1) RNA comprising a joined sequence of at least 24 nucleotides but not more than 70 nucleotides and having secondary structure defined by: (a) 3 nucleotides forming a first side of a first double stranded (ds) region; (b) 2 nucleotides forming a first side of an internal loop region; (c) 4 nucleotides forming a first side of a second ds region; (d) 4 or 5 nucleotides forming an end loop region; (e) 4 nucleotides forming a second side of the second ds region; (f) 4 nucleotides forming a second side of the internal loop region; and (g) 3 nucleotides forming a second side of the first ds region; (2) a purified and isolated RNA fragment comprising the human sequence UUUACACUUAUUCAGUUUACGAAAAAU (II). The methods and products can be used for identifying agents which modulate the activity of biomolecules, particularly RNA. Such agents can be used as pharmaceutical, agricultural or industrial compounds.

SQ Sequence 42 BP; 11 A; 8 C; 7 G; 16 U; 0 other;

Query Match	62.1%	Score 18:	DB 21:	Length 42:
Best Local Similarity	75.0%	Pred. No. 0.37:		
Matches 18:	Conservative	0:	Mismatches 6:	Indels 0:
				Gaps 0:

Qy	4	gauncuuuunguaagcccnangng	27
Db	7	gauccuuuunguaagccccaagcg	30

RESULT	7
AAA71115	
ID	AAA71115 standard; RNA; 42 BP.

AC AAA71115

DT 27-APR-2001 (first entry)

DE Molecular interaction site RNA #191

KW Modulator; identification; molecular interaction; virtual library; ss.

OS Unidentified.

PN W09958947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999; 99WO-US10361.

PR 12-MAY-1998; 98US-0076404.

XX

	(F	H	E	A	C)
X		D	O	N	T	S	
X		I	M	P	R	E	

PI	Hofstadler S, McNeil J:
et al	Baker DC, Bailey K, Crooke BT, Sampson R, Swartz E, Monahan V,

AA
DB
WPT: 2000-086439/07

Identifying compounds which m

PT Identifying compounds which modulate activity of target biomolecules
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
XX

PS Example 7; Figure 122; 405bp; English.

XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUUAUCUAGUUACACAAAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

XX
SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 42;

Best Local Similarity 75.0%; Pred. No. 0.37;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncununguaagcccnangng 27
DB 7 gauncununguaagcccaagg 30
||||| ||||| |||

RESULT 8

AAAT1116
ID AAAT1116 standard; RNA; 42 BP.

XX
AC AAAT1116;

XX
DT 27-APR-2001 (first entry)

XX
DE Molecular interaction site RNA #192.

XX
KW Modulator; Identification; molecular interaction; virtual library; ss.

XX
OS Unidentified.

XX
PN WO958947-A2.

XX
PD 18-NOV-1999.

XX
PF 12-MAY-1999; 99WO-US10361.

XX
PR 12-MAY-1998; 98US-0076404.

XX
PR 12-MAY-1998; 98US-0085092.

XX
PA (ISIS-) ISIS PHARM INC.

XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hostadler S, McNeil J;

XX
DR WPI: 2000-086439/07.

XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
XX

PS Example 7; Figure 122; 405bp; English.

XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUUAUCUAGUUACACAAAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

XX
SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 42;

Best Local Similarity 75.0%; Pred. No. 0.37;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncununguaagcccnangng 27
DB 7 gauncununguaagcccaagg 30
||||| ||||| |||

RESULT 9

AAAT1118
ID AAAT1118 standard; DNA; 42 BP.

XX
AC AAAT1118;

XX
DT 27-APR-2001 (first entry)

XX
DE Molecular interaction site DNA #124.

XX
KW Modulator; Identification; molecular interaction; virtual library; ss.

XX
OS Unidentified.

XX
PN WO958947-A2.

XX
PD 18-NOV-1999.

XX
PF 12-MAY-1999; 99WO-US10361.

XX
PR 12-MAY-1998; 98US-0076404.

XX
PR 12-MAY-1998; 98US-0085092.

XX
PA (ISIS-) ISIS PHARM INC.

XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hostadler S, McNeil J;

XX
DR WPI: 2000-086439/07.

XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
XX

PS Example 7; Figure 125; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACUAUACUGUUVUACGAAAAAUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 42 BP; 12 A; 7 C; 6 G; 17 T; 0 other;
XX
Query Match 62.1%; Score 18; DB 21; Length 42;
Best Local Similarity 54.2%; Pred. No. 0.37;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
QY 4 gauncunnnuaagcccnangng 27
||:|::|:||||| | | |
Db 7 gatctttt|gttaagcctaagcg 30
XX
RESULT 10
AAAT71119
ID AAAT71119 standard; DNA; 42 BP.
XX
AC AAAT71119;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site DNA #125.
XX
KW Modulator: identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
OS Unidentified.
XX
PN W09958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
DR WPI: 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
XX

PS Example 7; Figure 125; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACUAUACUGUUVUACGAAAAAUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 42 BP; 11 A; 8 C; 7 G; 16 T; 0 other;
XX
Query Match 62.1%; Score 18; DB 21; Length 42;
Best Local Similarity 54.2%; Pred. No. 0.37;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
QY 4 gauncunnnuaagcccnangng 27
||:|::|:||||| | | |
Db 7 gatctttt|gttaagcctaagcg 30
XX
RESULT 11
AAAT71120
ID AAAT71120 standard; DNA; 42 BP.
XX
AC AAAT71120;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site DNA #126.
XX
KW Modulator: identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
OS Unidentified.
XX
PN W09958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
DR WPI: 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
XX

PS Example 7; Figure 125; 405pp; English.

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACAUAAUCUAGUUACACAAAADC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

CC Sequence 42 BP; 13 A; 7 C; 7 G; 15 T; 0 other;

Query Match

Best Local Similarity 62.1%; Score 18; DB 21; Length 42;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncuununguaagcccnangng 27
||:|::|:||||| | |
DB 7 gattcttttgaagcccaagg 30

RESULT 12

AAA71121
ID AAA71121 standard; DNA; 42 BP.

AC AAA71121;

DT 27-APR-2001 (first entry)

XX Molecular interaction site DNA #127.

XX Modulator; identification; molecular interaction; virtual library; ss.

OS Unidentified.

PN WO9558947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999; 99WO-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

PA (ISIS-) ISIS PHARM INC.

PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

DR Hostadler S, McNeil J;

DR WPI; 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
XX

PS Example 7; Figure 125; 405pp; English.

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACAUAAUCUAGUUACACAAAADC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

CC Sequence 42 BP; 13 A; 7 C; 7 G; 15 T; 0 other;

Query Match

Best Local Similarity 62.1%; Score 18; DB 21; Length 42;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

OY 4 gauncuununguaagcccnangng 27
||:|::|:||||| | |
DB 7 gattcttttgaagcccaagg 30

RESULT 13

AAA71123
ID AAA71123 standard; DNA; 42 BP.

AC AAA71123;

DT 27-APR-2001 (first entry)

XX Molecular interaction site DNA #129.

XX Modulator; identification; molecular interaction; virtual library; ss.

OS Unidentified.

PN WO9558947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999; 99WO-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

PA (ISIS-) ISIS PHARM INC.

PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

DR Hostadler S, McNeil J;

DR WPI; 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
XX

Example 7; Figure 125; 405pp; English.

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACUAUCUUAUCGUAAGAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

Sequence 42 BP; 9 A; 6 C; 9 G; 18 T; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 42;
Best Local Similarity 54.2%; Pred. No. 0.37;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

Oy 4 gauncuununguaagccnang 27
||:|::|:||||| | | |
Db 7 gatcttctgttaagcctaagg 30

RESULT 14

AAA71124
ID AAA71124 standard; DNA; 42 BP.

XX AAA71124;

XX 27-APR-2001 (first entry)

XX Molecular interaction site DNA #130.

XX Modulator: identification; molecular interaction; virtual library; ss.

XX Unidentified.

XX WO958947-A2.

XX 18-NOV-1999.

XX 12-MAY-1999; 99WO-US10361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hotstadler S, McNeill J;

XX WPI: 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,
XX used to provide compounds which can be used as pharmacological,
XX agricultural and industrial compounds -

Example 7; Figure 125; 405pp; English.

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACUAUCUUAUCGUAAGAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

Sequence 42 BP; 11 A; 10 C; 7 G; 14 T; 0 other;

Query Match 62.1%; Score 18; DB 21; Length 42;
Best Local Similarity 54.2%; Pred. No. 0.37;
Matches 13; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

Oy 4 gauncuununguaagccnang 27
||:|::|:||||| | | |
Db 7 gatcttctgttaagcctaagg 30

RESULT 15

AAA71126
ID AAA71126 standard; RNA; 42 BP.

XX AAA71126;

XX 27-APR-2001 (first entry)

XX Molecular interaction site RNA #195.

XX Modulator: identification; molecular interaction; virtual library; ss.

XX Unidentified.

XX WO958947-A2.

XX 18-NOV-1999.

XX 12-MAY-1999; 99WO-US10361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hotstadler S, McNeill J;

XX WPI: 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,
XX used to provide compounds which can be used as pharmacological,
XX agricultural and industrial compounds -

PS Example 7; Figure 126; 405bp; English.

xx
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUCACACUAUUCUAGUUUCAGAAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

XX
SQ Sequence 42 BP; 12 A; 7 C; 6 G; 17 U; 0 other;

Query Match

Best Local Similarity 62.1%; Score 18; DB 21; Length 42;

Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 4 gauncuuuunguaagcccnangng 27
||| |||| |||| |||| ||||
DB 7 gaucuuuuuunguaagcccuacgag 30

Search completed: October 2, 2001, 05:03:56
Job Time: 3808 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 05:00:40 ; Search time 1315.38 seconds
(without alignments)
341.015 Million cell updates/sec

Title: US-09-310-844B-24
Perfect score: 29
Sequence: 1 uaugauuuuuuuuuaagccuagggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1344157 seqs, 773874588 residues
Total number of hits satisfying chosen parameters: 2688314

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl:*
1: gb_ba1:*
2: gb_ba2:*
3: gb_ba3:*
4: gb_in1:*
5: gb_in2:*
6: gb_in3:*
7: gb_om:*
8: gb_ov:*
9: gb_pat1:*
10: gb_pat2:*
11: gb_ph:*
12: gb_pl1:*
13: gb_pl2:*
14: gb_pl3:*
15: gb_pl4:*
16: em_ba1:*
17: em_ba2:*
18: em_fun:*
19: em_hcgo_hum:*
20: em_hcgo_inv:*
21: em_hcgo_rod:*
22: em_hcgo_hum1:*
23: em_hcgo_hum2:*
24: em_hcgo_hum3:*
25: em_hcgo_hum4:*
26: em_hcgo_hum5:*
27: em_hcgo_hum6:*
28: em_hcgo_hum7:*
29: em_hcgo_hum8:*
30: em_hcgo_inv1:*
31: em_hcgo_inv2:*
32: em_hcgo_other:*
33: em_hcgo_rod:*
34: em_hum1:*
35: em_hum2:*
36: em_hum3:*
37: em_hum4:*
38: em_hum5:*
39: em_hum6:*
40: em_hum7:*
41: em_in:*
42: em_om:*
43: em_or:*

44: em_ov:*
45: em_pat:*
46: em_ph:*
47: em_pl:*
48: em_ro:*
49: em_sts:*
50: em_sy:*
51: em_un:*
52: em_v1:*
53: gb_sts1:*
54: gb_sts2:*
55: gb_sts3:*
56: gb_sy:*
57: gb_un:*
58: gb_v1:*
59: gb_v12:*
60: gb_hcgo1:*
61: gb_hcgo2:*
62: gb_hcgo3:*
63: gb_hcgo4:*
64: gb_hcgo5:*
65: gb_hcgo6:*
66: gb_hcgo7:*
67: gb_hcgo8:*
68: gb_hcgo9:*
69: gb_hcgo10:*
70: gb_hcgo11:*
71: gb_hcgo12:*
72: gb_hcgo13:*
73: gb_hcgo14:*
74: gb_hcgo15:*
75: gb_hcgo16:*
76: gb_hcgo17:*
77: gb_hcgo18:*
78: gb_hcgo19:*
79: gb_hcgo20:*
80: gb_hcgo21:*
81: gb_hcgo22:*
82: gb_hcgo23:*
83: gb_hcgo24:*
84: gb_hcgo25:*
85: gb_pr1:*
86: gb_pr2:*
87: gb_pr3:*
88: gb_pr4:*
89: gb_pr5:*
90: gb_pr6:*
91: gb_pr7:*
92: gb_pr8:*
93: gb_pr9:*
94: gb_ro1:*
95: gb_ro2:*
96: gb_in4:*
97: gb_pr10:*
98: em_ba3:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	29	100.0	209 10	182323
2	29	100.0	292 54	G06364
3	29	100.0	689 9	A17717
4	29	100.0	698 9	A02159
5	29	100.0	698 9	A04681
6	29	100.0	698 9	A14089
7	29	100.0	722 10	I03416
8	29	100.0	730 91	GIBIL2

9 29 100.0 750 10 101391 101391 Sequence 3
10 29 100.0 769 10 E01460 E01460 CDNA encodi
11 29 100.0 769 10 E02201 E02201 DNA encodin
12 29 100.0 782 10 101101 101101 Sequence 2
13 29 100.0 784 9 A06879 A06879 Artificial
14 29 100.0 784 9 A14095 A14095 Synthetic D
15 29 100.0 784 9 A17732 A17732 Plasmid prg
16 29 100.0 784 10 E00250 E00250 DNA coding
17 29 100.0 788 10 108366 108366 Sequence 2
18 29 100.0 788 10 107944 107944 Sequence 1
19 29 100.0 790 10 104498 104498 Sequence 1
20 29 100.0 790 10 108377 108377 Sequence 1
21 29 100.0 794 10 E00210 E00210 CDNA encodi
22 29 100.0 794 10 E00211 E00211 CDNA encodi
23 29 100.0 794 10 E02011 E02011 CDNA encodi
24 29 100.0 794 10 E02018 E02018 CDNA encodi
25 29 100.0 795 10 E00214 E00214 CDNA encodi
26 29 100.0 795 10 E00267 E00267 DNA sequenc
27 29 100.0 795 10 E00271 E00271 DNA sequenc
28 29 100.0 801 9 A04961 A04961 Artificial
29 29 100.0 801 9 A06759 A06759 Artificial
30 29 100.0 801 10 E00336 E00336 Human inter
31 29 100.0 801 10 101197 101197 Sequence 1
32 29 100.0 801 10 104318 104318 Sequence 3
33 29 100.0 801 93 H00978 H00978 Human mRNA
34 29 100.0 810 10 E00978 E00978 CDNA sequen
35 29 100.0 810 10 101387 101387 Sequence 1
36 29 100.0 812 10 E00216 E00216 DNA encodin
37 29 100.0 812 10 E02540 E02540 CDNA encodi
38 29 100.0 812 97 S77834 S77834 Homo saplen
39 29 100.0 825 97 HSU25676 HSU25676 Human inter
40 29 100.0 844 93 HSU25676 HSU25676 Human mRNA
41 29 100.0 1028 97 S82652 S82652 Interleukin
42 29 100.0 5561 97 HUM1L2B HUM1L2B Human inter
43 29 100.0 6684 93 HSIL05 HSIL05 Human inter
44 29 100.0 6752 89 AF35939 AF35939 Homo sapi
45 29 100.0 8491 9 AR031529 AR031529 Sequence

ALIGNMENTS

RESULT 1
182323 LOCUS 182323 209 bp DNA
DEFINITION Sequence 8 from patent US 5712126.
ACCESSION 182323
VERSION 182323.1 GI:3210620
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 209)
TITLES Weissman,S.M. and Prashar,Y.
JOURNAL Analysis of gene expression by display of 3-end restriction
FEATURES fragments of CDNA
PATENT: US 5712126-A 8 27 -JAN-1998;
source Location/Qualifiers
1..209
BASE COUNT 56 a 30 c 33 g 90 t
ORIGIN /organism="unknown"

Query Match 100.0%; Score 29; DB 10; Length 209;
Best Local Similarity 58.6%; Pred. No. 0.0038;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY 1 uaugauucuuuuuuaagcccaaggguu 29
:||||:||||:||||:||||:||||:||||:
Db 33 TATGATCTCTTTTGTAAAGCCCTAGGGGCT 61

RESULT 2
G06364 LOCUS G06364 292 bp DNA
DEFINITION human STS WI-7035.
ACCESSION G06364
VERSION G06364.1 GI:859609
KEYWORDS STS sequence; primer; sequence tagged site.
SOURCE human STSs derived from sequences in dbEST and the Unigene collection.
ORGANISM Homo sapiens
Eukaryotes; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Gnathostomata; Osteichthyes; Sarcopterygii; Choeanata;
Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Archonta; Primates;
Carnivora; Homiidae; Homo.
REFERENCE 1 (bases 1 to 292)
AUTHORS Hudson,T.
TITLES Whitehead Institute/MIT Center for Genome Research; Physically
Mapped ESTs
JOURNAL Mapped ESTs
COMMENT Unpublished (1995)

Contact: Thomas Hudson
Whitehead Institute/MIT Center for Genome Research
Whitehead Institute for Biomedical Research
9 Cambridge Center, Cambridge MA 02142 USA
Tel: 617 252 1900
Fax: 617 252 1902
Email: thudson@genome.wi.mit.edu

Primer A: TAATTAAGTCCTCCACTTAAC
Primer B: ATTGTGGATTAATTAAGTAACCA
STS size: 200
PCR Profile:

Presoak:
Denaturation:
Annealing: 56 degrees C
Polymerization:
PCR Cycles: 35
Thermal Cycler:

Protocol:
Template: 10 ng
Primer: each 5 pm
dNTPs: each 4 mM
Tag Polymerase: 0.025 units/ul
Total Vol: 20 ul

Buffer:
MgCl2: 1.5 mM
KCl: 50 mM
Tris-HCL: 10 mM
pH: 9.3

Prepared with primer pairs derived from V00564 -- Unigene.
FEATURES location/Qualifiers
source 1..292
STS /organism="Homo sapiens"
primer_bind 1..200
primer_bind 1..25
complement(176..200)
BASE COUNT 92 a 32 c 32 g 124 t 12 others
ORIGIN

Query Match 100.0%; Score 29; DB 54; Length 292;
Best Local Similarity 58.6%; Pred. No. 0.0039;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY 1 uaugauucuuuuuuaagcccaaggguu 29
:||||:||||:||||:||||:||||:||||:
Db 141 TATGATCTCTTTTGTAAAGCCCTAGGGGCT 169

RESULT 3
A17717

LOCUS A17717 689 bp mRNA PAT 17-MAY-1994
DEFINITION Plasmid pTG 26 mRNA for human IL-2.
ACCESSION A17717
VERSION A17717.1 GI:513949
KEYWORDS
SOURCE unidentified.
ORGANISM plasmid unidentified
REFERENCE unclassified.
AUTHORS 1 (bases 1 to 689)
TITLE Kieny,M.P., Sondermeyer,P. and Lecocq,J.P.
Expression of human IL-2 in mammalian cells by a recombinant pox virus
JOURNAL Patent: EP 0206939-A 1 30-DEC-1986;
TRANSGENE S.A
FEATURES
source Location/Qualifiers
1..689
/organism="unidentified"
/plasmid="pTG26"
/db_xref="taxon:32644"
1..384
/partial
/codon_start=1
/product="human interleukin 2"
/protein_id="CAA01347.1"
/db_xref="GI:513950"
/translation="TKTQLOLEHLLDLQMTLNGINNYKNKPLTRMLTFKFKPMKKA
TELKHLOCLEELKPLEVNLNLAOSKNFHLRDLISNINVIIVLELKSSETTFMCEYA
DETATVEFLNRWITFCOSIISTLT"
BASE COUNT 251 a 117 c 99 g 222 t
ORIGIN
Query Match 100.0%; Score 29; DB 9; Length 689;
Best Local Similarity 58.6%; Pred. No. 0.0043;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;
OY 1 uaugauucuuuuuuaagccuaggggcu 29
:||||:||||:||||:||||:||||:||||:
Db 525 TATGATCTTTTGTGAAGCCCTAGGGGCT 553
RESULT 4
LOCUS A02159 698 bp DNA PAT 21-MAY-1993
DEFINITION Synthetic gene for interleukin 2 (IL-2) (partial).
ACCESSION A02159
VERSION A02159.1 GI:412310
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
REFERENCE artificial sequence.
AUTHORS 1 (bases 1 to 698)
TITLE VECTOR FOR THE EXPRESSION IN YEASTS OF INTERLEUKINE-2, TRANSFORMED
YEASTS AND METHOD FOR PREPARING INTERLEUKINE-2
JOURNAL Patent: WO 8503723-A 6 29-AUG-1985;
FEATURES
source Location/Qualifiers
1..698
/organism="synthetic construct"
/db_xref="taxon:32630"
10..393
/partial
/codon_start=1
/transl_table=11
/product="interleukin 2 (IL-2)"
/protein_id="CAA00227.1"
/db_xref="GI:412311"
/translation="TKKTQLOLEHLLDLQMTLNGINNYKNKPLTRMLTFKFKPMKKA
TELKHLOCLEELKPLEVNLNLAOSKNFHLRDLISNINVIIVLELKSSETTFMCEYA
DETATVEFLNRWITFCOSIISTLT"
BASE COUNT 251 a 117 c 107 g 222 t 1 others
ORIGIN

Query Match 100.0%; Score 29; DB 9; Length 698;
Best Local Similarity 58.6%; Pred. No. 0.0043;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;
OY 1 uaugauucuuuuuuaagccuaggggcu 29
:||||:||||:||||:||||:||||:||||:
Db 534 TATGATCTTTTGTGAAGCCCTAGGGGCT 562
RESULT 5
LOCUS A04681 698 bp DNA PAT 24-MAY-1993
DEFINITION Synthetic gene for interleukin 2 (IL-2) (partial).
ACCESSION A04681
VERSION A04681.1 GI:412434
KEYWORDS
SOURCE interleukin 2.
ORGANISM synthetic construct.
REFERENCE artificial sequence.
AUTHORS 1 (bases 1 to 698)
TITLE Lemoine,Y., Sondermeyer,P., Loison,G., Aigle,M. and Lecocq,J.P.
Yeast-expression vectors for interleukin-2, transformed yeasts and
process for the preparation of interleukin-2
JOURNAL Patent: EP 0152358-A 5 21-AUG-1985;
TRANSGENE S.A
FEATURES
source Location/Qualifiers
1..698
/organism="synthetic construct"
/db_xref="taxon:32630"
10..393
/partial
/codon_start=1
/transl_table=11
/product="interleukin 2 (IL-2)"
/protein_id="CAA00377.1"
/db_xref="GI:412435"
/translation="TKKTQLOLEHLLDLQMTLNGINNYKNKPLTRMLTFKFKPMKKA
TELKHLOCLEELKPLEVNLNLAOSKNFHLRDLISNINVIIVLELKSSETTFMCEYA
DETATVEFLNRWITFCOSIISTLT"
BASE COUNT 251 a 118 c 106 g 222 t 1 others
ORIGIN
Query Match 100.0%; Score 29; DB 9; Length 698;
Best Local Similarity 58.6%; Pred. No. 0.0043;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;
OY 1 uaugauucuuuuuuaagccuaggggcu 29
:||||:||||:||||:||||:||||:||||:
Db 534 TATGATCTTTTGTGAAGCCCTAGGGGCT 562
RESULT 6
LOCUS A14089 698 bp DNA PAT 28-FEB-1994
DEFINITION Synthetic DNA (pTG26) for human interleukin-2 (partial).
ACCESSION A14089
VERSION A14089.1 GI:491760
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
REFERENCE artificial sequence.
AUTHORS 1 (bases 1 to 698)
TITLE EXPRESSION OF HUMAN IL-2 IN MAMMAL CELLS BY MEANS OF A RECOMBINED
POXYVIRUS
JOURNAL Patent: WO 8607610-A 1 31-DEC-1986;
FEATURES
source Location/Qualifiers
1..698
/organism="synthetic construct"
/db_xref="taxon:32630"
10..393
CDS

[illegible][illegible]

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 769)
AUTHORS Onomichi, K., Eto, Y. and Shibai, H.
TITLE PRODUCTION OF VALUABLE SUBSTANCE USING HUMAN CELL
JOURNAL Patent: JP 198726592-A 1 18-NOV-1987;
AJINOMOTO CO INC
COMMENT OS Human
PN JP 198726592-A/1
PD 18-NOV-1987
PI 12-MAY-1986 JP 1986107981
PI ONOMICHI KAZUYA, ETO YUZURU, SHIBAI HIROSHIRO PC
C12P21/00.C12N15/00.C12P21/02.(C12P21/02.C12N1.91); CC
strandedness: Double;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
CC *source: clone=PSDI;
FH Key Location/Qualifiers
FT 5'UTR 1..2
FT CDS 3..507
FT 508..814 /product='human interleukin 2' FT 3'UTR
FT mat_peptide 3..504
FT Location/Qualifiers
1..769
/organism='Homo sapiens'
/db_xref='taxon:9606'
BASE COUNT 280 a 132 c 112 g 245 t
ORIGIN

Query Match 100.0%; Score 29; DB 10; Length 769;
Best Local Similarity 58.6%; Pred. No. 0.0044;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY 1 naugaucuuuuuuaagcccuagggcu 29
Db 605 TATGATTCTTTGTAGCCCTAGGGCT 633

RESULT 11
LOCUS E02201 769 bp RNA PAT 29-SEP-1997
DEFINITION DNA encoding interleukin2 (IL-2).
ACCESSION E02201
VERSION E02201.1 GI:2170439
KEYWORDS JP 1990009388-A/2.
SOURCE Homo sapiens.
ORGANISM Homo sapiens.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 769)
AUTHORS Murata, M., Eto, Y. and Shibai, H.
TITLE PRODUCTION OF PHYSIOLOGICALLY ACTIVE PROTEIN
JOURNAL Patent: JP 1990009388-A 2 12-JAN-1990;
AJINOMOTO CO INC
COMMENT OS Homo sapiens
PN JP 1990009388-A/2
PD 12-JAN-1990
PI 08-JUL-1988 JP 1988170142
PI 09-MAR-1988 JP 88P 552270
PI MORATA MASAHIRO, ETO YUZURU, SHIBAI HIROSHIRO PC
C12P21/00.C12N15/12.C12N15/26.C12P21/02.(C12P21/02.C12N1.91); CC
strandedness: Double;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
CC *source: library=PSD(1)/IL-2;
CC Feature is identified by experimental;

FEATURES
source Location/Qualifiers
1..769
/organism='Homo sapiens'
/db_xref='taxon:9606'
BASE COUNT 280 a 132 c 112 g 245 t
ORIGIN

Query Match 100.0%; Score 29; DB 10; Length 769;
Best Local Similarity 58.6%; Pred. No. 0.0044;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY 1 naugaucuuuuuuaagcccuagggcu 29
Db 605 TATGATTCTTTGTAGCCCTAGGGCT 633

RESULT 12
LOCUS I01101 782 bp ss-DNA PAT 21-MAY-1993
DEFINITION Sequence 2 from Patent US 4761375.
ACCESSION I01101
VERSION I01101.1 GI:269302
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 782)
AUTHORS Clark, S.C.
TITLE Human Interleukin-2 cDNA sequence
JOURNAL Patent: US 4761375-A 2 02-AUG-1988;
Genetics Institute, Inc.;
Cambridge, MA
FEATURES
source Location/Qualifiers
1..782
/organism='unknown'
BASE COUNT 272 a 143 c 113 g 253 t 1 others
ORIGIN

Query Match 100.0%; Score 29; DB 10; Length 782;
Best Local Similarity 58.6%; Pred. No. 0.0044;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY 1 naugaucuuuuuuaagcccuagggcu 29
Db 641 TATGATTCTTTGTAGCCCTAGGGCT 669

RESULT 13
LOCUS A06879 784 bp DNA PAT 10-NOV-1993
DEFINITION Artificial sequence for interleukin-related protein.
ACCESSION A06879
VERSION A06879.1 GI:490471
KEYWORDS synthetic construct.
SOURCE synthetic construct.
ORGANISM artificial sequence.
REFERENCE 1 (bases 1 to 784)
AUTHORS Fiers, W.C. and Devos, R.R.
TITLE DNA sequences, recombinant DNA molecules and processes for
producing human interleukin two-like polypeptides

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 05:01:46 ; Search time 57.41 Seconds
(without alignments)
95.628 Million cell updates/sec

Title: US-09-310-844B-24
Perfect score: 29
Sequence: 1 uaugauuuuuuuuagccuaggggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 324599 seqs, 9465562 residues

Total number of hits satisfying chosen parameters: 649198

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_NA:*
1: /cgn2_6/ptodata/2/lna/5A.COMB.seq:*
2: /cgn2_6/ptodata/2/lna/5B.COMB.seq:*
3: /cgn2_6/ptodata/2/lna/6A.COMB.seq:*
4: /cgn2_6/ptodata/2/lna/6B.COMB.seq:*
5: /cgn2_6/ptodata/2/lna/PTUS.COMB.seq:*
6: /cgn2_6/ptodata/2/lna/Backfile1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	100.0	209	1	US-08-510-032A-8
2	29	100.0	209	3	US-08-688-514-8
3	29	100.0	801	6	5314995-8
4	29	100.0	8491	2	US-08-757-439-1
5	18.4	63.4	2885	2	US-08-791-849A-15
6	17.8	61.4	4093	4	US-07-861-458C-5
7	17	58.6	8920	4	US-08-446-855A-1
8	17	58.6	8920	4	US-09-150-741-1
9	16.4	56.6	512	2	US-08-628-428-7
10	16.4	56.6	512	2	US-08-628-428-7
11	16.4	56.6	51259	3	US-08-781-891-209
12	16.4	56.6	51259	3	US-08-781-891-209
13	16.2	55.9	1846	3	US-09-173-581-15
14	16	55.2	223	3	US-08-621-018B-48
15	16	55.2	223	3	US-08-621-018B-48
16	16	55.2	230	3	US-08-621-018B-46
17	16	55.2	251	3	US-08-621-018B-42
18	16	55.2	260	3	US-08-621-018B-43
19	16	55.2	9493	2	US-08-639-857-23
20	15.8	54.5	15202	3	US-08-922-635-21
21	15.8	54.5	36519	3	US-08-923-137-2
22	15.6	53.8	1166	1	US-08-599-252-95
23	15.6	53.8	1166	5	PCT-US96-06352-95
24	15.6	53.8	1166	5	PCT-US96-06583-95
25	15.6	53.8	1801	1	US-08-391-000-41
26	15.6	53.8	1801	1	US-08-741-931-41
27	15.6	53.8	1897	1	US-08-245-688-1

28	15.6	53.8	1897	1	US-08-245-688-3	Sequence 3, Appl1
29	15.6	53.8	1897	1	US-08-245-688-5	Sequence 5, Appl1
30	15.6	53.8	1897	1	US-08-245-688-7	Sequence 7, Appl1
31	15.6	53.8	1897	1	US-08-245-688-9	Sequence 9, Appl1
32	15.6	53.8	1897	1	US-08-245-688-11	Sequence 11, Appl1
33	15.6	53.8	2300	1	US-08-103-998-3	Sequence 1, Appl1
34	15.6	53.8	2549	1	US-08-720-720-2	Sequence 2, Appl1
35	15.6	53.8	3611	2	US-08-727-118-1	Sequence 1, Appl1
36	15.6	53.8	4964	1	US-08-470-720-5	Sequence 5, Appl1
37	15.6	53.8	7208	3	US-09-166-186-107	Sequence 107, App
38	15.6	53.8	7208	4	US-09-313-932-107	Sequence 107, App
39	15.4	53.1	107	1	US-08-441-591-45	Sequence 45, Appl1
40	15.4	53.1	107	1	US-08-303-362A-45	Sequence 45, Appl1
41	15.4	53.1	107	5	PCT-US95-05600-62	Sequence 62, Appl1
42	15.4	53.1	246	3	US-08-617-860B-14	Sequence 14, Appl1
43	15.4	53.1	340	3	US-08-441-971-13	Sequence 13, Appl1
44	15.4	53.1	340	4	US-08-221-653-13	Sequence 13, Appl1
45	15.4	53.1	340	4	US-08-442-144A-13	Sequence 13, Appl1

ALIGNMENTS

RESULT 1
US-08-510-032A-8
Sequence 8, Application US/08510032A
Patent No. 5712126
GENERAL INFORMATION:
APPLICANT: Sherman Weissman and Yarlindra Prashar
TITLE OF INVENTION: Analysis of Gene Expression By Display of 3'-
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Yahwak & Associates
STREET: 25 Skytop Drive
CITY: Trumbull
STATE: Connecticut
COUNTRY: USA
ZIP: 06611
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: Macintosh
OPERATING SYSTEM: MS-DOS
SOFTWARE: Microsoft Word 4.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/510,032A
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: George M. Yahwak
REGISTRATION NUMBER: 26,824
REFERENCE/DOCKET NUMBER: Yale
TELECOMMUNICATION INFORMATION:
TELEPHONE: (203)268-1951
TELEFAX: (203)268-1951
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 209 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-510-032A-8

Query Match 100.0%; Score 29; DB 1; Length 209;
Best Local Similarity 58.6%; Pred. No. 7.4e-05;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

OY 1 uaugauuuuuuuuagccuaggggcu 29
DB 33 TATGATTCTTTTGTAAAGCCCTAGGGGCT 61

RESULT 2
 US-08-688-514-8
 Sequence 8, Application US/08688514
 Patent No. 6010850
 GENERAL INFORMATION:
 APPLICANT: Sherman Weissman and Yarlinda Prashar
 TITLE OF INVENTION: Analysis of Gene Expression by Display of 3'-
 TITLE OF INVENTION: end Restriction Fragments of cDNA
 NUMBER OF SEQUENCES: 14
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Yahwak & Associates
 STREET: 25 Skytop Drive
 CITY: Trumbull
 STATE: Connecticut
 COUNTRY: USA
 ZIP: 06611
 COMPUTER READABLE FORM:
 MEDIUM TYPE: floppy disk
 COMPUTER: Macintosh
 OPERATING SYSTEM: MS-DOS
 SOFTWARE: Microsoft Word 4.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/688,514
 FILING DATE:
 CLASSIFICATION: 536
 ATTORNEY/AGENT INFORMATION:
 NAME: George M. Yahwak
 REGISTRATION NUMBER: 26,824
 REFERENCE/DOCKET NUMBER: yale
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (203)268-1951
 TELEFAX: (203)268-1951
 INFORMATION FOR SEQ ID NO: 8:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 209 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA

```

Query Match          100.0%; Score 29; DB 3; Length 209;
Best Local Similarity 58.6%; Pred. No. 7.4e-05;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY      1 naugaauucuuuuuguaagcccaaggggcu 29
         |||||::|::::|:|||||:|||||:
    33 TATGATTCTTTTGTAAAGCCCTAAGGGCGCT 61

RESULT   3
5314995 -8
Patent No. 5314995
APPLICANT: FELL, HENRY P.; SAYLE, MARCIT A.
TITLE OF INVENTION: THERAPEUTIC INTERLEUKIN-2-ANTIBODY
BASED FUSION PROTEINS
NUMBER OF SEQUENCES: 8
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/468,390
FILING DATE: 22-JAN-1990
SEQ ID NO.: 8
LENGTH: 801
5314995-8

Query Match          100.0%; Score 29; DB 6; Length 801;
Best Local Similarity 58.6%; Pred. No. 9.3e-05;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY      1 naugaauucuuuuuguaagcccaaggggcu 29
         |||||:||||::::|:|||||:|||||:
```

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999

```

```

Query Match          100.0% ; Score 2; DB 2; length 8491;
Best Local Similarity    58.6%; Pred. No. 0.00014;
Matches      17; Conservative      0; Indels      0; Gaps      0;

QY       1   naugauuuuuuuuuuaagccuagggacu 29
           :|::||:|||||:|||||:|||||:
Db        6654 TATGATCTTTTGTAAAGCCCTAGGGCGT 6626

RESULT      5
US-08-791-849A-15/c
; Sequence 15, Application US/08791849A
; Patent No.: 5914449
; 
; GENERAL INFORMATION:
; APPLICANT: Makoto MURASE et al.
; TITLE OF INVENTION: Method for Increasing Storage
; TITLE OF INVENTION: Lipid Content in Plant Seed
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wenderoth, Lind & Ponack
; STREET: 805 Fifteenth Street, N.W., #700

```

```

1  RESULT: 6
2  -07-861-458C-5/c
3  Sequence 5, Application US/07861458C
4  Patent No. 6232061
5
6  GENERAL INFORMATION:
7  APPLICANT: Marchionni, Mark Andrew
8  APPLICANT: Johnson, Carl D.
9  TITLE OF INVENTION: HOMOLOGU CLONING
10 NUMBER OF SEQUENCES: 142
11
12 CORRESPONDENCE ADDRESS:
13 ADDRESSEE: Fish & Richardson
14 STREET: 225 Franklin Street
15 CITY: Boston
16 STATE: Massachusetts
17
18 COUNTRY: U.S.A.
19 ZIP: 02110-2804
20
21 COMPUTER READABLE FORM:
22 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
23 COMPUTER: IBM PS.2 Model 502 or 55SX
24 OPERATING SYSTEM: MS-DOS (Version 5.0)
25 SOFTWARE: Wordperfect (Version 5.1)
26
27 CURRENT APPLICATION DATA:
28 APPLICATION NUMBER: US/07/861,458C
29 FILING DATE: 04/01/92
30 CLASSIFICATION: 435
31
32 PRIOR APPLICATION DATA:
33 APPLICATION NUMBER:

```

```

1      COMPUTER READABLE FORM.
2      MEDIUM TYPE: Floppy disk
3      COMPUTER: IBM PC compatible
4      OPERATING SYSTEM: PC-DOS/MS-DOS
5      SOFTWARE: PatentIn Release #1.24
6      CURRENT APPLICATION DATA:
7      APPLICATION NUMBER: US/08/446,855A
8      FILING DATE: 06-Jul-1995
9      CLASSIFICATION: 435
10     ATTORNEY/AGENT INFORMATION:
11     NAME: Mithard, Leonard C
12     REGISTRATION NUMBER: 29,009
13     REFERENCE/DOCKET NUMBER: 47-80
14     TELECOMMUNICATION INFORMATION:
15     TELEPHONE: 703-816-4000
16     TELEFAX: 703-816-4100
17     INFORMATION FOR SEQ ID NO: 1:
18     SEQUENCE CHARACTERISTICS:
19     LENGTH: 8920 base pairs
20     TYPE: nucleic acid
21     STRANDEDNESS: single
22     TOPOLOGY: linear
23     MOLECULE TYPE: genomic
24     US-08-446-855A-1

```

Query Match	58.68;	Score 17;	DB 2;	length 8920;
Best Local Similarity	40.08;	Pred. No. 47;		

Matches 10: Conservative 10: Mismatches 5: Indels 0: Gaps 0:

Qy 2 augaucuuuuuuaagccuaggg 26
1:|||||:|||||:1111
Db 2277 ATGATTCCTTTTAAAGTATATATG 2301

RESULT 8

US-09-150-741-1
; Sequence 1, Application US/09150741
; Patent No. 6183996
; GENERAL INFORMATION:
; APPLICANT: Stewart et al.
; TITLE OF INVENTION: Nucleotide Sequence Encoding Carbamoyl Phosphate
; Patent No. 6183996
; TITLE OF INVENTION: Synthetase II
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/09/150,741
; CURRENT FILING DATE: 1998-09-10
; EARLIER APPLICATION NUMBER: PL6380
; EARLIER FILING DATE: 1992-12-16
; EARLIER APPLICATION NUMBER: A093/00617
; EARLIER FILING DATE: 1993-12-02
; EARLIER APPLICATION NUMBER: 08/446,855
; EARLIER FILING DATE: 1995-07-06
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 8920
; TYPE: DNA
; ORGANISM: Plasmodium falciparum
US-09-150-741-1

Query Match 58.6%; Score 17; DB 4; Length 8920;
Best Local Similarity 40.0%; Pred. No. 47;
Matches 10: Conservative 10: Mismatches 5: Indels 0: Gaps 0:

Qy 2 augaucuuuuuuaagccuaggg 26
1:|||||:|||||:1111
Db 2277 atgattctttttaagtatatag 2301

RESULT 9

US-08-628-428-4
; Sequence 4, Application US/08628428
; Patent No. 5885962
; GENERAL INFORMATION:
; APPLICANT: Lu, Hsieng
; TITLE OF INVENTION: SCF ANALOG COMPOSITIONS AND METHODS
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc.
; STREET: 1840 DeHavilland Drive
; CITY: Thousand Oaks
; STATE: CA
; COUNTRY: USA
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/628,428
; FILING DATE: 05-APR-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Knight, Matthew W
; REGISTRATION NUMBER: 36,846
; REFERENCE/DOCKET NUMBER: A-400
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:

; LENGTH: 512 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
US-08-628-428-4

Query Match 56.6%; Score 16.4; DB 2; Length 512;
Best Local Similarity 42.3%; Pred. No. 55;
Matches 11: Conservative 9: Mismatches 6: Indels 0: Gaps 0:

Qy 4 gaucuuuuuuaagccuagggcu 29
11:|||||:1111:11111
Db 298 GATTTTAAAGTCTCGGGTCT 323

RESULT 10

US-08-628-428-7
; Sequence 7, Application US/08628428
; Patent No. 5885962
; GENERAL INFORMATION:
; APPLICANT: Lu, Hsieng
; TITLE OF INVENTION: SCF ANALOG COMPOSITIONS AND METHODS
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc.
; STREET: 1840 DeHavilland Drive
; CITY: Thousand Oaks
; STATE: CA
; COUNTRY: USA
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/628,428
; FILING DATE: 05-APR-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Knight, Matthew W
; REGISTRATION NUMBER: 36,846
; REFERENCE/DOCKET NUMBER: A-400
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 512 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
US-08-628-428-7

Query Match 56.6%; Score 16.4; DB 2; Length 512;
Best Local Similarity 42.3%; Pred. No. 55;
Matches 11: Conservative 9: Mismatches 6: Indels 0: Gaps 0:

Qy 4 gaucuuuuuuaagccuagggcu 29
11:|||||:1111:11111
Db 298 GATTTTAAAGTCTCGGGTCT 323

RESULT 11

US-08-781-891-209
; Sequence 209, Application US/08781891
; Patent No. 6090620
; GENERAL INFORMATION:
; APPLICANT: Fu, Ying-Hui
; APPLICANT: Yu, Chang-En
; APPLICANT: Oshima, Junko
; APPLICANT: Mulligan, John T.

APPLICANT: Schellenberg, Gerald D.
TITLE OF INVENTION: GENE AND GENE PRODUCTS RELATED TO
NUMBER OF SEQUENCES: 209
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/781,891
FILING DATE: 27-DEC-1996
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: No. 6090620tenburg, Ph.D., Carol
REGISTRATION NUMBER: 39,317
REFERENCE/DOCKET NUMBER: 240052.419
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 209:
SEQUENCE CHARACTERISTICS:
LENGTH: 51259 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-781-891-209

Query Match 56.6%; Score 16.4; DB 3; Length 51259;
Best Local Similarity 42.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

QY 4 gaucuuuuuuaagccuagggcu 29

Db 26016 GTTCTTTTGGAGCAGCTAGAGCT 26041

RESULT 12
US-08-781-891-209/c
Sequence 209, Application US/08781891
Patent No. 6090620
GENERAL INFORMATION:
APPLICANT: Fu, Yang-Hui
APPLICANT: Yu, Chang-Bn
APPLICANT: Oshima, Junko
APPLICANT: Mulligan, John T.
APPLICANT: Schellenberg, Gerald D.
TITLE OF INVENTION: GENE AND GENE PRODUCTS RELATED TO
NUMBER OF SEQUENCES: 209
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/781,891
FILING DATE: 27-DEC-1996

CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: No. 6090620tenburg, Ph.D., Carol
REGISTRATION NUMBER: 39,317
REFERENCE/DOCKET NUMBER: 240052.419
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 209:
SEQUENCE CHARACTERISTICS:
LENGTH: 51259 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-781-891-209

Query Match 56.6%; Score 16.4; DB 3; Length 51259;
Best Local Similarity 42.3%; Pred. No. 1.2e+02;
Matches 11; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

QY 4 gaucuuuuuuaagccuagggcu 29

Db 10495 GTTCTTTTGGAGCAGCTAGAGCT 10470

RESULT 13
US-09-173-581-15/c
Sequence 15, Application US/09173581A
Patent No. 6013455
GENERAL INFORMATION:
APPLICANT: Bandman, Olga
APPLICANT: Tang, Y. Tom
APPLICANT: Hillman, Jennifer L.
APPLICANT: Yue, Henry
APPLICANT: Guegler, Karl J.
APPLICANT: Corley, Neil C.
APPLICANT: Gorgone, Gina
APPLICANT: Azimzai, Yalda
APPLICANT: Lu, Aina
TITLE OF INVENTION: Protein Kinase Homologs
FILE REFERENCE: PF-0614 US
CURRENT APPLICATION NUMBER: US/09/173,581A
CURRENT FILING DATE: 1998-10-15
NUMBER OF SEQ ID NOS: 18
SOFTWARE: PERL Program
SEQ ID NO 15
LENGTH: 1846
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE: -
OTHER INFORMATION: 1567782
US-09-173-581-15

Query Match 55.9%; Score 16.2; DB 3; Length 1846;
Best Local Similarity 38.1%; Pred. No. 85;
Matches 8; Conservative 10; Mismatches 3; Indels 0; Gaps 0;

QY 2 augauuuuuuuaagccu 22

Db 155 ATGATCTTTTCTAGGCAAT 135

RESULT 14
US-08-621-018B-48
Sequence 48, Application US/08621018B
Patent No. 6060239
GENERAL INFORMATION:
APPLICANT: Stuart, Susan G.
APPLICANT: Hawkins, Phillip R.
APPLICANT: Sellhammer, Jeffrey J.
APPLICANT: Murry, Lynn E.

1 TITLE OF INVENTION: CELLULREVIIN HOMOLOGS
 2 NUMBER OF SEQUENCES: 51
 3 CORRESPONDENCE ADDRESS:
 4 ADDRESSEE: Incyte Pharmaceuticals, Inc.
 5 STREET: 3174 Porter Drive
 6 CITY: Palo Alto
 7 STATE: CA
 8 COUNTRY: U.S.
 9 ZIP: 94304
 10
 11 COMPUTER READABLE FORM:
 12 MEDIUM TYPE: Diskette
 13 COMPUTER: IBM Compatible
 14 OPERATING SYSTEM: DOS
 15 SOFTWARE: FastSeq Version 1.5
 16 CURRENT APPLICATION DATA:
 17 APPLICATION NUMBER: US/08/621,018B
 18 FILING DATE: March 22, 1996
 19
 20 PRIOR APPLICATION DATA:
 21 APPLICATION NUMBER: 08/409,373
 22 FILING DATE: March 23, 1995
 23 ATTORNEY/AGENT INFORMATION:
 24 NAME: CERRONE, MICHAEL C.
 25 REGISTRATION NUMBER: 39,132
 26 REFERENCE/DOCKET NUMBER: PF-0029-1 CIP
 27 TELECOMMUNICATION INFORMATION:
 28 TELEPHONE: 650-855-0555
 29 TELEFAX: 650-845-4166
 30 INFORMATION FOR SEQ ID NO: 48:
 31 SEQUENCE CHARACTERISTICS:
 32 LENGTH: 223 base pairs
 33 TYPE: nucleic acid
 34 STRANDEDNESS: single
 35 TOPOLOGY: linear
 36 MOLECULE TYPE: cDNA
 37 IMMEDIATE SOURCE:
 38 LIBRARY: LUNGNOTO2
 39 CLONE: 375070
 40
 41 US-08-621-018B-48

```

Query Match          95.2%; Score 16; DB 3; Length 22;
Best Local Similarity 41.7%; Pred. No. 73;
Matches      10; Conservative    9; Mismatches      5; Indels      0; Gaps      0;

OY      6 uucuuuuuuaagcccaaggcgcu 29
       : |::|::||| | | | | |
Db      122 TACTTTTGTGAAGCACTACTGACT 145

S-SUIT 15
S-08-621-018B-49
Sequence 49, Application US/08621018B
Patent No. 6060239
GENERAL INFORMATION:
Applicant: Stuart, Susan G.
Applicant: Hawkins, Phillip R.
Applicant: Selhammer, Jeffrey J.
Applicant: Murty, Lynn E.
TITLE OF INVENTION: CELLULREVIN HOMOLOGS
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESS: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: U.S.
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:

```

```

1      APPLICATION NUMBER:  US/08/621,018B
2      FILING DATE:  March 22, 1996
3
4      PRIORITY APPLICATION DATA:
5
6      APPLICATION NUMBER:  08/409,373
7      FILING DATE:  March 23, 1995
8
9      ATTORNEY/AGENT INFORMATION:
10
11     NAME:  CERRONE, MICHAEL C.
12     REGISTRATION NUMBER:  39,132
13
14     REFERENCE/DOCKET NUMBER:  PF-0029-1 CIP
15
16     TELECOMMUNICATION INFORMATION:
17
18     TELEPHONE:  650-855-0555
19
20     TELEFAX:  650-845-4166
21
22     INFORMATION FOR SEQ. ID NO.:  49:
23
24     SEQUENCE CHARACTERISTICS:
25
26     LENGTH:  225 base pairs
27     TYPE:  nucleic acid
28     STRANDEDNESS:  single
29
30     TOPOLOGY:  linear
31
32     MOLECULE TYPE:  CDNA
33
34     IMMEDIATE SOURCE:
35
36     LIBRARY:  LATRNOT01
37
38     CLONE:  465647
39
40     US-08-621-018B-49

```

	Query Match	55.2%	Score 16;	DB 3;	Length 225;
	Best Local Similarity	41.7%;	Pred. No. 74;		
Matches	10; Conservative	9;	Mismatches	5;	Indels 0;
Oy	6 uuuuuuuuaagcccuaggagcu	29			
	: : : : : :	:			
Db	70 TACTTTTGTGAAGCACTACTGACT	93			

Search completed: October 2, 2001, 05:01:49
Job time: 5316 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 04:38:38 ; Search time 1643.83 Seconds
(without alignments)
166.765 Million cell updates/sec

Title: US-09-310-844B-24
Perfect score: 29
Sequence: 1 uaugauucuuuuuugaagccuaggggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 10228115 seqs, 4726426750 residues
Total number of hits satisfying chosen parameters: 20456230

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*

1: gb_est1:*
2: gb_est2:*
3: gb_est3:*
4: gb_est4:*
5: gb_est5:*
6: gb_est6:*
7: gb_est7:*
8: gb_est8:*
9: gb_est9:*
10: gb_est10:*
11: gb_est11:*
12: gb_est12:*
13: gb_est13:*
14: gb_est14:*
15: gb_est15:*
16: gb_est16:*
17: gb_est17:*
18: gb_est18:*
19: gb_est19:*
20: gb_est20:*
21: gb_est21:*
22: gb_est22:*
23: gb_est23:*
24: gb_est24:*
25: gb_est33:*
26: gb_est34:*
27: gb_est35:*
28: gb_est36:*
29: gb_est37:*
30: gb_est38:*
31: gb_est39:*
32: gb_est40:*
33: em_estba:*
34: em_estfun:*
35: em_esthum1:*
36: em_esthum2:*
37: em_esthum3:*
38: em_esthum4:*
39: em_esthum5:*
40: em_esthum6:*
41: em_esthum7:*
42: em_esthum8:*
43: em_esthum9:*

44: em_esthum10:*
45: em_esthum11:*
46: em_esthum12:*
47: em_esthum13:*
48: em_esthum14:*
49: em_esthum15:*
50: em_esthum16:*
51: em_esthum17:*
52: em_esthum18:*
53: em_esthum19:*
54: em_esthum20:*
55: em_esthum21:*
56: em_esthum22:*
57: em_esthum23:*
58: em_esthum24:*
59: em_esthum25:*
60: em_esthum26:*
61: em_esthum27:*
62: em_esthum28:*
63: em_estin1:*
64: em_estin2:*
65: em_estin3:*
66: em_estin4:*
67: em_estin5:*
68: em_estom1:*
69: em_estom2:*
70: em_estov1:*
71: em_estov2:*
72: em_estp11:*
73: em_estp12:*
74: em_estp13:*
75: em_estp14:*
76: em_estp15:*
77: em_estp16:*
78: em_estp17:*
79: em_estp18:*
80: em_estp19:*
81: em_estp110:*
82: em_estro1:*
83: em_estro2:*
84: em_estro3:*
85: em_estro4:*
86: em_estro5:*
87: em_estro6:*
88: em_estro7:*
89: em_estro8:*
90: em_estro9:*
91: em_estro10:*
92: em_estro11:*
93: em_estro12:*
94: em_estro13:*
95: em_estro14:*
96: em_estro15:*
97: em_estro16:*
98: em_estro17:*
99: em_estro18:*
100: em_estro19:*
101: em_estro20:*
102: gb_est25:*
103: gb_est26:*
104: gb_est27:*
105: gb_est28:*
106: gb_est29:*
107: gb_est30:*
108: gb_est31:*
109: gb_est32:*
110: gb_est41:*
111: gb_est42:*
112: gb_est43:*
113: gb_est44:*
114: gb_est45:*
115: gb_est46:*
116: gb_est47:*

117: gb_est48:*
118: gb_est49:*
119: gb_est50:*
120: gb_est51:*
121: gb_est52:*
122: gb_est53:*
123: gb_est54:*
124: gb_est55:*
125: gb_est56:*
126: gb_est57:*
127: gb_est58:*
128: gb_est59:*
129: gb_est60:*
130: gb_est61:*
131: gb_est62:*
132: gb_est63:*
133: gb_est64:*
134: gb_est65:*
135: gb_est66:*
136: gb_est67:*
137: gb_est68:*
138: gb_est69:*
139: gb_est70:*
140: gb_est71:*
141: gb_est72:*
142: gb_est73:*
143: gb_est74:*
144: gb_est75:*
145: gb_est76:*
146: gb_est77:*
147: gb_est78:*
148: gb_est79:*
149: gb_est80:*
150: gb_est81:*
151: gb_est82:*
152: gb_est83:*
153: gb_est84:*
154: gb_est85:*
155: gb_est86:*
156: gb_est87:*
157: gb_est88:*
158: gb_est89:*
159: gb_est90:*
160: gb_est91:*
161: gb_est92:*
162: gb_est93:*
163: gb_est94:*
164: gb_est95:*
165: gb_est96:*
166: gb_est97:*
167: gb_est98:*
168: gb_est99:*
169: gb_est100:*
170: gb_est101:*
171: gb_est102:*
172: gb_est103:*
173: gb_est104:*
174: gb_est105:*
175: gb_est106:*
176: gb_est107:*
177: gb_est108:*
178: gb_est109:*
179: gb_est110:*
180: gb_est111:*
181: gb_est112:*
182: gb_est113:*
183: gb_est114:*
184: gb_est115:*
185: gb_est116:*
186: gb_est117:*
187: gb_est118:*
188: gb_est119:*
189: gb_est120:*

190: gb_est110:*
191: gb_est111:*
192: gb_est112:*
193: gb_est113:*
194: gb_est114:*
195: gb_est115:*
196: gb_est116:*
197: gb_est117:*
198: gb_est118:*
199: gb_est119:*
200: gb_est120:*
201: gb_est121:*
202: gb_est122:*
203: gb_est123:*
204: gb_est124:*
205: gb_est125:*
206: gb_est126:*
207: gb_est127:*
208: gb_est128:*
209: gb_est129:*
210: gb_est130:*
211: gb_est131:*
212: gb_est132:*
213: gb_est133:*
214: gb_est134:*
215: gb_est135:*
216: gb_est136:*
217: gb_est137:*
218: gb_est138:*
219: gb_est139:*
220: gb_est140:*
221: gb_est141:*
222: gb_est142:*
223: gb_est143:*
224: gb_est144:*
225: gb_est145:*
226: gb_est146:*
227: gb_est147:*
228: gb_est148:*
229: gb_est149:*
230: gb_est150:*
231: gb_est151:*
232: gb_est152:*
233: gb_est153:*
234: gb_est154:*
235: gb_est155:*
236: gb_est156:*
237: gb_est157:*
238: gb_est158:*
239: gb_est159:*
240: gb_est160:*
241: gb_est161:*
242: gb_est162:*
243: gb_est163:*
244: gb_est164:*
245: gb_est165:*
246: gb_est166:*
247: gb_est167:*
248: gb_est168:*
249: gb_est169:*
250: gb_est170:*
251: gb_est171:*
252: gb_est172:*
253: gb_est173:*
254: gb_est174:*
255: gb_est175:*
256: gb_est176:*
257: gb_est177:*
258: gb_est178:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score being printed, and is derived by analysis of the total score distribution.

	Matches	13, Conservative	10, Mismatches	4, Indels	0, Gaps	0
QY	3	ugaauucuuuuuuuaagcccuaggggcu	29			
		: : :::: : : :				
Db	394	TGACTTTTTTTTGTAAAGCCCTGCGGCT	368			

[illegible]

PERENCE	1 (bases 1 to 494)
AUTHORS	Morgan, R.
TITLE	Chicken T cell ESTs
JOURNAL	Unpublished (1999)
COMMENT	Contact: Robin Morgan

Clones can be ordered online at <http://www.chickest.udel.edu>.

Location/Qualifiers

1. 494

BASE COUNT	ORIGIN
151 a	82 c 96 g 143 t 22 others

Query Match 67.6%; Score 19.6; DB 113; Length 494;
 Best Local Similarity 46.4%; Pred. No.2,1e+02;
 Matches 13; Conservative 9; Mismatches 6; Indels 0; Gaps 0

RESULT	6
LOCUS	A2349700
DEFINITION	A2349700 619 bp DNA GSS 29-SEP-2000
ACCESSION	U0086K17R Mouse 10bp plasmid U00C1M library Mus musculus genomic clone U00C1M0086K17 R, DNA sequence.
VERSION	A2349700
KEYWORDS	A2349700.1 GI:10428937
SOURCE	GSS.
ORGANISM	house mouse. Mus musculus
REFERENCE	Eukaryota: Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 619)
AUTHORS	Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,

TITLE
Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL
unpublished (2000)
COMMENT
Contact: Robert B. Weiss
University of Utah, Center for

FEATURES
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert length: 10000 Std Error: 0.00
 Plate: 0086 row: K column: 17
 Seq primer: CACACAGCAAAACACCTATGAC
 Class: plasmid ends
 High quality sequence stop: 619.
 location/qualifiers

FEATURES	Location/Qualifiers
source	1. .619
	Location: "Mus musculus"

```

BASE COUNT      111 a      173 c      106 g      229 t
ORIGIN
/oliganu5m="mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U06C1M0086k17"
/clone_lib="Mouse 10kb plasmid u06C1M library"
/sex="Male"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"  

/note="Vector: PWD42nv; Purified genomic DNA from M.  

musculus C57BL/6J (male) was obtained from the Jackson  

Laboratory Mouse DNA Resource  

(http://www.jax.org/resources/documents/dnares/). The DNA  

was hydrodynamically sheared by repeated passage through a  

0.005 inch orifice at constant velocity. The sheared DNA  

was blunt end-repaired with T4 DNA polymerase and T4  

polynucleotide kinase. Adaptor oligonucleotides were  

ligated to the blunt ends in high molar excess. The  

adaptored DNA was purified and size-selected for a 9.5 to  

10.5 kb range using preparative agarose gel  

electrophoresis. Vector DNA was prepared from a derivative  

of PWD42 (g114732114[gblAF129072.1]), a copy-number  

inducible derivative of plasmid R1. The vector was ligated  

with adaptors complementary to the insert adaptors and  

purified. The sheared, adaptored mouse DNA was annealed to  

adaptored vector DNA, and transformed into  

chemically-competent E. coli XL10-Gold (Stratagene) cells  

and selected for ampicillin resistance."

```

Query Match	67.6%	Score 19.6	DB 242	Length 619
Best Local Similarity	53.8%	Pred. No. 2.1e+07		
Matches 14	Conservative 8	Mismatches 4	Indels 0	Gaps 0
OY	4	gaucuuuuuuuagaccuaggggacuu	29	
Db	289	gattctttctgcgagacccttagtgct	314	

[illegible]

TITLE Mouse BAC End Sequences from Library RPCI-24.
JOURNAL Unpublished (1999)

Automated filtration-based high-throughput plasmid preparation system. *Genome Res.* 9 (5), 463-470 (1999)

BASE COUNT
ORIGIN

145 a 163 c 119 g 239 t

```
/db_xref="taxon:10090"  
/clone="U08C1M0367H06"  
/clone_lib="Mouse 10kb plasmid U08C1M library"  
/sex="Male"  
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
/note="Vector: PMD42nv; Purified genomic DNA from M.  
musculus C57BL/6J (male) was obtained from the Jackson  
Laboratory Mouse DNA Resource  
(http://www.jax.org/resources/documents/dnares/). The DNA  
was hydrodynamically sheared by repeated passage through a  
0.005 inch orifice at constant velocity. The sheared DNA  
was blunt end-repaired with T4 DNA polymerase and T4  
polynucleotide kinase. Adaptor oligonucleotides were  
ligated to the blunt ends in high molar excess. The  
adapted DNA was purified and size-selected for a 9.5 to  
10.5 kb range using preparative agarose gel  
electrophoresis. Vector DNA was prepared from a derivative  
of PMD42 (g11473211419b|AF129072.1), a copy-number  
inducible derivative of plasmid R1. The vector was ligated  
with adaptors complementary to the insert adaptors and  
purified. The sheared, adapted mouse DNA was annealed to  
adapted vector DNA, and transformed into  
chemically-competent E. coli XL10-Gold (Stratagene) cells  
and selected for ampicillin resistance."
```

```
Query Match Summary      66.9% Score 19.4; DB 246; Length 666;  
Best Local Similarity   48.3%; Pred. No. 2.6e+02;  
Matches    14; Conservative     9; Mismatches     6; Indels     0; Gaps     0
```

```
Oy          1 uaugaucuuuuuguuaagcccaaggcgcu 29  
            :|::||:::-|||::|||::||  
Db           52 TACCAFTCTTTCGTGCGCCATCAGGGCGT 80
```

```
RESULT 12  
LOCUS       AQ239971/c  
DEFINITION  AQ239971              309 bp DNA             GSS               30-SEP-1998  
ACCSSION    CIT-HSP-2386F6.TK.1 CIT-HSP Homo sapiens genomic clone 2386f6, DNA sequence.  
VERSION      AQ239971  
KEYWORDS     AQ239971..1 GI:3672169  
SOURCE       GSS.
```

human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Hmoio.
Adams M.D., Rounsley S.D., Zhao S., Bass S., Linhar K., Golden K.,
Berry K., Granger D., Suh E., Wible C., Shizuya H., Simon M. and Venter J.C.
Use of a random human BAC End Sequence Database for Sequence-Ready Map Building
Unpublished (1998)
Other_GSSES: CIT-HSP-2386F6.TF.1
Contact: Mark Adams
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel.: 301 838 0200
Fax: 301 838 0208
Email: mdadams@tigr.org
Clones are available from Research Genetics (info@resgen.com). BAC end search page:
http://www.tigr.org/tdb/humgen/bac_end_search/bac_end_search.html.
Seq primer: M13 Reverse
Class: BAC ends.

```
FEATURES  
         Location/Qualifiers  
         .....
```

```
source        1..309  
                /organism="Homo sapiens"  
                /db_xref="taxon:9606"
```

[illegible]

RESULT	13
LOCUS	A0072238/c
DEFINITION	A0072238 348 bp DNA GSS 05-AUG-1998
ACCESSION	HS_3024_B1.F02.L7 CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3024 Col=3 Row=L, DNA sequence.
VERSION	A0072238
KEYWORDS	A0072238.1 GI:3391087
SOURCE	GSS.
ORGANISM	human.
REFERENCE	Homo sapiens
AUTHORS	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. 1 (bases 1 to 348)
TITLE	Mahairas,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T., Keller,A., Shaker,R., Furlong,J.J., Young,J., Zhao,S., Adams,M.D. and Hood,L.
JOURNAL MEDLINE	Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999)
COMMENT	99380589 Contact: Mahairas GG, Wallace JC, Hood L High Throughput Sequencing Center University of Washington 401 Queen Anne Avenue North, Seattle, WA 98109, USA Tel: (206) 616-3618 Fax: (206) 616-3887 Email: jwallace@u.washington.edu Sequence Tagged Connector Plate: 3024 row: L column: 3 Class: BAC ends High quality sequence stomp: 348. Location/Qualifiers 1..348 /organism="Homo sapiens" /db_xref="taxon:9606" /clone="plate=3024 Col=3 Row=L" /clone_libs="CIT Approved Human Genomic Sperm Library.D" /sex="male" /note="Organ: sperm; Vector: pBeloBac11; BAC Clones in E-Coli DH10B"
BASE COUNT	111 a 59 c 49 g 129 t
ORIGIN	
Query Match	65.5%; Score 19; DB 224; Length 348;
Best Local Similarity	44.4%; Pred. No. 3.6e+02;
Matches	Conservative 10; Mismatches 5; Indels 0; Gaps 0;
OY	3 ugaucuuuuuguaagccuaggggcu 29 .: ::: :: :
Db	70 TTATCTTTTGGAGGTCCTGATGCT 44
RESULT	14

AI808918
 LOCUS AI808918 358 bp mRNA EST 07-JUL-1999
 DEFINITION w66h01.x1 Soares_NFL.T.GBC.S1 Homo sapiens cDNA clone
 IMAGE:2360593 3', mRNA sequence.
 ACCESSION AI808918
 VERSION AI808918.1 GI:5395484
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 REFERENCE 1 (bases 1 to 358)
 NCBI-CCAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 JOURNAL Unpublished (1997)
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgaps-r@mail.nih.gov
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 Seq primer: -40UP from c1bco
 High quality sequence stop: 345.
 Location/Qualifiers
 1..358
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:2360593"
 /clone_lib="Soares_NFL.T.GBC.S1"
 /lab_host="DH10B"
 /note="Organ: pooled; Vector: pT7T3D-Pac (Pharmacia) with
 a modified polylinker; Site.1: Not I; Site.2: Eco RI;
 Equal amounts of plasmid DNA from three normalized
 libraries (fetal lung Nbh119w, testis NHT, and B-cell
 NCI-CGAP-GC81) were mixed, and ss circles were made in
 vitro. Following HAP purification, this DNA was used as
 tracer in a subtractive hybridization reaction. The driver
 was PCR-amplified cDNAs from pools of 5,000 clones made
 from the same 3 libraries. The pools consisted of
 I.M.A.G.E. clones 297480-302087, 682633-682239,
 726408-728711, and 729096-731399. Subtraction by Bento
 Soares and M. Fatima Bonaldo.
 BASE COUNT 86 a 75 c 69 g 127 t 1 others
 ORIGIN
 Query Match 65.5%; Score 19; DB 102; Length 358;
 Best Local Similarity 48.1%; Pred. No. 3.7e+02;
 Matches 13; Conservative 9; Mismatches 5; Indels 0; Gaps 0;
 1 uagauuuuuuuuagcccuagggg 27
 :||:||||:|||||||
 Db 36 TATGATTCTCTTGGAATCCCTGGCG 62
 RESULT 15
 LOCUS AI047736 408 bp mRNA EST 08-JUL-1998
 DEFINITION ub82f05.r1 Soares mouse urogenital ridge NMUR Mus musculus cDNA
 clone IMAGE:1764225 5', mRNA sequence.
 ACCESSION AI047736
 VERSION AI047736.1 GI:3296023
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1 (bases 1 to 408)
 Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
 Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
 Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
 Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
 Waterston,R.
 TITLE The WashU-HMI Mouse EST Project

JOURNAL Unpublished (1996)
 COMMENT Contact: Marra M/Mouse EST Project
 WashU-HMI Mouse EST Project
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: mouseest@watson.wustl.edu
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 MGI:963749
 Seq primer: -28m13 rev2 ET from Amersham
 High quality sequence stop: 385.
 Location/Qualifiers
 1..408
 /organism="Mus musculus"
 /db_xref="taxon:10090"
 /clone="IMAGE:1764225"
 /clone_lib="Soares mouse urogenital ridge NMUR"
 /sex="equal ratio of male:female"
 /tissue_type="urogenital ridge (embryonic)"
 /dev_stage="fetal, mixture of 11.5 and 12.5 dpc"
 /lab_host="DH10B"
 /note="Organ: gonad; Vector: pT7T3D-Pac (Pharmacia) with a
 modified polylinker; Site.1: Not I; Site.2: Eco RI; 1st
 strand cDNA was primed with a Not I - oligo(dT) primer [5'
 T 3']; double-stranded cDNA was ligated to Eco RI
 adaptors (Pharmacia), digested with Not I and cloned into
 the Not I and Eco RI sites of the modified pT7T3 vector.
 Library went through two rounds of normalization, and was
 constructed by Bento Soares and M. Fatima Bonaldo."
 BASE COUNT 117 a 102 c 102 g 87 t
 ORIGIN
 Query Match 65.5%; Score 19; DB 15; Length 408;
 Best Local Similarity 44.4%; Pred. No. 3.7e+02;
 Matches 12; Conservative 10; Mismatches 5; Indels 0; Gaps 0;
 3 ugaauuuuuuuuagcccuagggcu 29
 :||:||||:|||||||
 Db 342 TGAGCTCTTTCTAGGACCTAGCGCCT 316

Search completed: October 2, 2001, 04:38:42
 Job time: 4064 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 05:03:56 ; Search time 122.48 Seconds
(without alignments)
148.670 Million cell updates/sec

Title: US-09-310-844B-24
Perfect score: 29
Sequence: 1 uauuauuuuuuuuagccuaggggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 730101 seqs, 313950809 residues
Total number of hits satisfying chosen parameters: 1460202

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
N.Geneseq_0601: *
1: /SIDSI/gcgdata/geneseq/NA1980.DAT: *
2: /SIDSI/gcgdata/geneseq/NA1981.DAT: *
3: /SIDSI/gcgdata/geneseq/NA1982.DAT: *
4: /SIDSI/gcgdata/geneseq/NA1983.DAT: *
5: /SIDSI/gcgdata/geneseq/NA1984.DAT: *
6: /SIDSI/gcgdata/geneseq/NA1985.DAT: *
7: /SIDSI/gcgdata/geneseq/NA1986.DAT: *
8: /SIDSI/gcgdata/geneseq/NA1987.DAT: *
9: /SIDSI/gcgdata/geneseq/NA1988.DAT: *
10: /SIDSI/gcgdata/geneseq/NA1989.DAT: *
11: /SIDSI/gcgdata/geneseq/NA1990.DAT: *
12: /SIDSI/gcgdata/geneseq/NA1991.DAT: *
13: /SIDSI/gcgdata/geneseq/NA1992.DAT: *
14: /SIDSI/gcgdata/geneseq/NA1993.DAT: *
15: /SIDSI/gcgdata/geneseq/NA1994.DAT: *
16: /SIDSI/gcgdata/geneseq/NA1995.DAT: *
17: /SIDSI/gcgdata/geneseq/NA1996.DAT: *
18: /SIDSI/gcgdata/geneseq/NA1997.DAT: *
19: /SIDSI/gcgdata/geneseq/NA1998.DAT: *
20: /SIDSI/gcgdata/geneseq/NA1999.DAT: *
21: /SIDSI/gcgdata/geneseq/NA2000.DAT: *
22: /SIDSI/gcgdata/geneseq/NA2001.DAT: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	29	100.0	29	21	AAA70828
2	29	100.0	42	21	AAA71123
3	29	100.0	42	21	AAA71131
4	29	100.0	209	18	AA761453
5	29	100.0	209	21	AA259456
6	29	100.0	698	6	AA550132
7	29	100.0	698	8	AA60101
8	29	100.0	722	7	AA70144
9	29	100.0	769	11	AA001764
10	29	100.0	784	5	AA40046
11	29	100.0	784	7	AA60787

12	29	100.0	784	7	AA60102	Sequence of human
13	29	100.0	788	10	AA90253	Interleukin-2. Ho
14	29	100.0	794	5	AA40441	Gene encoding poly
15	29	100.0	794	10	AA90381	Recombinant human
16	29	100.0	800	6	AA50219	Sequence encoding
17	29	100.0	801	4	AA30031	Sequence of Interl
18	29	100.0	801	5	AA40057	Cloned human inter
19	29	100.0	801	5	AA40254	Sequence encoding
20	29	100.0	802	6	AA50279	DNA sequence conta
21	29	100.0	810	7	AA60840	Sequence encoding
22	29	100.0	844	21	AA620965	Human low adenosin
23	29	100.0	844	21	AA34843	Human adenosine re
24	29	100.0	5561	21	AA620964	Human low adenosin
25	29	100.0	5561	21	AA34842	Human adenosine re
26	29	100.0	22421	21	AA620966	Human low adenosin
27	29	100.0	22421	21	AA34844	Human adenosine re
28	29	96.6	45	21	AA70824	Human adenosine re
29	29	96.6	46	21	AA71087	Molecular interact
30	28	96.6	46	21	AA71096	Molecular interact
31	28	96.6	46	21	AA71099	Molecular interact
32	28	96.6	46	21	AA71100	Molecular interact
33	28	96.6	46	21	AA71104	Molecular interact
34	25.8	89.0	42	21	AA71113	Molecular interact
35	25.8	89.0	42	21	AA71118	Molecular interact
36	25.8	89.0	42	21	AA71126	Molecular interact
37	24.8	85.5	46	21	AA71085	Molecular interact
38	24.8	85.5	46	21	AA71103	Molecular interact
39	23.8	82.1	42	21	AA71114	Molecular interact
40	23.8	82.1	42	21	AA71119	Molecular interact
41	23.8	82.1	42	21	AA71127	Molecular interact
42	23.8	82.1	46	21	AA71094	Molecular interact
43	23.8	82.1	46	21	AA71110	Molecular interact
44	23.2	80.0	29	21	AA70829	Molecular interact
45	23.2	80.0	29	21	AA70830	Molecular interact

ALIGNMENTS

RESULT 1	
ID	AAA70828 standard; RNA: 29 BP.
XX	AAA70828:
XX	27-APR-2001 (first entry)
XX	
DE	Molecular interaction site RNA #28.
XX	
KW	Modulator; identification; molecular interaction; virtual library; ss.
OS	Homo sapiens.
XX	
PN	W0958947-A2.
XX	
PD	18-NOV-1999.
XX	
PF	12-MAY-1999; 99MO-US10361.
XX	
PR	12-MAY-1998; 98US-0076404.
PR	12-MAY-1998; 98US-0085092.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Baker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI	Hofstadler S, McNeill J;
XX	
DR	WPI; 2000-086439/07.
XX	
PT	Identifying compounds which modulate activity of target biomolecules,
PT	used to provide compounds which can be used as pharmacological,
PT	agricultural and industrial compounds -
XX	

PS Claim 235; Page 235; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACUUAUCUGUUUACGAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 29 BP; 5 A; 5 C; 7 G; 12 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 29;
Best Local Similarity 100.0%; Pred. No. 0.00034;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 uaugauuuuuuuuuaagccuaggggcu 29
DB 1 uaugauuuuuuuuuaagccuaggggcu 29
|||||:|||||:|||||:|||||:|||||:

RESULT 2
AAA71123
ID AAA71123 standard; DNA; 42 BP.
XX
AC AAA71123;
XX
DT 27-APR-2001 (first entry)
XX
KW Molecular interaction site DNA #129.
XX
OS Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
PN W09958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX
PI Hofstadler S, McNeill J;
XX
DR WPI: 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
XX
PT used to provide compounds which can be used as pharmacological,
XX
XX agricultural and industrial compounds -

PS Example 7; Figure 125; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACUUAUCUGUUUACGAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 42 BP; 9 A; 6 C; 9 G; 18 T; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 42;
Best Local Similarity 58.6%; Pred. No. 0.00035;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY 1 uaugauuuuuuuuuaagccuaggggcu 29
DB 4 tatgatctcttttgaagccctaggggct 32
|||||:|||||:|||||:|||||:|||||:

RESULT 3
AAA71131
ID AAA71131 standard; RNA; 42 BP.
XX
AC AAA71131;
XX
DT 27-APR-2001 (first entry)
XX
KW Molecular interaction site RNA #200.
XX
OS Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
PN W09958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX
PI Hofstadler S, McNeill J;
XX
DR WPI: 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
XX
PT used to provide compounds which can be used as pharmacological,
XX
XX agricultural and industrial compounds -

PS Example 7; Figure 126; 405pp; English.

XX This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming an end loop region; (d) 4 or 5
CC nucleotides forming a second side of a second ds region; (e) 4 nucleotides forming a
CC second side of the internal loop region; and (f) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUAAUCUAGUUUACAGAAAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

CC Sequence 42 BP; 9 A; 6 C; 9 G; 18 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 42;

Best Local Similarity 100.0%; Pred. No. 0.00035;

Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 uaugauuuuuuuuagccuaggggcu 29

|||||

Db 4 uaugauuuuuuuuagccuaggggcu 32

RESULT 4

AAT61453

ID AAT61453 standard; CDNA; 209 BP.

XX AAT61453;

XX 30-OCT-1997 (first entry)

XX IL-2 CDNA 3'end.

XX Reverse transcription; restriction enzyme; adapter; PCR;
XX amplification; isolation; T-cell; activation; expression; ss.

XX Synthetic.

XX WO9705286-A1.

XX 13-FEB-1997.

XX 30-JUL-1996; 96WO-US12468.

XX 01-AUG-1995; 95US-0510032.

XX (UYVA) UNIV YALE.

XX Prashar Y, Weissman S;

XX WPI; 1997-145720/13.

XX Isolating DNA complementary to mRNA in a sample - by reverse

XX transcription, restriction enzyme cutting, ligation to a Y-shaped

XX adapter and selective PCR amplification

XX Example 1; Page 13; 46pp; English.

XX

CC The sequences given in AAT61442 to AAT61453 are claimed and are used
CC to exemplify the new method for isolating DNA in a nucleic acid
CC sample. RNA expression during early T-cell activation was studied
CC as test system.

XX Sequence 209 BP; 56 A; 30 C; 33 G; 90 T; 0 other;

Query Match 100.0%; Score 29; DB 18; Length 209;

Best Local Similarity 58.6%; Pred. No. 0.00044;

Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

OY 1 uaugauuuuuuuuagccuaggggcu 29

|||||

Db 33 tatgattctttgtaagccctaagggt 61

RESULT 5

AA259456

ID AA259456 standard; DNA; 209 BP.

XX AA259456;

XX 11-APR-2000 (first entry)

XX Interleukin-2 fragment nucleotide sequence.

XX Selective amplification method; gene expression; analysis; interleukin-2;

XX mRNA level comparison; IL-2; human; ss.

XX Homo sapiens.

XX US6010850-A.

XX 04-JAN-2000.

XX 30-JUL-1996; 96US-0688514.

XX 01-AUG-1995; 95US-0510032.

XX (UYVA) UNIV YALE.

XX Prashar Y, Weissman SM;

XX WPI; 2000-105493/09.

XX DNA amplification method useful for studying changes in gene expression

XX between cell populations

XX Example 1; Column 7-8; 23pp; English.

XX This is a fragment of the interleukin-2 nucleotide sequence, which can be

XX amplified by the method of the invention. The invention relates to a

XX method for selectively amplifying DNA, where the DNA has a sequence

XX complementary to a 3' end of an mRNA comprising ligating digested cDNA to

XX a adaptor. The method mediates selective PCR amplification of cDNAs under

XX high stringency. The method can be used for comparing the levels of mRNA

XX expression in two cell populations by selectively amplifying a DNA

XX fragment in a nucleic acid sample from each cell and comparing the

XX amounts of amplified fragments obtained. The comparison can be carried

XX out where at least one of the primers is labelled, preferably with a

XX radiolabel or fluorescent label, and where one of the cell populations is

XX a treated population (the other being a control population).

XX Sequence 209 BP; 56 A; 30 C; 33 G; 90 T; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 209;

Best Local Similarity 58.6%; Pred. No. 0.00044;

Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

OY 1 uaugauuuuuuuuagccuaggggcu 29

Db 33 tatgattcttttgaagccctaggagct 61

RESULT 6

AAAN50132 ID AAN50132 standard; DNA; 698 BP.

AC AAN50132;

DT 15-OCT-1991 (first entry)

DE DNA sequence encoding Interleukin-2.

KW Interleukin-2; ss.

OS Homo sapiens.

Key Location/Qualifiers
CDS 10..391
/*tag= a
/label= Interleukin-2

EP152358-A.

PD 21-AUG-1985.

PF 16-FEB-1984; 84EP-0002350.

PR 16-FEB-1984; 84FR-0002350.

PS (TRAN-) TRANSGENE SA.

PI Lemoine Y, Sondermeyer P, Loison G, Aigle M, Lecocq JP;

XX WPI; 1985-204923/34.

DR P-PSDB; AAP50111.

XX Vectors for expression of Interleukin-2 yeasts - contg. yeast

PT promoter and sequence coding for Interleukin.

XX Disclosure; Fig 2; 18pp; French.

CC The human interleukin-2 gene is cloned and expressed in

CC Saccharomyces cerevisiae in a mature form without post-translational

XX modification.

XX Sequence 698 BP; 251 A; 119 C; 106 G; 222 T; 0 other;

Query Match 100.0%; Score 29; DB 6; Length 698;

Best Local Similarity 58.6%; Pred. No. 0.00052;

Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY 1 naugauucuuuuuuaagcccuaggggcu 29

Db 534 tatgattcttttgaagccctaggagct 562

RESULT 7

AAAN60101 ID AAN60101 standard; cDNA; 698 BP.

AC AAN60101;

DT 02-JUL-1991 (first entry)

DE Sequence of human Interleukin 2 (IL2) gene on plasmid pTG 26.

KW Pox virus vector; vaccinia; ss.

OS Homo sapiens.

Key Location/Qualifiers
CDS 10..393

FT conflict /*tag= a (T_45,G_45)

FT /*tag= b /citation= 1 (G_387,T_387)

FT conflict /*tag= c /citation= 1

EP206939-A.

PD 30-DEC-1986.

PF 19-JUN-1986; 86EP-0401349.

PR 21-JUN-1985; 85FR-0009480.

PS (TRAN-) TRANSGENE SA.

PI (KIEIN/) KIENT M-P.

XX Kiemy MP, Sondermeyer P, Lecocq JP;

XX WPI; 1986-341222/52.

DR P-PSDB; AAP60086.

XX Genetically modified pox viruses - contg. DNA coding for human

XX Interleukin 2

XX Example; Fig 1; 33pp; French.

CC cDNA coding for IL2 in plasmid pTG26 is restructured by inserting a

CC 92bp synthetic peptide signal fragment, giving a plasmid pTG36. A

CC plasmid pTG186-POLY is prep'd. as in EP 206920. This is digested with

CC PstI and ligated with PstI-digested pTG36. The recombinants are used

CC to transform E. coli and selected to give plasmid pVIT2 (pTG186)

CC which is cloned in vaccinia virus. Citation 1 - Taniguchi, T. et al.

CC (1983) Nature, 302, p305. The conflicts are silent wrt translation.

XX Sequence 698 BP; 251 A; 117 C; 108 G; 222 T; 0 other;

Query Match 100.0%; Score 29; DB 7; Length 698;

Best Local Similarity 58.6%; Pred. No. 0.00052;

Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY 1 naugauucuuuuuuaagcccuaggggcu 29

Db 534 tatgattcttttgaagccctaggagct 562

RESULT 8

AAAN70144 ID AAN70144 standard; cDNA; 722 BP.

AC AAN70144;

DT 17-APR-1991 (first entry)

DE Sequence encoding human Interleukin-2 (IL-2).

KW Mastitis therapy; parasitic infection; lymphokine; ss.

OS Homo sapiens.

Key Location/Qualifiers
CDS 8..67
FT mat_peptide /*tag= a 68..469
FT misc_feature /*tag= b 11..719
FT /*tag= c
FT /note= "used to probe bovine cDNA library"

```

XX EP215576-A.
PN
XX
PD 25-MAR-1987.
XX
XX 15-AUG-1986; 86EP-0306303.
XX
XX 31-JUL-1986; 86US-0888994.
PR 16-AUG-1985; 85US-0766643.
XX
XX (IMMO-) IMMUNEX CORP.
XX
XX Anderson DM, Baker PE, Cantrell MA, Cerretti DP, Cosman DJ,
PI Gimpel SD, Grabstein KH, Larsen AD, McKereghan KN;
XX
XX WPI; 1987-081523/12.
DR P-PSDB; AAP70090.
XX
XX Recombinant bovine interleukin-2 - for treating mastitis,
XX respiratory and gastro-intestinal syndromes and parasitic
XX infections
XX
XX Disclosure; Fig 1; 47pp; English.
XX
XX A bovine cDNA library was screened using a probe which was essentially
XX the entire length of human IL-2 cDNA (AAN70144). A single positive
XX host colony was identified. Plasmid bIL-2-4 was prepd. and the
XX nucleotide sequence detd. (AAN70145). The specific activity of the
XX bIL-2 is 4.5 x 10(4) units/mg protein.
XX
XX Sequence 722 BP; 245 A; 130 C; 112 G; 235 T; 0 other;
SQ

```

Query Match 100.0%; Score 29; DB 8; Length 722;
 Best Local Similarity 58.6%; Pred. No. 0.00052;
 Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

```

OY 1 uaugauuuuuuuuagaccuagggcu 29
DB 610 tatgatcttttggtaagccctagggc 638

```

RESULT 9
 ID AAO01764
 XX AAO01764 standard; DNA; 769 BP.
 AC AAO01764;
 XX 27-JUL-1990 (first entry)
 DE Human interleukin-2 gene.
 XX
 XX IL-2; dhfr; dihydrofolic acid reductase; differentiation.
 KM
 XX Homo sapiens.
 OS
 XX
 XX Key Location/Qualifiers
 FH 3..506
 FT /*tag= a
 FT
 FT
 XX JP02009388-A.
 PN
 XX 12-JAN-1990.
 PD
 XX 08-JUL-1988; 88JP-0170142.
 PF
 XX 09-MAR-1988; 88JP-0055270.
 PR
 XX (AJIN) AJINOMOTO KK.
 PA
 XX WPI; 1990-055348/08.
 DR P-PSDB; AAR05414.
 XX

```

PT Physiologically active protein prep.
PT by transforming plasmid having gene coding physiologically
PT active protein and gene of dihydrofolic acid reductase to hamster
PT ovary etc.
XX
XX Example 2; Fig 4; 12pp; Japanese.
XX
XX Gene may be expressed by transforming a dhfr negative strain of CHO cells
CC with an active IL-2 gene and dhfr carrying vector.
CC
XX
XX Sequence 769 BP; 280 A; 131 C; 113 G; 245 T; 0 other;
SQ

```

Query Match 100.0%; Score 29; DB 11; Length 769;
 Best Local Similarity 58.6%; Pred. No. 0.00053;
 Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

```

OY 1 uaugauuuuuuuuagaccuagggcu 29
DB 605 tatgatcttttggtaagccctagggc 633

```

RESULT 10
 ID AAN40046
 XX AAN40046 standard; cDNA; 784 BP.
 AC AAN40046;
 XX 14-JAN-1992 (first entry)
 DE
 DE Sequence encoding interleukin-2 (IL-2) related polypeptide in
 DE clone pSV-HIL-2L-O.
 XX
 XX Diagnosis; therapy; cancer; tumour-specific cytotoxic cell; AIDS;
 KM multiple sclerosis; lupus; rheumatoid arthritis; herpes;
 KW viral disease; lymphokine; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX Key Location/Qualifiers
 FH 48..509
 FT /*tag= a
 FT polyA_signal 771..776
 FT /*tag= b
 XX
 XX EP118977-A.
 PN
 XX 19-SEP-1984.
 PD
 XX 25-JAN-1984; 84EP-0300439.
 PF
 XX 10-JUN-1983; 83GB-0015981.
 PR 08-FEB-1983; 83GB-0003383.
 XX
 XX (BIOJ) BIOGEN NV.
 PA
 XX Fiers WC, Devos RR;
 PI
 XX WPI; 1984-232548/38.
 DR P-PSDB; AAP40055.
 DR
 XX Prodn. of human interleukin 2-like polypeptide(s) - useful
 PT instead of IL-2 for stimulating the immune system etc.
 PT
 XX Disclosure; Fig 4; 69pp; English.
 PS
 XX The DNA sequence is esp. selected from a human chromosomal gene bank,
 CC e.g. it is a hIL-2 related portion of lambda CHA-ghIL-2-1 or -2, or
 CC of lambda I47-ghIL-2-1, -2 or -3. Transformed hosts are also claimed,
 CC esp. E.coli, Ps spp.; B.subtilis, B.steartotherophilus. IL-2-like
 CC polypeptides are also claimed. AAN40046 is an IL-2 related DNA sq of
 CC the invention. It is missing at least part of the coding region for
 CC the amino acids of the putative signal sequence of pre hIL-2 and the

DT 01-NOV-1989 (first entry)
XX Interleukin-2.
DE Interleukin-2.
XX Interleukin-2; lysine-depleted variant; site-directed
KW mutagenesis; human.
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FT CDS 43..501
FT /*tag= a
XX
XX W08905824-A.
XX
XX
XX PD 29-JUN-1989.
XX
XX PF 22-DEC-1988; 88WO-US04633.
XX
XX PE 23-DEC-1987; 87US-0137043.
XX
XX (GENE) GENETICS INST INC.
XX
XX Shaw G;
XX
XX WPI: 1989-206594/28.
XX
XX DR P-PSDB: AAP90467.
XX
XX New lysine depleted variants of polypeptide
PT - opt. modified with hydrophilic residues,
PT biologically active but with altered solubility, stability etc.
XX
XX PS Disclosure; fig 1: 35pp; English.
XX
XX CC DNA of interleukin-2 (see corresp. AAP90467). Used in the patent
CC to create lysine depleted variants by site-directed mutagenesis, or
CC synthesis.
XX
XX SQ Sequence 788 BP; 272 A; 146 C; 113 G; 257 T; 0 other;

Query Match 100.0%; Score 29; DB 10; Length 788;
Best Local Similarity 58.6%; Pred. No. 0.00053;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

OY 1 uaugauucuuuuuuaagccuagggcu 29
Db :|||:|||||:|||||:|||||:
645 tatgattctttgttaagccctagggcct 673

RESULT 14
AAN40441
ID AAN40441 standard; cDNA; 794 BP.
XX
XX AC AAN40441;
XX
XX DT 21-JUL-1992 (first entry)
XX
XX DE Gene encoding polypeptide having IL-2 activity.
XX
XX KW Interleukin.
XX
XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
FT CDS 47..508
FT /*tag= a
FT PolYA_signal 770..775
FT /*tag= b
FT PolYA_site 788..794
FT /*tag= c
XX
XX JP59139349-A.

XX
PD 10-AUG-1984.
XX
XX PE 29-DEC-1982; 82JP-0230372.
XX
XX PR 29-DEC-1982; 82JP-0230372.
XX
XX PA (AJIN) AJINOMOTO KK.
XX (GANK-) GAN KENKYUKAI ZH.
XX
XX DR WPI: 1984-233967/38.
XX
XX PT Polypeptide having interleukin-2 activity - with amino acid sequence
PT having C-terminal threonine.
XX
XX PS Disclosure; Page 7; 16pp; Japanese.
XX
XX CC The DNA was obt'd. from mRNA of human Leukaemia cells.
XX
XX SQ Sequence 794 BP; 276 A; 147 C; 113 G; 258 T; 0 other;

Query Match 100.0%; Score 29; DB 5; Length 794;
Best Local Similarity 58.6%; Pred. No. 0.00053;
Matches 17; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

OY 1 uaugauucuuuuuuaagccuagggcu 29
Db :|||:|||||:|||||:|||||:
649 tatgattctttgttaagccctagggcct 677

RESULT 15
AAN90381
ID AAN90381 standard; cDNA; 794 BP.
XX
XX AC AAN90381;
XX
XX DT 03-NOV-1989 (first entry)
XX
XX DE Recombinant human interleukin-2 DNA.
XX
XX KW Recombinant human interleukin-2 DNA; jurkat cells; leukaemia.
XX
XX OS Homo sapiens (human).
XX
XX FH Key Location/Qualifiers
FT sig_peptide 47..106
FT /*tag= a
FT mat_peptide 107..505
FT /*tag= b
XX
XX JP01165399-A.
XX
XX PD 29-JUN-1989.
XX
XX PE 24-DEC-1982; 82JP-0292084.
XX
XX PR 24-DEC-1982; 82JP-0292084.
XX
XX PA (AJIN) AJINOMOTO KK.
XX (GANK-) ZH GAN KENKYUKAI.
XX
XX DR WPI: 1989-230772/32.
XX P-PSDB: AAP90614.
XX
XX PT Recombinant human interleukin-2
PT - produced by irradiating hIL-2-producing
PT jurkat cells, extracting mRNA, forming cDNA, inserting into
PT pBR322 and transforming E. coli.
XX
XX PS Claim 1; page 737; 16pp; Japanese.
XX
XX CC Recombinant human interleukin-2 (hIL-2) DNA (see AAP90614). Isolated

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 04:38:42 ; Search time 1643.83 seconds
(without alignments)
166.765 Million cell updates/sec

Title: US-09-310-844B-25
Perfect score: 29
Sequence: 1 aaagaucuuuuuuaagccccaagggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 10228115 seqs, 4726426750 residues
Total number of hits satisfying chosen parameters: 20456230

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*

1: gb_est1:*
2: gb_est2:*
3: gb_est3:*
4: gb_est4:*
5: gb_est5:*
6: gb_est6:*
7: gb_est7:*
8: gb_est8:*
9: gb_est9:*
10: gb_est10:*
11: gb_est11:*
12: gb_est12:*
13: gb_est13:*
14: gb_est14:*
15: gb_est15:*
16: gb_est16:*
17: gb_est17:*
18: gb_est18:*
19: gb_est19:*
20: gb_est20:*
21: gb_est21:*
22: gb_est22:*
23: gb_est23:*
24: gb_est24:*
25: gb_est33:*
26: gb_est34:*
27: gb_est35:*
28: gb_est36:*
29: gb_est37:*
30: gb_est38:*
31: gb_est39:*
32: gb_est40:*
33: em_estba:*
34: em_estfun:*
35: em_esthum1:*
36: em_esthum2:*
37: em_esthum3:*
38: em_esthum4:*
39: em_esthum5:*
40: em_esthum6:*
41: em_esthum7:*
42: em_esthum8:*
43: em_esthum9:*

44: em_esthum10:*
45: em_esthum11:*
46: em_esthum12:*
47: em_esthum13:*
48: em_esthum14:*
49: em_esthum15:*
50: em_esthum16:*
51: em_esthum17:*
52: em_esthum18:*
53: em_esthum19:*
54: em_esthum20:*
55: em_esthum21:*
56: em_esthum22:*
57: em_esthum23:*
58: em_esthum24:*
59: em_esthum25:*
60: em_esthum26:*
61: em_esthum27:*
62: em_esthum28:*
63: em_estin1:*
64: em_estin2:*
65: em_estin3:*
66: em_estin4:*
67: em_estin5:*
68: em_estom1:*
69: em_estom2:*
70: em_estov1:*
71: em_estov2:*
72: em_estp11:*
73: em_estp12:*
74: em_estp13:*
75: em_estp14:*
76: em_estp15:*
77: em_estp16:*
78: em_estp17:*
79: em_estp18:*
80: em_estp19:*
81: em_estp110:*
82: em_estro1:*
83: em_estro2:*
84: em_estro3:*
85: em_estro4:*
86: em_estro5:*
87: em_estro6:*
88: em_estro7:*
89: em_estro8:*
90: em_estro9:*
91: em_estro10:*
92: em_estro11:*
93: em_estro12:*
94: em_estro13:*
95: em_estro14:*
96: em_estro15:*
97: em_estro16:*
98: em_estro17:*
99: em_estro18:*
100: em_estro19:*
101: em_estro20:*
102: gb_est25:*
103: gb_est26:*
104: gb_est27:*
105: gb_est28:*
106: gb_est29:*
107: gb_est30:*
108: gb_est31:*
109: gb_est32:*
110: gb_est41:*
111: gb_est42:*
112: gb_est43:*
113: gb_est44:*
114: gb_est45:*
115: gb_est46:*
116: gb_est47:*

117: gb_est148:*
118: gb_est149:*
119: gb_est150:*
120: gb_est151:*
121: gb_est152:*
122: gb_est153:*
123: gb_est154:*
124: gb_est155:*
125: gb_est156:*
126: gb_est157:*
127: gb_est158:*
128: gb_est159:*
129: gb_est160:*
130: gb_est161:*
131: gb_est162:*
132: gb_est163:*
133: gb_est164:*
134: gb_est165:*
135: gb_est166:*
136: gb_est167:*
137: gb_est168:*
138: gb_est169:*
139: gb_est170:*
140: gb_est171:*
141: gb_est172:*
142: gb_est173:*
143: gb_est174:*
144: gb_est175:*
145: gb_est176:*
146: gb_est177:*
147: gb_est178:*
148: gb_est179:*
149: gb_est180:*
150: gb_est181:*
151: gb_est182:*
152: gb_est183:*
153: gb_est184:*
154: gb_est185:*
155: gb_est186:*
156: gb_est187:*
157: gb_est188:*
158: gb_est189:*
159: gb_est190:*
160: gb_est191:*
161: gb_est192:*
162: gb_est193:*
163: gb_est194:*
164: gb_est195:*
165: gb_est196:*
166: gb_est197:*
167: gb_est198:*
168: gb_est199:*
169: gb_est200:*
170: gb_est201:*
171: gb_est202:*
172: gb_est203:*
173: gb_est204:*
174: gb_est205:*
175: gb_est206:*
176: gb_est207:*
177: gb_est208:*
178: gb_est209:*
179: gb_est210:*
180: gb_est211:*
181: gb_est212:*
182: gb_est213:*
183: gb_est214:*
184: gb_est215:*
185: gb_est216:*
186: gb_est217:*
187: gb_est218:*
188: gb_est219:*
189: gb_est220:*

190: gb_est110:*
191: gb_est111:*
192: gb_hic:*
193: em_gss_fun:*
194: em_gss_hum1:*
195: em_gss_hum2:*
196: em_gss_hum3:*
197: em_gss_hum4:*
198: em_gss_hum5:*
199: em_gss_hum6:*
200: em_gss_hum7:*
201: em_gss_hum8:*
202: em_gss_hum9:*
203: em_gss_inv1:*
204: em_gss_inv2:*
205: em_gss_inv3:*
206: em_gss_other:*
207: em_gss_pin1:*
208: em_gss_pin2:*
209: em_gss_pro:*
210: em_gss_rod1:*
211: em_gss_rod2:*
212: em_gss_rod3:*
213: em_gss_rod4:*
214: em_gss_rod5:*
215: em_gss_vrt1:*
216: em_gss_vrt2:*
217: em_gss_vrt3:*
218: gb_gss1:*
219: gb_gss2:*
220: gb_gss3:*
221: gb_gss4:*
222: gb_gss5:*
223: gb_gss6:*
224: gb_gss7:*
225: gb_gss8:*
226: gb_gss9:*
227: gb_gss10:*
228: gb_gss11:*
229: gb_gss12:*
230: gb_gss13:*
231: gb_gss14:*
232: gb_gss15:*
233: gb_gss16:*
234: gb_gss17:*
235: gb_gss18:*
236: gb_gss19:*
237: gb_gss20:*
238: gb_gss21:*
239: gb_gss22:*
240: gb_gss23:*
241: gb_gss24:*
242: gb_gss25:*
243: gb_gss26:*
244: gb_gss27:*
245: gb_gss28:*
246: gb_gss29:*
247: gb_gss30:*
248: gb_gss31:*
249: gb_gss32:*
250: gb_gss33:*
251: gb_gss34:*
252: em_gss_inv4:*
253: em_gss_rod6:*
254: em_gss_rod7:*
255: em_gss_rod8:*
256: gb_gss35:*
257: gb_gss36:*
258: gb_gss37:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

ALIGNMENTS

9712 Medical Center Dr., Rockville, MD 20850, USA

Tel: 301 838 0200
Fax: 301 838 0208
Email: mdams@tigr.org
Clones are derived from the human BAC library RPC1-11. For BAC library availability, please contact Pieter de Jong (pieter@jlong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (http://bacpac.med.buffalo.edu/ordering) or from Research Genetics (info@resgen.com). BAC end search page: http://www.tigr.org/tldb/humgen/bac_end_search/bac_end_search.html
Seq primer: SP6
Class: BAC ends.

FEATURES

source

Location/Qualifiers

1..527
/organism="Homo sapiens"
/db_xref="GDB:7527754"
/db_xref="taxon:9606"
/clone="RPC1-11-73E11"
/clone_lib="RPC1-11"
/sex="Male"
/cell_type="Lymphocytes"
/note="Vector: pBACe3.6; Site_1: EcoRI; Site_2: EcoRI;
RPC11 Human Male BAC Library"
BASE COUNT 203 a 78 c 77 g 167 t 2 others
ORIGIN

Query Match 80.0%; Score 23.2; DB 226; Length 527;
Best Local Similarity 57.1%; Pred. No. 6.5;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

OY 2 aagaauuuuuuuaagcccaaggcu 29
|||||:|||||:|||||:|||||:
Db 357 ATGATTCCTTTTGTAGCCCTAGGGGCT 330

RESULT 3
LOCUS AQ267210 596 bp DNA 27-APR-1999
DEFINITION RPC11-73C7.7J RPC1-11 Homo sapiens genomic clone RPC1-11-73C7, DNA sequence.
ACCESSION AQ267210
VERSION AQ267210.1 GI:3794814
KEYWORDS GSS.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
1 (bases 1 to 596)
Adams, M.D., Rounsley, S.D., Zhao, S., Bass, S., Linher, K., Golden, K., Berry, K., Granger, D., Suh, E., Middle, C., de Jong, P., and Venter, J.C.
Use of human BAC End Sequences for Sequence-Ready Map Building
Unpublished (1998)
Other GSSs: RPC11-73C7.TK
Contact: Mark Adams
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
Email: mdams@tigr.org
Clones are derived from the human BAC library RPC1-11. For BAC library availability, please contact Pieter de Jong (pieter@jlong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (http://bacpac.med.buffalo.edu/ordering) or from Research Genetics (info@resgen.com). BAC end search page: http://www.tigr.org/tldb/humgen/bac_end_search/bac_end_search.html
Seq primer: SP6
Class: BAC ends.
Location/Qualifiers
1..596
/organism="Homo sapiens"
/db_xref="GDB:7527702"
/db_xref="taxon:9606"

FEATURES

source

Location/Qualifiers
1..596
/organism="Homo sapiens"
/db_xref="GDB:7527702"
/db_xref="taxon:9606"

/clone="RPC1-11-73C7"
/clone_lib="RPC1-11"
/sex="Male"
/cell_type="Lymphocytes"
/note="Vector: pBACe3.6; Site_1: EcoRI; Site_2: EcoRI;
RPC11 Human Male BAC Library"
BASE COUNT 227 a 92 c 88 g 186 t 3 others
ORIGIN

Query Match 80.0%; Score 23.2; DB 226; Length 596;
Best Local Similarity 57.1%; Pred. No. 6.6;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

OY 2 aagaauuuuuuuaagcccaaggcu 29
|||||:|||||:|||||:|||||:
Db 357 ATGATTCCTTTTGTAGCCCTAGGGGCT 330

RESULT 4
LOCUS BG365004 246 bp mRNA EST 08-MAR-2001
DEFINITION 112339 MARC 1BOV Bos taurus cDNA 5', mRNA sequence.
ACCESSION BG365004
VERSION BG365004.1 GI:13254101
KEYWORDS EST.
SOURCE cow.
ORGANISM Bos taurus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovidae; Bovinae; Bos.
1 (bases 1 to 246)
Smith, T.P.L., Casas, E., Stone, R.T., Heaton, M.P., Grosse, W.M., Bennett, G.A., Fahrenkrug, S.C., Freking, B.A., Rohrer, G.A., Laegreid, W.W., and Keefe, J.W.
Design and use of four pooled tissue normalized cDNA libraries for EST discovery in cattle
Unpublished (2000)
Contact: Smith TPL
USDA, ARS, US Meat Animal Research Center
PO Box 166, Clay Center, NE 68933-0166, USA
Tel: 402 762 4366
Fax: 402 762 4390

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
Email: smith@mail.marc.usda.gov
Single pass sequencing. Bases called and alt. trimmed with phred v0.980904.e. Vector identified by cross-match with the -minscore 18 and -minmatch 12 options.
PCR primers
FORWARD: AGGAACACGATATGACCAT
BACKWARD: GTTTCACGACGACGACG
Plate: 103 row: K column: 22
Seq primer: ATTAGGACACATATAG.
Location/Qualifiers
1..246
/organism="Bos taurus"
/db_xref="taxon:9913"
/clone_lib="MARC 1BOV"
/tissue_type="Pooled"
/lab_host="DH10B"
/note="Vector: pCMV SPORT6; Site_1: XbaI; Site_2: XhoI;
Library made from pooled tissue from lymph node, ovary, fat, hypothalamus, and pituitary."

FEATURES
source
Location/Qualifiers
1..246
/organism="Bos taurus"
/db_xref="taxon:9913"
/clone_lib="MARC 1BOV"
/tissue_type="Pooled"
/lab_host="DH10B"
/note="Vector: pCMV SPORT6; Site_1: XbaI; Site_2: XhoI;
Library made from pooled tissue from lymph node, ovary, fat, hypothalamus, and pituitary."

BASE COUNT 62 a 49 c 68 g 67 t

Query Match 72.4%; Score 21; DB 152; Length 246;
Best Local Similarity 51.7%; Pred. No. 53;
Matches 15; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

OY 1 aagaauuuuuuuaagcccaaggcu 29
|||||:|||||:|||||:|||||:
Db 198 AAGGCTTTTGTAGCCCTAGGGGCT 170

RESULT 5
 A0809431/c 516 bp DNA GSS 10-AUG-1999
 LOCUS HS_3149_B1_A05_TTC CIT Approved Human Genomic Sperm Library D Homo
 DEFINITION sapiens genomic clone Plate=3149 Col=9 Row=B, DNA sequence.
 A0809431
 ACCESSION A0809431.1 GI:5728673
 KEYWORDS GSS.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 516)
 Kellier,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and
 Hood,L.
 TITLE Sequence-tagged connectors: A sequence approach to mapping and
 scanning the human genome
 JOURNAL Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999)
 MEDLINE 99380589
 COMMENT Contact: Mahairas GG, Wallace JC, Hood L
 High Throughput Sequencing Center
 University of Washington
 401 Queen Anne Avenue North, Seattle, WA 98109, USA
 Tel: (206) 616-3618
 Fax: (206) 616-3887
 Email: jwallace@u.washington.edu
 Clones may be purchased from Research Genetics (info@resgen.com).
 BAC end Web Server: http://www.htsc.washington.edu
 Plate: 3149 row: B column: 9
 Seq primer: T7
 Class: BAC ends
 High quality sequence stop: 516.
 FEATURES
 source Location/Qualifiers
 1..516
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="Plate=3149 Col=9 Row=B"
 /clone_1ib="CIT Approved Human Genomic Sperm Library D"
 /sex="male"
 /note="Organ: sperm; Vector: pBelobAC11; BAC Clones in
 E-Coli DH10B"
 BASE COUNT 162 a 112 c 99 g 139 t 4 others
 ORIGIN
 Query Match 72.4%; Score 21; DB 233; Length 516;
 Best Local Similarity 58.6%; Pred. No. 60;
 Matches 17; Conservative 7; Mismatches 5; Indels 0; Gaps 0;
 OY 1 aaagaucuuuuuaggaagcccaaggcu 29
 ||| | : : : ||||| ||| | :
 Db 90 AAACACTCTGTTGTAAAGCCGCAAGTGT 62

RESULT 6
 A0239971/c 309 bp DNA GSS 30-SEP-1998
 LOCUS CIT-HSP-2386F6.TR.1 CIT-HSP Homo sapiens genomic clone 2386F6, DNA
 DEFINITION sequence.
 A0239971
 ACCESSION A0239971.1 GI:3672169
 KEYWORDS GSS.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 309)
 Adams,M.D., Rounsley,S.D., Zhao,S., Bass,S., Linher,K., Golden,K.,
 Berry,K., Granger,D., Suh,E., Wible,C., Shizuya,H., Simon,M. and
 Venter,J.C.

TITLE Use of a random human BAC End Sequence Database for Sequence-Ready
 Map Building
 JOURNAL Unpublished (1998)
 COMMENT Other_GSS: CIT-HSP-2386F6.TR.1
 Contact: Mark Adams
 Department of Eukaryotic Genomics
 The Institute for Genomic Research
 9712 Medical Center Dr., Rockville, MD 20850, USA
 Tel: 301 838 0200
 Fax: 301 838 0208
 Email: mdadams@tigr.org
 Clones are available from Research Genetics (info@resgen.com). BAC
 end search page:
 http://www.tigr.org/tldb/hungen/bac_end_search/bac_end_search.html.
 Seq primer: M13 Reverse
 Class: BAC ends.
 FEATURES
 source Location/Qualifiers
 1..309
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="2386F6"
 /clone_1ib="CIT-HSP"
 /sex="Male"
 /cell_type="Sperm"
 /note="Vector: pBelobAC11; Site_1: HindIII; Site_2:
 HindIII"
 BASE COUNT 105 a 56 c 58 g 90 t
 ORIGIN
 Query Match 71.7%; Score 20.8; DB 226; Length 309;
 Best Local Similarity 58.3%; Pred. No. 68;
 Matches 14; Conservative 8; Mismatches 2; Indels 0; Gaps 0;
 OY 6 uucuuuuuaggaagcccaaggcu 29
 : : : : : ||||| ||| | :
 Db 80 TTCTATTGTAAAGCCCATGGCT 57

RESULT 7
 A2407430 646 bp DNA GSS 03-OCT-2000
 LOCUS IM0178F16F Mouse 10kb plasmid UGCCIM library Mus musculus genomic
 DEFINITION clone UGCCIM0178F16 F, DNA sequence.
 A2407430
 ACCESSION A2407430.1 GI:10531539
 KEYWORDS GSS.
 ORGANISM Mus musculus
 house mouse.
 SOURCE Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 646)
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
 M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
 and Wright,D., Weiss,R.
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts
 JOURNAL Unpublished (2000)
 COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0178 row: F column: 16
 Seq primer: CGTTGTAACGACGCGCAGT
 Class: Plasmid ends
 High quality sequence stop: 646.
 FEATURES
 Location/Qualifiers

Source

```

source
1. .646
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U06C1M018F16"
/clone_id="Mouse 10kb plasmid U06C1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/note="Vector: PWD42ny, Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 (gii4732114[gb|AF129072.1]), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
151 a 96 c 115 g 204 t
BASE COUNT
ORIGIN

```

[illegible]

RESULT	8				
LOCUS	AO592351/c				
DEFINITION	AO592351	470 bp	DNA	GSS	08-JUN-1999
ACCESSION	HS_5446_A1-B11-SP6E	RCPII-11	Human Male	BAC Library	Homo sapiens
VERSION	AO592351				
KEYWORDS	AO592351..1	GI:5024003			
ORIGIN	GSS.				
ORGANISM	human.				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. 1 (bases 1 to 470)				
AUTHORS	Mahairas,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T., Keller,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and Hood,L.				
TITLE	Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome				
JOURNAL	Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999)				
COMMENT	99380589				
CONTACT	Mahairas GG, Wallace JC, Hood L				

```

Plate: 1022 row: C column: 21
Seq primer: SP6
Class: BAC ends
High quality sequence stop: 470
Location/Qualifiers
1. 470
FEATURES
source
```

BASE COUNT	144 a	89 c	89 g	147 t	1 others
ORIGIN					

	68.3%;	Score 19.8;	DB 230;	Length 470;
Query Match	Best Local Similarity	60.9%;	Pred. No. 2e+02;	
Matches	14;	Conservative	7;	Mismatches 2;
			Indels	0;
Gaps	0;			
QY	4	gaucuuuuuuugaaagccccaag	26	
	:	: : : : : :		
Db	76	grrtcttttttgaaaccccccaagg	54	

RESULT	9
LOCUS	AQ487601
DEFINITION	AQ487601 679 bp - DNA
ACCESSION	RPC1-11-242H19.TJ RPC1-11 Homo sapiens genomic clone RPC1-11-242H19
VERSION	, AQ487601
KEYWORDS	' DNA sequence.
SOURCE	AQ487601.1 GI:4673475
ORGANISM	GSS.
REFERENCE	human.
AUTHORS	Homo sapiens
TITLE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo. 1 (bases 1 to 679) Zhao,S., Adams,M.D., Niernan,W., Malek,J., de Jong,P. and Venter ,J.C.
JOURNAL	Use of BAC End Sequences from Library RPC1-11 for Sequence-Ready Map Building
COMMENT	Unpublished (1997) Other_GSSs: RPC1-11-242H19.TV Contact: Shaying Zhao, William Niernan, Mark Adams Department of Eukaryotic Genomics The Institute for Genomic Research 9712 Medical Center Dr., Rockville, MD 20850 Tel.: 301 838 0200 Fax: 301 838 0208 Email: hbe@tigr.org Clones are derived from the human BAC library RPC1-11. For BAC library availability, please contact Pieter de Jong (piet@dejong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (http://bacpac.med.buffalo.edu/ordering) or from Research Genet cs (info@resgen.com). BAC end search page: http://www.tldb.org/tldb/hungen/bac_end_search/bac_end_search.html . Seq primer: SP6 Class: BAC ends.
FEATURES	Location/Qualifiers
SOURCE	1..679

[illegible]

BASE COUNT 93 a 69 c 52 g 136 t
ORIGIN

Query Match 67.6%; Score 19.6; DB 11; Length 350;
Best Local Similarity 61.5%; Pred. No. 2.3e+02;
Matches 16; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

OY 1 aaagaucuuuuuagcccccaag 26
|||||:|:::| ||| |||||
Db 192 AAAGATCTTTTGGAGGCCCAAG 217

RESULT 15

LOCUS AO561664 428 bp DNA GSS 29-MAY-1999
DEFINITION HS_5206_A1_C10_SPEE RPCI-11 Human Male BAC library Homo sapiens
genomic clone Plate=782 Col=19 Row=E, DNA sequence.

ACCESSION AO561664
VERSION AO561664.1 GI:4921135

KEYWORDS GSS.

SOURCE human.
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
1 (bases 1 to 428)
Mahairas, G.G., Wallace, J.C., Smith, K., Swartzell, S., Holzman, T.,
Keller, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M.D., and
Hood, L.

TITLE Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome
Proc. Natl. Acad. Sci. U. S. A. 96 (17), 9739-9744 (1999)
99380589
Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3687

Email: jwallace@u.washington.edu

Clones are derived from the human BAC library RPCI-11. For BAC
library availability, please contact Pieter de Jong
(pieterdejong.med.bufileo.edu). Clones may be purchased from
BACPAC Resources (http://bacpac.med.bufileo.edu/ordering_bac.htm)
or from Research Genetics (<http://www.htsc.washington.edu>). BAC end Web Server:
<http://www.htsc.washington.edu>
Plate: 782 row: E column: 19
Seq primer: SP6
Class: BAC ends

High quality sequence stop: 428.

FEATURES
source Location/Qualifiers
1..428
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_plate="782 Col=19 Row=E"
/clone_lib="RPCI-11 Human Male BAC library"
/sex="male"
/note="Vector: pBAC3.6; Site_1: EcoRI; Site_2: EcoRI;
Male blood DNA was isolated from one randomly chosen donor
and partially digested with a combination of EcoRI and
EcoRI Methylase. Size selected DNA was cloned into the
pBAC3.6 vector at EcoRI sites"

BASE COUNT 140 a 95 c 72 g 116 t 5 others
ORIGIN

Query Match 67.6%; Score 19.6; DB 230; Length 428;
Best Local Similarity 53.8%; Pred. No. 2.4e+02;
Matches 14; Conservative 8; Mismatches 4; Indels 0; Gaps 0;

OY 1 aaagaucuuuuuagcccccaag 26
|||||:|:::| ||| |||||
Db 61 AAAGATCTTTTGGAGGCCCAAG 86

Search completed: October 2, 2001, 04:38:47
Job time: 4069 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 05:00:41 ; Search time 1315.38 Seconds
(without alignments)
341.015 Million cell updates/sec

Title: US-09-310-844B-25

Perfect score: 29
Sequence: 1 aaagaunuuuuuuuuaagccccaagggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1344157 seqs, 7733874588 residues
Total number of hits satisfying chosen parameters: 2688314

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GeneBml: *
1: gb_ba1: *
2: gb_ba2: *
3: gb_ba3: *
4: gb_in1: *
5: gb_in2: *
6: gb_in3: *
7: gb_om: *
8: gb_ov: *
9: gb_pat1: *
10: gb_pat2: *
11: gb_ph: *
12: gb_p11: *
13: gb_p12: *
14: gb_p13: *
15: gb_p14: *
16: em_ba1: *
17: em_ba2: *
18: em_fun: *
19: em_hugo_hum: *
20: em_hugo_inv: *
21: em_hugo_rnd: *
22: em_hug_hum1: *
23: em_hug_hum2: *
24: em_hug_hum3: *
25: em_hug_hum4: *
26: em_hug_hum5: *
27: em_hug_hum6: *
28: em_hug_hum7: *
29: em_hug_hum8: *
30: em_hug_inv1: *
31: em_hug_inv2: *
32: em_hug_other: *
33: em_hug_rnd: *
34: em_hum1: *
35: em_hum2: *
36: em_hum3: *
37: em_hum4: *
38: em_hum5: *
39: em_hum6: *
40: em_hum7: *
41: em_in: *
42: em_om: *
43: em_or: *

44: em_ov: *
45: em_pat: *
46: em_ph: *
47: em_p1: *
48: em_ro: *
49: em_sta: *
50: em_sy: *
51: em_un: *
52: em_v1: *
53: gb_sts1: *
54: gb_sts2: *
55: gb_sts3: *
56: gb_sy: *
57: gb_un: *
58: gb_v11: *
59: gb_v12: *
60: gb_hc1: *
61: gb_hc2: *
62: gb_hc3: *
63: gb_hc4: *
64: gb_hc5: *
65: gb_hc6: *
66: gb_hc7: *
67: gb_hc8: *
68: gb_hc9: *
69: gb_hc10: *
70: gb_hc11: *
71: gb_hc12: *
72: gb_hc13: *
73: gb_hc14: *
74: gb_hc15: *
75: gb_hc16: *
76: gb_hc17: *
77: gb_hc18: *
78: gb_hc19: *
79: gb_hc20: *
80: gb_hc21: *
81: gb_hc22: *
82: gb_hc23: *
83: gb_hc24: *
84: gb_hc25: *
85: gb_p1: *
86: gb_p2: *
87: gb_p3: *
88: gb_p4: *
89: gb_p5: *
90: gb_p6: *
91: gb_p7: *
92: gb_p8: *
93: gb_p9: *
94: gb_p10: *
95: gb_p11: *
96: gb_p12: *
97: gb_p13: *
98: em_ba3: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	DB ID	Description
1	29	100.0	740 95	RATIL2
2	29	100.0	822 94	MMIL03
3	29	100.0	825 10	E00849
4	29	100.0	825 10	I01928
5	29	100.0	825 94	MUSIL2T
6	29	100.0	868 94	MMINTL2
7	29	100.0	870 94	MUSIL2A03
8	29	100.0	939 45	E10514

E00849	LOCUS	E00849	825 bp	RNA	PAT	29-SEP-1997
DEFINITION	Nucleic acid sequence of cDNA encoding a polypeptide possessing murine IL-2 activity.					
ACCESSION	E00849					
VERSION	E00849.1	GI:2169110				
KEYWORDS	JP 1986119197-A/1.					
SOURCE	unidentified.					
ORGANISM	unclassified.					
REFERENCE	1 (bases 1 to 825)					
AUTHORS	Furanuku,D.R., Yokota,T. and Arai,K.					
TITLE	CDNA CLONE FOR CODING POLYPEPTIDE SHOWING RAT INTERLEUKIN-2 ACTIVITY					
JOURNAL	Patent: JP 1986119197-A 1 06-JUN-1986;					
COMMENT	SHIERINGU BAIOTETSUKU CORP OS Human (Homo sapiens) PN JP 1986119197-A/1 PD 06-JUN-1986 PF 04-OCT-1985 JP 1985221684 PR 05-OCT-1984 US 84 658183 PI FURANKU DON RII, YOKOTA TAKASHI, ARAI KENICHI PC C12P21/02.C07K13/00.C07K15/04.C12N1/00.C12M5/00.C12N15/00, PC G01N33/50// PC G01N33/53.G01N33/577.(C12P21/02.C12R1.19).(C12P21/02, PC C12R1.865).(C12P21/02, PC C12R1.91).(C12N1/00,C12R1.19),(C12N1/00,C12R1.865),(C12N5/00, PC C12R1.91); CC strandedness: Double; CC topology: linear; CC hypothetical: No; CC anti-sense: No; CC *source: tissue_type=Blood; CC *source: cell_type=T-cell; CC *source: cell_line=LB2-1 cell; CC *source: clone=LB2-1 clone; FH Key Location/Qualifiers FT CDS 49..558 FT /product='polypeptide possessing murine IL-2 FT activity'. FEATURES source location/qualifiers 1..825 /organism='unidentified' /db_xref='taxon:32644' BASE COUNT 252 a 179 c 155 g 239 t ORIGIN Query Match 100.0%; Score 29; DB 10; Length 825; Best Local Similarity 69.0%; Pred. NO. 0.004; Matches 20; Conservative 9; Mismatches 0; Indels 0; Gaps 0; Oy 1 aaagauuuuuuuuaagcccaaggcu 29 :::.....t: 11111111: Db 688 AAAGATCTTTTGTAAAGCCCAAGGCT 716 RESULT 4 LOCUS I01928 825 bp ss-DNA PAT 21-MAY-1993 DEFINITION Sequence 1 from Patent US 4798789. ACCESION I01928 VERSION I01928.1 GI:269761 KEYWORDS SOURCE Unknown. ORGANISM Unknown. REFERENCE Unclassified. AUTHORS 1 (bases 1 to 825) TITLE Lee,F.D., Yokota,T. and Arai,K. CDNA clones coding for polypeptides exhibiting murine interleukin-2 activity Patent: US 4798789-A 1 17-JAN-1989;					

FEATURES		Location/Qualifiers	
source		1..825	
		/organism="unknown"	
BASE COUNT	252 a 179 c 155 g 239 t		
ORIGIN			
Query Match			
Best Local Similarity		100.0%;	Score 29; DB 10; Length 825;
Matches 20; Conservative		69.0%;	Pred. No. 0.004;
		9;	Mismatches 0; Indels 0; Gaps 0;
Oy	1 aagaauucuuuuuuaagcccaaggcu 29		
	: : : : :		
Db	688 AAGATCTCTTTTGTAAAGCCCAAGGCT 716		
RESULT 5			
LOCUS	MUSIL2T	825 bp	mRNA
DEFINITION	Mouse interleukin-2 mRNA, complete cds.	ROD	12-JUN-1993
ACCESSION	K02292		
VERSION	K02292.1	GI:198330	
KEYWORDS	T-cell growth factor; interleukin; interleukin 2.		
SOURCE	Mouse (T-cell line DB2-1, from T-cell line C57BL/6), cDNA to mRNA, clone Mt-1.		
ORGANISM	Mus musculus		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.		
REFERENCE	1 (bases 1 to 825)		
AUTHORS	Yokota,T., Arai,N., Lee,F., Rennick,D., Mosmann,T. and Arai,K.-I.		
TITLE	Use of a cDNA expression vector for isolation of mouse interleukin 2 cDNA clones: Expression of T-cell growth-factor activity after transfection of monkey cells		
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 82, 68-72 (1985)		
MEDLINE	85113172		
FEATURES	Location/Qualifiers		
source	1..825		
	/organism="Mus musculus"		
	/db_xref="taxon:10090"		
sig_peptide	49..108		
	/note="interleukin 2 signal peptide"		
CDS	49..558		
	/note="interleukin 2 prepeptide"		
	/codon_start=1		
	/protein_id="AA39289.1"		
	/db_xref="GI:309404"		
	/translation="MYSMQLASCVTLIVLVNSAPPTSSSTSSSTAEEAQQQQQQQQQQQ		
	QQHLEQLMDLQELLRMENRNLKPLMLTFKFLYLPQATFLDLQLEDELGLPLRLH		
	VLDTQGSQFQLEDAENFISNIRVTYVVKLKGSDNTFECQFDDESATVDFLRRIAFGC		
	QSISTSPQ"		
	109..555		
mat_peptide	/note="interleukin 2"		
BASE COUNT	252 a 179 c 155 g 239 t		
ORIGIN	45 bp upstream of PstI site.		
Query Match			
Best Local Similarity		100.0%;	Score 29; DB 94; Length 825;
Matches 20; Conservative		69.0%;	Pred. No. 0.004;
		9;	Mismatches 0; Indels 0; Gaps 0;
Oy	1 aagaauucuuuuuuaagcccaaggcu 29		
	: : : : :		
Db	688 AAGATCTCTTTTGTAAAGCCCAAGGCT 716		
RESULT 6			
LOCUS	MMINTLK2	868 bp	mRNA
DEFINITION	M. musculus mRNA for interleukin-2.	ROD	17-FEB-1997
ACCESSION	X73040		
VERSION	X73040.1	GI:397468	

KEYWORDS	interleukin 2.
SOURCE	house mouse.
ORGANISM	Mus musculus
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus
AUTHORS	1 (bases 1 to 868)
TITLE	Todd, J.A.
JOURNAL	Direct Submission
REFERENCE	Submitted (26-APR-1993) J.A. Todd, Nuffield Dept of Surgery, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
AUTHORS	2 (bases 1 to 868)
TITLE	Ghosh, S., Palmer, S.M., Rodrigues, N.R., Cordell, H.J., Hearne, C.M., Cornell, R.J., Prins, J.B., McShane, P., Lathrop, G.M., Peterson, L.B., Wicker, L.S. and Todd, J.A.
JOURNAL	Polygenic control of autoimmune diabetes in nonobese diabetic mice
REFERENCE	Nat. Genet. 4 (4), 404-409 (1993)
AUTHORS	3 (bases 1 to 868)
TITLE	Kashima, N., Nishi-Takaoka, C., Fujita, T., Taki, S., Yamada, G., Hamuro, J. and Taniguchi, T.
JOURNAL	Unique structure of murine interleukin-2 as deduced from cloned cDNAs
REFERENCE	Nature 313 (6001), 402-404 (1985)
AUTHORS	85111148
COMMENT	Related sequence: X01772.
FEATURES	Location/Qualifiers
SOURCE	1..868
ORIGIN	/organism="Mus musculus"
ORIGIN	/strain="NOD"
ORIGIN	/db_xref="taxon:10090"
ORIGIN	<1..>868
ORIGIN	/product="interleukin-2"
ORIGIN	81
ORIGIN	/citation=[3]
ORIGIN	/replace="t"
ORIGIN	123
ORIGIN	/citation=[3]
ORIGIN	/replace="t"
ORIGIN	133..146
ORIGIN	/note="insertion in NOD"
ORIGIN	/citation=[3]
ORIGIN	/replace="gc"
ORIGIN	161..162
ORIGIN	/note="deletion of trinucleotide repeat (cag) in NOD"
ORIGIN	/citation=[3]
ORIGIN	/replace="acagcagcagcagc"
ORIGIN	BASE COUNT 265 a 190 c 163 g 250 t
ORIGIN	ORIGIN
ORIGIN	Query Match 100.0%; Score 28; DB 94; Length 868;
ORIGIN	Best Local Similarity 69.0%; Pred. No. 0.004;
ORIGIN	Matches 20; Conservative 9; Mismatches 0; Indels 0; Gaps 0
ORIGIN	Oy 1 aagaauuuuuuuuagagcccaagaggu 29
ORIGIN	: : : : :
ORIGIN	Db 687 AAAGATTCTTTTGTGAAGCCCAAGGCT 715
ORIGIN	RESULT 7
ORIGIN	MUSIL2A03
ORIGIN	LOCUS MUSIL2A03 870 bp DNA ROD 03-JUN-1994
ORIGIN	DEFINITION Mouse Interleukin 2 (IL-2) gene, exon 4.
ORIGIN	ACCESSION M16762
ORIGIN	VERSION M16762.1 GI:198306
ORIGIN	KEYWORDS T-cell growth factor; interleukin 2.
ORIGIN	SEGMENT 3 of 3
ORIGIN	SOURCE Mouse DNA, clones pATgMIL2-A and pBRgMIL2-3.
ORIGIN	ORGANISM Mus musculus
ORIGIN	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus
ORIGIN	1 (bases 1 to 870)

AUTHORS	Deigrave,W.M., Simons,G., Devos,R., Plaetnick,G., Remaut,E., Tavernier,J.J. and Piers,W.
TITLE	Cloning and structure of a mouse interleukin-2 chromosomal gene
JOURNAL	Mol. Biol. Rep. 11, 57-61 (1986)
MEDLINE	86118396
FEATURES	
source	location/Qualifiers 1..870 /organism="Mus musculus" /db_xref="taxon:10090" /map="3" gene join(M16760.1:213..648,M16761.1:1..559,1..870) /gene="il2" join(M16760.1:260..448,M16760.1:548..607, M16761.1:148..294,70..183) /gene="il2" /note="precursor" /codon_start=1 /product="interleukin 2" /protein_id="AA39281.1" /db_xref="GI:387384" /translacion="MYSMOLACVLTLLVLVNSAPTSSTSSFAEAOOQOOOQO OOHLEOHMDLOETLSMENYRMLKLPRLMTFFEVLPKATTELKDLCLEDGLRH VLDTEESQLDEAEINISINIVYVKLKGSDNTECEQDDESATVPFLRWIRAF QSITSPQ" join(M16760.1:320..448,M16760.1:548..607, M16761.1:148..294,70..180) /gene="il2" /note="precursor" /product="interleukin 2" <1..69 /gene="il2" /number=3 70..>870 /gene="il2" /number=4 introns <1..69 /gene="il2" /number=3 70..>870 /gene="il2" exons BASE COUNT 284 a 150 c 135 g 301 t ORIGIN 1 bp upstream of HindIII site; about 1900 bp after segment 1. Query Match 100.0%; Score 29; DB 94; Length 870; Best Local Similarity 69.0%; Pred. No.0.004; Matches 20; Conservative 9; Mismatches 0; Indels 0; Gaps 0; DB 1 aaagaucuuuuuuaagcccaaggcu 29 ::: 313 AAAGATTCTTTTGAAGCCCAAGGCT 341 RESULT 8 ID E10514 EI E10514 standard; RNA; ROD: 939 BP. XX XX E10514; XX XX E10514.1 XX XX XX 08-OCT-1997 (Rel. 52, Created) DT 02-SEP-2000 (Rel. 65, Last updated, Version 2) XX XX cdna encoding mouse interleukin-2. DE DE JP 1996000272-A/1. XX XX XX Mus sp. OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia OC Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. RN [1] RP Kashiwa S., Hamuro J., Taniguchi K., Sugano H.; RA "DNA FRAGMENT CONTAINING GENE CODING MOUSE INTERLEUKIN-2, RECOMBINANT RT VECTOR HAVING THE SAME, AND TRANSFORMANT HOLDING THE"; DL Patent number JP1996000272-A/1, 09-JAN-1996.


```

/db_xref="GI:6941954"
/translation="SPEKSLTSMASRLCRAMLSRENTLAKKEATDLDLEARYTHAAK
CMGSPQDEAKALKAYILQQGGYCSWIKSPCIEQFSF"
complement(19651..20127)
/note="LINE"
/rpt_family="I1"
/rpt_type-dispersed
repeat_region complement(20958..21142)
/note="LINE"
/rpt_family="I1"
/rpt_type-dispersed
repeat_region complement(22450..22619)
/note="LINE"
/rpt_family="I1"
/rpt_type-dispersed
repeat_region complement(24776..24898)
/note="SINE"
/rpt_family="B2"
/rpt_type-dispersed
repeat_region complement(4720 c 4896 g 7278 t 58 others
BASE COUNT 7948 a 4720 c 4896 g 7278 t 58 others
ORIGIN
Query Match 100.0%; Score 29; DB 94; Length 24900;
Best Local Similarity 69.0%; Prd. No. 0.0068;
Matches 20; Conservative 9; Mismatches 0; Indels 0; Caps 0;
OY 1 aaagaucuuuuuguaagcccaaggcgu 29
|||||:::|||||||
Db 9497 AAAGATTCTTTGTGAAGCCCAAGGCT 9525

RESULT 11
LOCUS BOVIL2 764 bp mRNA MM 27-APR-1993
DEFINITION Bovine interleukin 2 (IL-2) mRNA, complete cds.
ACCESSION M12791
VERSION M12791.1 GI:163204
KEYWORDS interleukin 2.
SOURCE Bovine lymph node, cDNA to mRNA, clone pBIL2-4.
ORGANISM Bos taurus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidea;
Bovidae; Bovinae; Bos.
REFERENCE
AUTHORS Cerretti,D.P., McKereghan,K., Larsen,A., Cantrell,M.A.,
Anderson,D., Gallis,S., Cosman,D. and Baker,P.E.
TITLE Cloning, sequence, and expression of bovine interleukin 2
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 83, 3223-3227 (1986)
MEDLINE 86205869
COMMENT Draft entry and clean copy sequence for [1] kindly provided by
D.Cerretti, 12-AUG-1986.
There is probably only one copy of the interleukin 2 gene in the
bovine genome.
FEATURES
source location/Qualifiers
1..764
/organism="Bos taurus"
/db_xref="taxon:9913"
/tissue_type="lymph"
<1..764
/gene="IL-2"
1..764
/gene="IL-2"
18..77
/gene="IL-2"
18..485
/gene="IL-2"
/gene="prepeptide"
/codon_start=1

```

mat_peptide

/product="interleukin 2"
/protein_id="AAA30586.1"
/db_xref="GI:163205"
/translation="MYKQLLSCTALTLAVANGAPTSSSTGTMTKEVKSLLDLQL
LEKVNPEKLSRMHFDYKYNATLELKHLCLELKEEVLNLAPEKSNLMP
EIKDSMDNIRKIRLVLELQSGSTFCEYDQATVNAVEFLNKWITTFQSYSTMT"
78..482
/gene="IL-2"
/product="interleukin 2"
BASE COUNT 257 a 133 c 123 g 251 t
ORIGIN 80 bp upstream of Hg1a1 site.

Query Match 85.5%; Score 24.8; DB 7; Length 764;
Best Local Similarity 60.7%; Pred. No. 0.38;
Matches 17; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

QY 2 aagaauuuuuuuaagccccaaggcu 29
|||||:|||||:|||||:|||||:
P 620 AAGATTCTTTTGTAGCCCTAGCGGCT 647

RESULT 12
LOCUS CF028141 773 bp mRNA MAM 29-JUN-1995
DEFINITION Canis familiaris interleukin-2 mRNA, complete cds.
ACCESSION U28141
VERSION U28141.1 GI:881935
KEYWORDS
SOURCE dog.
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
1 (bases 1 to 773)
Somerby, R. L., Tipold, A., Henthorn, P. S. and Felsburg, P. J.
REFERENCE
Unpublished
2 (bases 1 to 773)
Somerby, R. L.
TITLE Direct Submission
JOURNAL Submitted (31-MAY-1995) Richard L. Somberg, Clinical Studies,
University of Pennsylvania, 3850 Spruce Street, Philadelphia, PA
19104, USA

FEATURES
source Location/Qualifiers
1..773
/organism="Canis familiaris"
/db_xref="taxon:9615"
39..506
CDS
/codon_start=1
/product="interleukin-2"
/protein_id="AAA68969.1"
/db_xref="GI:881936"
/translation="MYKQLLSCTALTLAVANGAPTSSSTGTMTKEVKSLLDLQL
LLNGVNNENPQLSRMLTFKFTYPPKATFTHLQCLAEELKMLEEVLGLPQSKNVHLT
DTKELISNNNVTLTKGSESYNCEYDEDTATITFEFLNKWITTFQSYSTLT"
773
/note="38 A nucleotides"
polyA_site
BASE COUNT 265 a 145 c 118 g 245 t
ORIGIN
polyA_site

Query Match 85.5%; Score 24.8; DB 7; Length 773;
Best Local Similarity 60.7%; Pred. No. 0.38;
Matches 17; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

QY 2 aagaauuuuuuuaagccccaaggcu 29
|||||:|||||:|||||:|||||:
Db 641 AAGATTCTTTTGTAGCCCTAGCGGCT 668

RESULT 13
LOCUS I82323 209 bp DNA PAT 10-JUN-1998
DEFINITION Sequence 8 from patent US 5712126.

ACCESSION I82323
VERSION I82323.1 GI:3210620
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 209)
Weissman, S. M. and Prashar, Y.
TITLE Analysis of gene expression by display of 3'-end restriction
fragments of cDNA
JOURNAL Patent: US 5712126-A 8 27-JAN-1998;
FEATURES
source Location/Qualifiers
1..209
/organism="unknown"
BASE COUNT 56 a 30 c 33 g 90 t
ORIGIN

Query Match 80.0%; Score 23.2; DB 10; Length 209;
Best Local Similarity 57.1%; Pred. No. 1.7;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 2 aagaauuuuuuuaagccccaaggcu 29
|||||:|||||:|||||:|||||:
Db 34 ATGATTCTTTTGTAGCCCTAGCGGCT 61

RESULT 14
LOCUS G06364 292 bp DNA STS 19-OCT-1995
DEFINITION human STS WI-7035.
ACCESSION G06364
VERSION G06364.1 GI:859609
KEYWORDS STS sequence; primer; sequence tagged site.
SOURCE human STS derived from sequences in dbEST and the UniGene
collection.
ORGANISM Homo sapiens
Eukaryota; Eukaryota; Metazoa; Chordata;
Vertebrata; Gnathostomata; Osteichthyes; Sarcopterygii; Chonata;
Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Archonta; Primates;
Cathartini; Hominiidae; Homo.
1 (bases 1 to 292)
Hudson, T.
REFERENCE
Whitehead Institute/MIT Center for Genome Research; Physically
Mapped ESTs
JOURNAL Unpublished (1995)
COMMENT

Contact: Thomas Hudson
Whitehead Institute/MIT Center for Genome Research
Whitehead Institute for Biomedical Research
9 Cambridge Center, Cambridge MA 02142 USA
Tel: 617 252 1900
Fax: 617 252 1902
Email: thudson@genome.wi.mit.edu
Primer A: TAATTAGTCTCCACTTAAC
Primer B: ATTTGGGATTAATAGTGAACCA
STS size: 200
PCR Profile:
Presoak:
Denaturation:
Annealing: 56 degrees C
Polymerization:
PCR Cycles: 35
Thermal Cycler:
Protocol:
Template: 10 ng
Primer: each 5 pM
dNTPs: each 4 mM
Taq Polymerase: 0.025 units/ul
Total Vol: 20 ul
Buffer:

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 05:03:57 ; Search time 122.48 Seconds
(without alignments)
148.670 Million cell updates/sec

Title: US-09-310-844B-25
Perfect score: 29
Sequence: 1 aaagaauuuuuuuaagccccaaggcgu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 730101 seqs, 313950809 residues
tal number of hits satisfying chosen parameters: 1460202

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

N.Geneseq_0601:*

- 1: /SIDSI/gcgdata/geneseq/geneseqn/NA1980.DAT:*
- 2: /SIDSI/gcgdata/geneseq/geneseqn/NA1981.DAT:*
- 3: /SIDSI/gcgdata/geneseq/geneseqn/NA1982.DAT:*
- 4: /SIDSI/gcgdata/geneseq/geneseqn/NA1983.DAT:*
- 5: /SIDSI/gcgdata/geneseq/geneseqn/NA1984.DAT:*
- 6: /SIDSI/gcgdata/geneseq/geneseqn/NA1985.DAT:*
- 7: /SIDSI/gcgdata/geneseq/geneseqn/NA1986.DAT:*
- 8: /SIDSI/gcgdata/geneseq/geneseqn/NA1987.DAT:*
- 9: /SIDSI/gcgdata/geneseq/geneseqn/NA1988.DAT:*
- 10: /SIDSI/gcgdata/geneseq/geneseqn/NA1989.DAT:*
- 11: /SIDSI/gcgdata/geneseq/geneseqn/NA1990.DAT:*
- 12: /SIDSI/gcgdata/geneseq/geneseqn/NA1991.DAT:*
- 13: /SIDSI/gcgdata/geneseq/geneseqn/NA1992.DAT:*
- 14: /SIDSI/gcgdata/geneseq/geneseqn/NA1993.DAT:*
- 15: /SIDSI/gcgdata/geneseq/geneseqn/NA1994.DAT:*
- 16: /SIDSI/gcgdata/geneseq/geneseqn/NA1995.DAT:*
- 17: /SIDSI/gcgdata/geneseq/geneseqn/NA1996.DAT:*
- 18: /SIDSI/gcgdata/geneseq/geneseqn/NA1997.DAT:*
- 19: /SIDSI/gcgdata/geneseq/geneseqn/NA1998.DAT:*
- 20: /SIDSI/gcgdata/geneseq/geneseqn/NA1999.DAT:*
- 21: /SIDSI/gcgdata/geneseq/geneseqn/NA2000.DAT:*
- 22: /SIDSI/gcgdata/geneseq/geneseqn/NA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	29	100.0	29	AAA70829	Molecular interact
2	29	100.0	29	AAA70830	Molecular interact
3	29	100.0	42	AAA71115	Molecular interact
4	29	100.0	42	AAA71116	Molecular interact
5	29	100.0	42	AAA71120	Molecular interact
6	29	100.0	42	AAA71121	Molecular interact
7	29	100.0	42	AAA71128	Molecular interact
8	29	100.0	42	AAA71129	Molecular interact
9	29	100.0	825	AA60149	Sequence encoding
10	29	100.0	940	AA60906	Molecular interact
11	28	96.6	45	AAA70825	Molecular interact

12	28	96.6	45	AAA70826	Molecular interact
13	28	96.6	46	AAA71088	Molecular interact
14	28	96.6	46	AAA71089	Molecular interact
15	28	96.6	46	AAA71090	Molecular interact
16	28	96.6	46	AAA71105	Molecular interact
17	28	96.6	46	AAA71106	Molecular interact
18	28	96.6	46	AAA71107	Molecular interact
19	24.8	85.5	42	AAA71113	Molecular interact
20	24.8	85.5	42	AAA71118	Molecular interact
21	24.8	85.5	42	AAA71126	Molecular interact
22	23.8	82.1	46	AAA71085	Molecular interact
23	23.8	82.1	46	AAA71103	Molecular interact
24	23.2	80.0	29	AAA70828	Molecular interact
25	23.2	80.0	42	AAA71123	Molecular interact
26	23.2	80.0	42	AAA71131	Molecular interact
27	23.2	80.0	209	AA61453	IL-2 CDNA 3' end.
28	23.2	80.0	209	AA61453	Interleukin-2 frag
29	23.2	80.0	698	AA559456	DNA sequence encod
30	23.2	80.0	698	AA60101	Sequence of human
31	23.2	80.0	722	AA60144	Sequence encoding
32	23.2	80.0	769	AA601764	Human Interleukin-
33	23.2	80.0	784	AA60046	Sequence encoding
34	23.2	80.0	784	AA60787	Cloned sequence en
35	23.2	80.0	784	AA60102	Sequence of human
36	23.2	80.0	788	AA60253	Interleukin-2. Ho
37	23.2	80.0	794	AA60441	Gene encoding poly
38	23.2	80.0	794	AA60381	Recombinant human
39	23.2	80.0	800	AA50219	Sequence encoding
40	23.2	80.0	801	AA50031	Sequence of Interl
41	23.2	80.0	801	AA50057	Cloned human inter
42	23.2	80.0	801	AA60254	Sequence encoding
43	23.2	80.0	802	AA50279	DNA sequence conta
44	23.2	80.0	810	AA60840	Sequence encoding
45	23.2	80.0	844	AA620965	Human low adenosin

ALIGNMENTS

RESULT 1

ID AAA70829 standard; RNA: 29 BP.

AC AAA70829;

XX

DT 27-APR-2001 (first entry)

XX

DE Molecular interaction site RNA #29.

XX

KW Modulator; identification; molecular interaction; virtual library; ss.

XX

OS Mus sp.

XX

PN WO958947-A2.

XX

PD 18-NOV-1999.

XX

PF 12-MAY-1999; 99WO-US10361.

XX

PR 12-MAY-1998; 98US-0076404.

XX

PR 12-MAY-1998; 98US-0085092.

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX

DR Hofstadler S, McNeill J;

XX

WP1: 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,

PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -

XX

PS Claim 235; Page 235; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUAAUUCUUAACAAAUAUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 29;
Best Local Similarity 100.0%; Pred. No. 0.00036;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 aaagaucuuuuuuuagagccccaagggcu 29
DB 1 aaagaucuuuuuuuagagccccaagggcu 29

RESULT 2
AAAT0830
ID AAA70830 standard; RNA; 29 BP.
XX
AC AAA70830;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #30.
XX
PM Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Rattus sp.
XX
PN WO958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX
PI Hofstadler S, McNeill J;
XX
DR WPI: 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
XX
PT used to provide compounds which can be used as pharmacological,
XX
PT agricultural and industrial compounds -
XX

PS Claim 235; Page 235; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUAAUUCUUAACAAAUAUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 29;
Best Local Similarity 100.0%; Pred. No. 0.00036;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 aaagaucuuuuuuuagagccccaagggcu 29
DB 1 aaagaucuuuuuuuagagccccaagggcu 29

RESULT 3
AAAT1115
ID AAA71115 standard; RNA; 42 BP.
XX
AC AAA71115;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #191.
XX
KM Modulator; identification; molecular interaction; virtual library; ss.
XX
OS unidentified.
XX
PN WO958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX
PI Hofstadler S, McNeill J;
XX
DR WPI: 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
XX
PT used to provide compounds which can be used as pharmacological,
XX
PT agricultural and industrial compounds -
XX

PS Example 7; Figure 122; 405bp; English.

XX This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUAAUUCAGUUUACGAAAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

XX Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 42;

Best Local Similarity 100.0%; Pred. No. 0.00038;

Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 aaagaucuuuuuuuuaagccccaaggcgc 29
DB 4 aaagaucuuuuuuuuaagccccaaggcgc 32

RESULT 4

AAAT71116 standard; RNA; 42 BP.

XX AAA71116;

XX 27-APR-2001 (first entry)

XX Molecular interaction site RNA #192.

XX Modulator; identification; molecular interaction; virtual library; ss.

XX Unidentified.

XX WO958947-A2.

XX 18-NOV-1999.

XX 12-MAY-1999; 99MO-US10361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hofstadler S, McNeil J;

XX WPI; 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
XX

PS Example 7; Figure 122; 405bp; English.

XX This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACAUAAUUCAGUUUACGAAAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

XX Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 42;

Best Local Similarity 100.0%; Pred. No. 0.00038;

Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 aaagaucuuuuuuuuaagccccaaggcgc 29
DB 4 aaagaucuuuuuuuuaagccccaaggcgc 32

RESULT 5

AAAT71120 standard; DNA; 42 BP.

XX AAA71120;

XX 27-APR-2001 (first entry)

XX Molecular interaction site DNA #126.

XX Modulator; identification; molecular interaction; virtual library; ss.

XX Unidentified.

XX WO958947-A2.

XX 18-NOV-1999.

XX 12-MAY-1999; 99MO-US10361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hofstadler S, McNeil J;

XX WPI; 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
XX

Example 7; Figure 125; 405pp; English.

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating in silico a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of compounds to generate a hierarchy of the compounds ranked in accordance with their respective ability to form physical interactions with the molecular interaction site. The method also describes (1) RNA comprising a joined sequence of at least 24 nucleotides but not more than 70 nucleotides and having secondary structure defined by: (a) 3 nucleotides forming a first side of a first double stranded (ds) region; (b) 2 nucleotides forming a first side of an internal loop region; (c) 4 nucleotides forming a first side of a second ds region; (d) 4 or 5 nucleotides forming an end loop region; (e) 4 nucleotides forming a second side of the second ds region; (f) 4 nucleotides forming a second side of the internal loop region; and (g) 3 nucleotides forming a second side of the first ds region; (2) a purified and isolated RNA fragment comprising the human sequence UUUACACUAUUAUCAGUUUACAGAAAUU (11). The methods and products can be used for identifying agents which modulate the activity of biomolecules, particularly RNA. Such agents can be used as pharmaceutical, agricultural or industrial compounds.

SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 T; 0 other;

Query Match	100.0%	Score 29;	DB 21;	Length 42;
Best Local Similarity	69.0%	Pred. No.	0.00038;	
Matches	20;	Conservative	9;	Mismatches 0;
				Indels 0;
				Gaps 0;

QY 1 aaagaauccuuuuuuaagcccccaaggcu 23
 |||||::||:::||:|||||
Db 4 aaagatcttlttgtaagcccacaaggct 32

RESULT	6
AAA71121	
ID	AAA71121 standard; DNA; 42 BP.

AC AAA71121;

DT 27-APR-2001 (first entry)

DE Molecular interaction site DNA #127.

Modulator; identification; molecular interaction; virtual library; ss.

Unidentified.

PN WO9958947-A2.
YY

PD 18-NOV-1999 .
YY

PF 12-MAY-1999; 99NO-US10361.
XY

PR	12-MAY-1998;	98US-0076404.
PR	12-MAY-1998.	98US-0085092

XX
PA (TSTS-) TSTS PHABM TNC

XX	Ecker D.J	Griffey B
PI		

Pl Holstadter S, McNeill J;
XX

DR WP1; 2000-086439/07
XX

PT Identifying compounds which modulate activity of target biomolecules, used to provide compounds which can be used as pharmacological

PT agricultural and industrial compounds -
XY

PS Example 7; Figure 125; 405pp; English.

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating in silico a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of compounds to generate a hierarchy of the compounds ranked in accordance with their respective ability to form physical interactions with the molecular interaction site. The method also describes (1) RNA comprising a joined sequence of at least 24 nucleotides but not more than 70 nucleotides and having secondary structure defined by: (a) 3 nucleotides forming a first side of a first double stranded (ds) region; (b) 2 nucleotides forming a first side of an internal loop region; (c) 4 nucleotides forming a first side of a second ds region; (d) 4 or 5 nucleotides forming an end loop region; (e) 4 nucleotides forming a second side of the second ds region; and (f) 3 nucleotides forming a second side of the internal loop region; and (g) 3 nucleotides forming a second side of the first ds region; (2) a purified and isolated RNA fragment comprising the human sequence UUUACACUAUUAUCUGUUACGAGAAAU (II). The methods and products can be used for identifying agents which modulate the activity of biomolecules, particularly RNA. Such agents can be used as pharmaceutical, agricultural or industrial compounds.

Sequence 42 BP; 13 A; 7 C; 7 G; 15 T; 0 other;

Query Match	100.0%	Score 29;	DB 21;	Length 42;
Best Local Similarity	69.0%	Pred. No. 0	00038;	
Matches 20;	Conservative	9;	Mismatches	0;
			Indels	0;
			Gaps	0;

QY 1 aaagaauucuuuuuagagccccaagggcu 23
 |||||:::|:|||||||:
 Db 4 aaagatcttttgytaagccccaagggct 32

RESULT	7
AAA71128	
ID	AAA71128 standard; RNA; 42 BP.

AC AAA71128;
xy

DT 27-APR-2001 (first entry)

DE Molecular interaction site RNA #197.
yy

Modulator; identification; molecular interaction; virtual library; ss.

Unidentified.
OS
XY

PN W09958947-A2.
XX'

PD 18-NOV-1999 .
XY

PE 12-MAY-1999; 99WO-0510361.
XX

PR	12-MAY-1998;	98US-0076404.
PR	12-MAY-1998;	98US-0085092

XX
PA (TSTS-) TSTS PHARM INC

XX	Ecker D.T.	Griffey B
PT		

Pl Horstader S, McNeill J;
XX

DK WPL; 2000-086439/0/

PT Identifying compounds which modulate ac

Pf agricultural and industrial compounds -
XY

xx New poly:peptide(s) showing murine interleukin-2 activity - are
PT prepd. by recombinant DNA procedures with complementary DNA
PT clones as vectors in escherichia coli
xx
xx
PS Claim 16; Fig 1; 53pp; English.
CC The pure murine IL-2 polypeptides facilitate the study of T-cell
CC biology and the immune response, so that improvements in therapy are
CC possible.
xx
SQ Sequence 825 BP; 252 A; 179 C; 155 G; 239 T; 0 other;

Query Match 100.0%; Score 29; DB 7; Length 825;
Best Local Similarity 69.0%; Pred. No. 0.00064;
Matches 20; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Oy 1 aaagaauuuuuuuaagccccaaggcu 29
|||||:|||||:|||||:|||||:|||||:
688 aaagattcttttgaagccccaaggct 716

RESULT 10
AAN60906
ID AAN60906 standard; cDNA; 940 BP.
xx
xx AAN60906;
AC
xx 03-SEP-1991 (first entry)
DT
xx
xx Sequence encodes mouse interleukin-2 (MIL-2).
DE
xx IL-2; lymphoma; ds.
KW
xx Mus musculus.
OS
xx
xx Key Location/Qualifiers
FT CDS 49..555
FT /*tag= a
FT
xx JP61058590-A.
PN
xx 25-MAR-1986.
PD
xx 29-AUG-1984; 84JP-0180086.
PE
xx 29-AUG-1984; 84JP-0180086.
PR
xx (DAIL) DAICEL CHEM IND KK.
DR WPI; 1986-117207/18.
DR P-PSDB; MAP61032..
xx
xx New immobilised microorganism - in porous particles of cellulose
PT acetate.
PT
xx Disclosure; Page 545; 13pp; Japanese.
PS
xx Gne product may be expressed by a transformed host such as yeast, it
CC is expressed in much larger quantities than from lymphoma and
CC hybridoma cells.
CC See also AAN60907-8.
CC
xx
SQ Sequence 940 BP; 288 A; 202 C; 173 G; 277 T; 0 other;

Query Match 100.0%; Score 29; DB 7; Length 940;
Best Local Similarity 69.0%; Pred. No. 0.00065;
Matches 20; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Oy 1 aaagaauuuuuuuaagccccaaggcu 29
|||||:|||||:|||||:|||||:|||||:

DB 688 aaagattcttttgaagccccaaggct 716
RESULT 11
AAA70825
ID AAA70825 standard; RNA; 45 BP.
xx
xx AAA70825;
AC
xx 27-APR-2001 (first entry)
DT
xx
xx Molecular interaction site RNA #25.
DE
xx
xx Modulator; identification; molecular interaction; virtual library; ss.
KW
xx Mus sp.
OS
xx WO9598947-A2.
PN
xx 18-NOV-1999.
PD
xx 12-MAY-1999; 99WO-US10361.
PE
xx 12-MAY-1998; 98US-0076404.
PR 12-MAY-1998; 98US-0085092.
xx
xx (ISIS-) ISIS PHARM INC.
xx
xx Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
PI
xx WPI; 2000-086439/07.
DR
xx
xx Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,
PT agricultural and industrial compounds -
PT
xx Claim 221; Page 232; 405pp; English.
PS
xx This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence uuuaacacaaucuaucuuuacgaaaaanac (ii). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
xx
SQ Sequence 45 BP; 14 A; 7 C; 9 G; 15 U; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 45;
Best Local Similarity 100.0%; Pred. No. 0.0011;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 aaagaauuuuuuuaagccccaaggc 28
|||||:|||||:|||||:|||||:|||||:

DB 18 aaagaauuuuuuuaagccccaaggc 45

RESULT 12

AAA70826
ID AAA70826 standard; RNA; 45 BP.

AC AAA70826;

DT 27-APR-2001 (first entry)

DE Molecular interaction site RNA #26.

KW Modulator; identification; molecular interaction; virtual library; ss.

OS Rattus sp.

PN W09958947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999; 99WO-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

PA (ISIS-) ISIS PHARM INC.

PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

PI Hofstadler S, McNeill J;

DR WPI: 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,
used to provide compounds which can be used as pharmacological,
agricultural and industrial compounds -

PS Claim 222; Page 232; 405pp; English.

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAAUUAUCAGUUUCAGAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

CC Sequence 45 BP: 14 A; 7 C; 9 G; 15 U; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 45;

Best Local Similarity 100.0%; Pred. No. 0.0011;

Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 aaagaauuuuuuuaagccccaaggc 28
|||||

DB 18 aaagaauuuuuuuaagccccaaggc 45

RESULT 13

AAA71088
ID AAA71088 standard; DNA; 46 BP.

AC AAA71088;

DT 27-APR-2001 (first entry)

DE Molecular interaction site DNA #111.

KW Modulator; identification; molecular interaction; virtual library; ss.

OS Unidentified.

PN W09958947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999; 99WO-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

PA (ISIS-) ISIS PHARM INC.

PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

PI Hofstadler S, McNeill J;

DR WPI: 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,
used to provide compounds which can be used as pharmacological,
agricultural and industrial compounds -

PS Example 7; Figure 121; 405pp; English.

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAAUUAUCAGUUUCAGAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

CC Sequence 46 BP: 14 A; 7 C; 9 G; 16 T; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 46;

Best Local Similarity 71.4%; Pred. No. 0.0011;

Matches 20; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1 aaagaauuuuuuuaagccccaaggc 28
|||||

Db 19 aaagattcttttgytaagccccaagggc 46

Search completed: October 2, 2001, 05:03:57
Job time: 3809 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 2, 2001, 05:01:49 ; Search time 57.41 seconds

(without alignments)
95.628 Million cell updates/sec

Title: US-09-310-844B-25

Sequence: 1 aagaauuuuuuuuagcccccaggagcu 29

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 324599 seqs, 94655562 residues

Cal number of hits satisfying chosen parameters: 649198

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : Issued_Patents_NA.*

1: /cgn2_6/ptodata/2/ina/5A.COMB.seq:*
2: /cgn2_6/ptodata/2/ina/5B.COMB.seq:*
3: /cgn2_6/ptodata/2/ina/6A.COMB.seq:*
4: /cgn2_6/ptodata/2/ina/6B.COMB.seq:*
5: /cgn2_6/ptodata/2/ina/PTUS.COMB.seq:*
6: /cgn2_6/ptodata/2/ina/Backfile1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	length	DB ID	Description
1	23.2	80.0	209	1	US-08-510-032A-8
2	23.2	80.0	209	3	US-08-688-514-8
3	23.2	80.0	801	6	5314995-8
4	23.2	80.0	8491	2	US-08-757-439-1
5	17.6	60.7	72928	3	US-09-009-913-1
6	17.4	60.0	51259	3	US-08-781-891-209
7	17.4	60.0	51259	3	US-08-781-891-209
8	17.2	59.3	2287	1	US-08-222-619-1
9	17.2	59.3	2287	4	US-08-221-767-23
10	17.2	59.3	2287	5	PCT-US95-04075-1
11	16.8	57.9	610	2	US-08-928-926A-2
12	16.8	57.9	610	3	US-09-212-149-2
13	16.6	57.2	711	4	US-08-998-416-900
14	16.6	57.2	2446	3	US-08-834-306-17
15	16.6	57.2	2446	4	US-08-993-674A-17
16	16.4	56.6	2311	2	US-08-712-709-6
17	16.4	56.6	2311	3	US-09-111-444-6
18	16.4	56.6	2311	4	US-09-541-228-6
19	16.2	55.9	1201	1	US-09-286-805-1
20	16.2	55.9	3383	1	US-07-707-367-1
21	16.2	55.9	3846	4	US-08-845-161A-5
22	16.2	55.9	3846	4	US-09-270-751-5
23	16.2	55.9	24417	2	US-08-846-762-1
24	16.2	55.9	72928	3	US-09-009-913-1
25	16.2	55.2	1803	3	US-08-458-922-2
26	16.2	55.2	6911	1	US-08-311-174-4
27	15.8	54.5	325	2	US-08-483-695-38

28	15.8	54.5	325	2	US-07-965-285-38	Sequence 38, Appl
29	15.8	54.5	325	4	US-08-487-231-38	Sequence 38, Appl
30	15.8	54.5	325	4	US-09-201-912-38	Sequence 38, Appl
31	15.8	54.5	743	4	US-08-821-994-38	Sequence 86, Appl
32	15.8	54.5	1102	4	US-08-821-994-86	Sequence 1, Appl
33	15.8	54.5	1207	1	US-08-460-806-1	Sequence 1, Appl
34	15.8	54.5	1207	1	US-08-325-630-1	Sequence 1, Appl
35	15.8	54.5	1333	4	US-09-142-551A-1	Sequence 61, Appl
36	15.8	54.5	1390	4	US-08-821-994-61	Sequence 63, Appl
37	15.8	54.5	1434	4	US-08-821-994-62	Sequence 63, Appl
38	15.8	54.5	1441	4	US-08-821-994-63	Sequence 7, Appl
39	15.8	54.5	2646	1	US-08-365-189-7	Sequence 3, Appl
40	15.8	54.5	2688	1	US-08-088-633-3	Sequence 3, Appl
41	15.8	54.5	2688	1	US-08-245-756-3	Sequence 3, Appl
42	15.8	54.5	2688	1	US-08-441-750-3	Sequence 3, Appl
43	15.8	54.5	2688	2	US-08-441-751-3	Sequence 3, Appl
44	15.8	54.5	2688	5	PCT-US92-02521-3	Sequence 3, Appl
45	15.8	54.5	2696	1	US-07-961-522-1	Sequence 1, Appl

ALIGNMENTS

RESULT 1
US-08-510-032A-8
; Sequence 8, Application US/08510032A
; Patent No. 5712126
; GENERAL INFORMATION:
; APPLICANT: Sherman Weissman and Yarlindra Prashar
; TITLE OF INVENTION: Analysis of Gene Expression by Display of 3'-
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Yahwak & Associates
; STREET: 25 Skytop Drive
; CITY: Trumbull
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06611
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: Microsoft Word 4.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/510,032A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: George M. Yahwak
; REGISTRATION NUMBER: 26,824
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203)268-1951
; TELEFAX: (203)268-1951
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 209 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-510-032A-8

Query Match 80.0%; Score 23.2; DB 1; Length 209;
Best Local Similarity 57.1%; Pred. No. 0.051;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

OY 2 aagaauuuuuuagcccccaggagcu 29
DB 34 ATGATTCTTTTGTAGCCCTAGGCGCT 61

RESULT 2
US-08-688-514-8
; Sequence 8, Application US/08688514
; Patent No. 6010850
; GENERAL INFORMATION:
; APPLICANT: Sherman Weissman and Yarlindra Prashar
; TITLE OF INVENTION: Analysis of Gene Expression By Display of 3'-
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESS: Yahwak & Associates
; STREET: 25 Skytop Drive
; CITY: Trumbull
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06611
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: Microsoft Word 4.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/688,514
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: George M. Yahwak
; REGISTRATION NUMBER: 26,824
; REFERENCE/DOCKET NUMBER: Yale
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203)268-1951
; TELEFAX: (203)268-1951
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 209 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-688-514-8

Query Match 80.0%; Score 23.2; DB 3; Length 209;
Best Local Similarity 57.1%; Pred. No. 0.051;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

OY 2 aagaauuuuuuuaagcccaaggcu 29
| |||:|||||:||||| |||||
34 ATGATCTTTTGTAGCCCTAGGGCT 61

RESULT 3
5314995-8
; Patent No. 5314995
; APPLICANT: FELL, HENRY P.; GAYLE, MARGIT A.
; TITLE OF INVENTION: THERAPEUTIC INTERLEUKIN-2-ANTIBODY
; BASED FUSION PROTEINS
; NUMBER OF SEQUENCES: 8
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/468,390
; FILING DATE: 22-JAN-1990
; SEQ ID NO: 8:
; LENGTH: 801
5314995-8

Query Match 80.0%; Score 23.2; DB 6; Length 801;
Best Local Similarity 57.1%; Pred. No. 0.063;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

OY 2 aagaauuuuuuuaagcccaaggcu 29
| |||:|||||:||||| |||||

Db 651 atgattcttttgaagccctagggct 678

RESULT 4
US-08-757-439-1/c
; Sequence 1, Application US/08757439
; Patent No. 5866371
; GENERAL INFORMATION:
; APPLICANT: BADZIONG, Werner
; APPLICANT: HABERMANN, Paul
; APPLICANT: MOELLER, Joerg
; APPLICANT: ARETZ, Werner
; TITLE OF INVENTION: PROCESS FOR USING THE YEAST ADH II
; PROMOTER SYSTEM FOR THE PRODUCTION OF HETEROLOGOUS
; TITLE OF INVENTION: PROTEINS IN HIGH YIELDS
; NUMBER OF SEQUENCES: 1
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,439
; FILING DATE: 27-NOV-1996
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE 19544233.4
; FILING DATE: 28-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/303/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8491 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-757-439-1

Query Match 80.0%; Score 23.2; DB 2; Length 8491;
Best Local Similarity 57.1%; Pred. No. 0.094;
Matches 16; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

OY 2 aagaauuuuuuuaagcccaaggcu 29
| |||:|||||:||||| |||||
Db 6653 ATGATCTTTTGTAGCCCTAGGGCT 6626

RESULT 5
US-09-009-913-1/c
; Sequence 1, Application US/09009913
; Patent No. 6087485
; GENERAL INFORMATION:
; APPLICANT: Axy's Pharmaceuticals, Inc.
; TITLE OF INVENTION: Asthma Related Genes
; NUMBER OF SEQUENCES: 339
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bozicevic & Reed, LLP
; STREET: 285 Hamilton Ave, Suite 200
; CITY: Palo Alto

STATE: CA
COUNTRY: USA
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/009,913
FILING DATE: 21-JAN-1998
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
ATTORNEY/AGENT INFORMATION:
NAME: Sherwood, Pamela J
REGISTRATION NUMBER: 36,677
REFERENCE/DOCKET NUMBER: SEQ-4P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-327-3231
TELEFAX: 650-327-3231
TELEX:
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 72928 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: Genomic DNA
US-09-009-913-1

Query Match 60.7%; Score 17.6; DB 3; Length 72928;
Best Local Similarity 45.8%; Pred. No. 46;
Matches 11; Conservative 9; Mismatches 4; Indels 0; Gaps 0;
QY 6 unuuuuuuuagccccaagggcu 29
Db 37671 TTTTCTTTTAACTCCCAAGGCT 37648

RESULT 6
US-08-781-891-209
Sequence 209, Application US/08781891
Patent No. 6090620
GENERAL INFORMATION:
APPLICANT: Fu, Ying-Hui
APPLICANT: Yu, Chang-En
APPLICANT: Oshima, Junko
APPLICANT: Mulligan, John T.
APPLICANT: Schellenberg, Gerald D.
TITLE OF INVENTION: GENE AND GENE PRODUCTS RELATED TO
NUMBER OF SEQUENCES: 209
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/781,891
FILING DATE: 27-DEC-1996
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: No. 6090620tenburg Ph.D., Carol

REGISTRATION NUMBER: 39,317
REFERENCE/DOCKET NUMBER: 240052.419
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 209:
SEQUENCE CHARACTERISTICS:
LENGTH: 51259 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-781-891-209

Query Match 60.0%; Score 17.4; DB 3; Length 51259;
Best Local Similarity 48.1%; Pred. No. 54;
Matches 13; Conservative 8; Mismatches 6; Indels 0; Gaps 0;
QY 3 agauuuuuuuuagccccaagggcu 29
Db 26015 AGTTCTTTTGGAGACCTTAGACT 26041

RESULT 7
US-08-781-891-209/c
Sequence 209, Application US/08781891
Patent No. 6090620
GENERAL INFORMATION:
APPLICANT: Fu, Ying-Hui
APPLICANT: Yu, Chang-En
APPLICANT: Oshima, Junko
APPLICANT: Mulligan, John T.
APPLICANT: Schellenberg, Gerald D.
TITLE OF INVENTION: GENE AND GENE PRODUCTS RELATED TO
NUMBER OF SEQUENCES: 209
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/781,891
FILING DATE: 27-DEC-1996
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: No. 6090620tenburg Ph.D., Carol
REGISTRATION NUMBER: 39,317
REFERENCE/DOCKET NUMBER: 240052.419
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 209:
SEQUENCE CHARACTERISTICS:
LENGTH: 51259 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-781-891-209

Query Match 60.0%; Score 17.4; DB 3; Length 51259;
Best Local Similarity 48.1%; Pred. No. 54;
Matches 13; Conservative 8; Mismatches 6; Indels 0; Gaps 0;
QY 3 agauuuuuuuuagccccaagggcu 29

Db 10496 AGTTCCTTTTGTGACACTTAGAGCT 10470

RESULT 8

US-08-222-619-1/c
; Sequence 1, Application US/08222619
; Patent No. 5652352
; GENERAL INFORMATION:
; APPLICANT: Lichenstein, Henri
; APPLICANT: Lyons, David
; APPLICANT: Wurfel, Mark
; APPLICANT: Wright, Samuel
; TITLE OF INVENTION: Afamin: A Human Serum Albumin-Like
; TITLE OF INVENTION: Protein
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Amgen Center, Patent Operations/RRC
; STREET: 1840 DeHavilland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: U.S.
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentln Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,619
; FILING DATE:
; CLASSIFICATION: 435
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2287 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 318..2117
; FEATURE:
; NAME/KEY: mat_peptide
; LOCATION: 381..2114
; FEATURE:
; NAME/KEY: sig_peptide
; LOCATION: 318..380
; -08-222-619-1

Query Match 59.3%; Score 17.2; DB 1; Length 2287;
Best Local Similarity 54.5%; Pred. No. 40;
Matches 12; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 3 agauuuuuuuuagcccccacaa 24

Db 175 AGACTCTTTTGTGACACCAA 154

RESULT 9

US-08-221-767-23/c
; Sequence 23, Application US/08221767
; Patent No. 6268212
; GENERAL INFORMATION:
; APPLICANT: Lichenstein, William S.
; APPLICANT: Lyons, David E.
; APPLICANT: Lyons, David E.
; TITLE OF INVENTION: Tissue Specific Transgene Expression
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Amgen Inc., U.S. Patent Operations/NAO
; STREET: 1840 DeHavilland Drive

CITY: Thousand Oaks
; STATE: California
; COUNTRY: USA
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentln Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/221,767
; FILING DATE:
; CLASSIFICATION: 800
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2287 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 318..2117
; FEATURE:
; NAME/KEY: mat_peptide
; LOCATION: 381..2114
; FEATURE:
; NAME/KEY: sig_peptide
; LOCATION: 318..380
; US-08-221-767-23

Query Match 59.3%; Score 17.2; DB 4; Length 2287;
Best Local Similarity 54.5%; Pred. No. 40;
Matches 12; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 3 agauuuuuuuuagcccccacaa 24

Db 175 AGACTCTTTTGTGACACCAA 154

RESULT 10

PCT-US95-04075-1/c
; Sequence 1, Application PC/TUS9504075
; GENERAL INFORMATION:
; APPLICANT: AMGEN INC.
; TITLE OF INVENTION: Afamin: A Human Serum Albumin-Like
; TITLE OF INVENTION: Protein
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Amgen Center, Patent Operations/RRC
; STREET: 1840 DeHavilland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: U.S.
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentln Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/04075
; FILING DATE:
; CLASSIFICATION:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2287 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: cDNA
; FEATURE:

APPLICANT: Knechtle, Philipp
APPLICANT: Redischung, Corinne
TITLE OF INVENTION: GENOMIC DNA SEQUENCES OF ASHBYA GOSYPITII
TITLE OF INVENTION: AND USES THEREOF
NUMBER OF SEQUENCES: 1152
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 6239264rtis Corporation
STREET: 3054 Cornwallis Road
CITY: Research Triangle Park
STATE: No. 6239264th Carolina
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/998,416
FILING DATE: 24-DEC-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: CH 0016/97
FILING DATE: 31-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: Weigs, J. Timothy
REGISTRATION NUMBER: 38,241
REFERENCE/DOCKET NUMBER: PF/5-30306/A/CGC1976
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 900:
SEQUENCE CHARACTERISTICS:
LENGTH: 711 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
ORGANISM: PAG1561UP
US-08-998-416-900

Query Match 57.2%; Score 16.6; DB 4; Length 711;
Best Local Similarity 47.8%; Pred. No. 61;
Matches 11; Conservative 8; Mismatches 4; Indels 0; Gaps 0;

OY 6 uucuuuuuagcccaaggc 28
:::|||||:|||||
168 TTCTTTTCTTTTCACCAAGGC 190

RESULT 14
US-08-834-306-17/c
Sequence 17, Application US/08834306
Patent No. 6054135
GENERAL INFORMATION:
APPLICANT: Reed, Steven G.
APPLICANT: Skelky, Yasir A.W.
APPLICANT: Lodes, Michael J.
APPLICANT: Houghton, Raymond L.
TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DETECTION AND PREVENTION OF T
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/834,306
FILING DATE: 15-APR-1997
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Makl, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 210121.422C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 2446 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-834-306-17

Query Match 57.2%; Score 16.6; DB 3; Length 2446;
Best Local Similarity 56.5%; Pred. No. 75;
Matches 13; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

OY 6 uucuuuuuagcccaaggc 28
Db 370 TTCTTCTGTACTCCCAAGGC 348

RESULT 15
US-08-993-674A-17/c
Sequence 17, Application US/08993674A
Patent No. 6228372
GENERAL INFORMATION:
APPLICANT: Reed, Steven G.
APPLICANT: Skelky, Yasir A.W.
APPLICANT: Lodes, Michael J.
APPLICANT: Houghton, Raymond L.
APPLICANT: Smith, John M.
APPLICANT: McNeill, Patricia D.
TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DETECTION AND PREVENTION OF
NUMBER OF SEQUENCES: 81
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/993,674A
FILING DATE: 18-DEC-1997
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Makl, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 210121.422C2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 2446 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

THIS PAGE BLANK (USPTO)